|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤U¤È 08:57:55²Ä 1920 ½g¦^À³
|
¤Ñ©R¤j ¤p©_¤j ²Ä32Ó¤ë®ÉOBI-822 ²Öp¦³47¤H¬°¦³®Ä¼Ë¥», ¦©°£¤w¸g¦º¤`¡]©Îµo¥ÍEvent¡^©ÎªÌ³]¡]Censor¡A¤¤³~°h¥X,¡^ªÌ ¥i¥H¦A¥Õ¸Ü¤@ÂI»¡©ú? Åý¤j®a¯àÁA¸Ñ ¦ó¿×¦³®Ä¼Ë¥»? ¦p¦ó»PP13 Total events 50¤H ¤@¨Ö »¡©ú? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/8 ¤U¤È 08:42:31²Ä 1919 ½g¦^À³
|
Cliff¤j®¦®v ÁÂÁ±zªºÄYÂÔ»P»{¯u ¤p§Ì»Ê·P¤¤º |
|
|
·|û¡Gming10140949 µoªí®É¶¡:2016/6/8 ¤U¤È 08:02:28²Ä 1918 ½g¦^À³
|
§Ú·Q6/27ªÑªF·|´N¯àºÉ¶q°Ý¤½¥q,¥]¬A,±ÂÅv,FDA½Í§P,ÃĪ«µo®i,ADRµ¥µ¥ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/8 ¤U¤È 07:57:36²Ä 1917 ½g¦^À³
|
QQ¤j ¤p§Ì¹Á¸Õ¦^µª¬Ý¬Ý 1.¾î¶b¥H¤U¼Æ¦r¬OÃnÀI¤H¼Æ ¤]´N¬O®É¶¡¶b·í¬Y©P¶}©l®É³B©ó¥i¯àPFS©ÎOSµo¥Íªº¤H¼Æ 2.KM¦±½u«æ³t¤U©Ô ¦n¹³¶¥±è ªí¥Ü·í©P¥X²{¸û¦hPFS©ÎOSªºµo¥Í¤H¼Æ ¦Ó¨Ï¹ïÀ³Y¶bªº¦s¬¡¾÷²vȤU° ¦p¤£¤F¸Ñ ¥i¥H¬d¸ß¦s¬¡¤ÀªR¬ÛÃö¸ê®Æ©Î°Ý¤½¥q |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤U¤È 07:57:18²Ä 1916 ½g¦^À³
|
pie ¤j §A°Ñ¥[¹L´X¦¸ªÑªF·| ªk»¡·|? §A¹ï±i¸³ÁA¸Ñ¦h¤Ö? ±i¸³ÅÞ¿è²M´· ±ø²z¤À©ú ¥Ñ¥L¨Ó¦^µª°ÝÃD«D±`¦X¾A ¦³¬ü°ê³Ð·~¦¨¥\ªº¸gÅç ¥x³Ð·~§ä¦^ÄÝ©ó¥xÆWºaÄ£¤§¤ß ¦^µª°ÝÃD®É·|§â¥i¯à±¡ªp»¡©ú,¹ï¨Sµo¥Íªº¨Æ¤£·|¥h¹w´ú ¤£¤îÃö¤ß¯E¹©ªºµo®i,¤]Ãö¤ß¥xÆW¥Í§Þ²£·~ªºµo®i §Ú³Ì³ßÅwÅ¥¥L½×z°ÝÃD §A»Ýn¦hÁA¸Ñ±i¸³ ¤]³\¬Ýªk´N·|¤£¤@¼Ë |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/8 ¤U¤È 06:50:54²Ä 1915 ½g¦^À³
|
¦³«í¤j ÁÂÁ§AªºÆg¬ü, ¹ê¦b¬O¹LÅA¤F Ãö©ó§Aªº°ÝÃD 1. n¬Ý¤½¥q³W¹º, §Ú¤]¤£²M·¡ 2. ¦pªG¹êÅç²Õ³£¥´§¹¤E°w, ¥i¥H½T©wªº¬O²£¥Í°ª§ÜÅé¤ñ¨Ò·|¤ñ²{¦b°ª¤£¤Ö. ¦Ü©óPFS¦±½u·|¤£·|©¹¥k¤W¤è²¾, ÅܼƤӦh, Ãø¥H¹wª¾ 3. Ãö©ó±ÂÅv, °O±o¤½¥q»¡ªk¬O¶i«×·|¥[§Ö, ¥¼¥²¦bASCO¤§«á, ¥i¯à¦bASCO¤§«e´N¦³¦nµ²ªG. ¤½¥q¨Ã¨S¦³»¡¤@©w¦bASCO¤§«e´N·|§¹¦¨. ¨ä¹ê§Ú¤ä«ù¤½¥q«ö·ÓÀ³¦³ªº¨B½Õ, ¦b³Ì¨Îªº®É¶¡ÂI½Í±ÂÅv, ¤£n¨ü©óASCO«e©Î«á. ¥u¬OÅ¥¨ì¤½¥q³o»ò»¡, ¤ß¤¤Ãø§KÁÙ¬O¦³©Ò´Á«Ý. §Úı±o, Ãö©ó±ÂÅvªº¶i«×, ¦pªG¤½¥q¨S¦³½T©wªº³W¹º, À³¸Ó¬O¥i¥H¤£n¥[¥Hµû½×, µ¥µo¥Í¤F¦A¤½§i´N¦n. Ãö©ó´£¨ìCNN³ø¾É³o¥ó¨Æ, ÁÂÁ§A¹ï®É¶¡ªº§ó¥¿»P¸É¥R. ¦P¼Ëªº, §Úı±o¥~°ê´CÅé·|¤£·|³ø¾É, ¤£¦b¤½¥qªº´x´¤, ¤½¥q¤]À³ÁקK´£¥X³oÓ¹w´Á. ì«h¤W, §Úı±oµLªk´x´¤ªº¨Æ, ÁÙ¨Sµo¥Íªº¨Æ, ¥i¯à·|©Î¬O§Æ±æ·|ªº¨Æ, ¤½¥qÀ³ÁקK´£¤Î. °O±o3/31»¡©ú·|, Ãö©ólate-breaking, ¦³¥ó¨Æ®¼¦³½ì ±i¸³: late-breaking ªí¥Ü§Ú̬O«nªº½×¤å ¶ÀÁ`: late-breaking ¥uªí¥Ü§Ṳ́ñ¸û±ß§â¸ê®Æ°e¶i¥h ´¿«ß®v: ASCO¥u¬OÅý§ÚÌ¥hµoªí½×¤å¦Ó¤w, ¤£¬OÀ°OBI822ªºÀø®ÄI®Ñ ¶ÀÁ`¹ïlate-breakingªº»¡ªk¬O¤ñ¸û¶Kªñ¨Æ¹êªº, ´¿«ß®v¬O³Ì«O¦uªº, §Úı±o¤½¶}µo¨¥®É¥H´¿«ß®vªº·®æ·|¬O³Ì¾A¦Xªº §ÚÓ¤H«Ü³ßÅw±i¸³©M¶ÀÁ`, ASCOºKn¤½¥¬¤§«á, ¹ï¸gÀ綥¼hªº«H¥ô¬O§ÚÄ~Äò«ùªÑªº«H¤ß¨Ó·½ ¦ý©Z¥Õ»¡, §Úı±o±i¸³¤£¤Ó¾A¦X°µ¤½¶}ªºµo¨¥, ¦³®ÉÅ¥§¹¥Lªº¦^µª, ÁÙ¬O¦³¼Ò½kªºªÅ¶¡, ©Î¬Ol¥Í·sªº°ÝÃD ¦Ó¥B, ±i¸³¤]±`§âÓ¤H¥DÆ[ªº, ¼ÖÆ[ªº´Á«Ý, §¨±a¦bµo¨¥¸Ì, ¦pªG«á¨Ó¨S¦³¹ê²{, ´N·|¦³¥¢¸¨·P ·íµM³o¤]¥i¯à¬O§ÚÓ¤Hªº°ÝÃD |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/8 ¤U¤È 06:10:39²Ä 1914 ½g¦^À³
|
www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=77 ASCO¬ÛÃö´£°Ý¡A±N¤½¶}µªÂСC ·q·Rªº¯E¹©§ë¸ê¤H¡G ¥xÆW¯E¹©¦bASCO·|ij¤§«á¡A¦P¨B´¦ÅS¤FOBI-822/821¦bASCO©Òµoªíªº³ø§i¡Aì¬O¬°¤FÅý§ë¸êªÌ§ó¤F¸ÑOBI-822Á{§É¸ÕÅç¸Ñª¼«á©Ò§e²{ªº¼Æ¾Ú¤Î¨ä·N¸q¡F¤]¦]¦¹¡A5¤é¤G³õ»¡©ú·|©Ò¤Þ¥ÎªºÂ²³ø¬°Dr.Rugo·|¤¤µoªíªºª©¥»¡C§Ų̨́ä¤ÎASCO±ÂÅvªºn¨D¡AìÀÀ»EµJ¦b·|ij³ø§iªº¤º®e¡AÅý¥x¬üÂù¤è¸ê°T§¹¥þ¹ïµ¥¡A¦Ó¤£©µ¦ù¦Ü½×¤å³ø§i¥H¥~ªº¸ê°T¡C¤£·N¡A³o¼Ëªº«ä¼{¥i¯à¥¼ºÉ©P¸Ô¡A¤]¥¼¥þ½LÅU¤Î§ë¸ê¤Hªº´Á«Ý»P·P¨ü¡AP¨Ï§ë¸ê¤H¦bªk»¡·|«á§ó¬°§x´b¡A¼W¥[³\¦h¯ÉÂZ¤£¦w¡A¤]Åý§Ú̲`²`¤Ï¬Ù¡A¨Ã¿Ñ¨D«áÄò¿n·¥³B²z¤§¹D¡C §ÚÌpµe¦bÁ{§ÉÂå¾Ç»P¬ãµo¹Î¶¤ªñ¤é¦ÛASCO³°Äòªð°ê«á¡A±N¤½¶}¦^µª¤j®aªº°ÝÃD¡G¤Z¥i¥H¤½¶}ÄÀºÃªº¡A¤@©w¾¨¶q¦^ÂСA¦ÓÁÙ¦b¶i¦æ¤¤¡B©|¥¼§¹¦¨ªº¤ÀªR¡A©ÎÁÙ¥¼ª¾ªºµª®×¡A§Ṳ́]·|¸[«ù¡¨¦³´X¤Àµý¾Ú¡B»¡´X¤À¸Ü¡¨ªººë¯«¡A¾Ú¹ê¥H§i¡F¤£¹L¡A¹ï©ó¤@¨Ç°²³]©Î¹L«×ªº´¢´ú¡A¨Ò¦p±Ù°vºIÅK¦a¹w´ú¡GOBI-822¦Ü¤Ön¤¨ì¤K¦~«á¤~¤W¥«¡A³oÃþ»¡ªk¤]½Ð®¤§Ṳ́£¦A¦^À³©Î¤@¤@»é¥¸¡C ¦AªÌ¡A¥²¶·»¡©úªº¬O¡G¦bASCO©Ò´£¥XªºOBI-822/821³ø§i¡A¨Ã«D¦¹¤@Á{§É¸ÕÅç¸Ñª¼¼Æ¾Úªº¥þ³¡¡F¤@¶µ¶i¦æ¤¦~¦hªºÁ{§É¸ÕÅç¡A´N¹³¤@³õ²±®b¡A¤]¹³ÄÂÃÂ×´IªºÄq²£¡A¦A¦nªº¹§÷¤´¶·ºë¤õºC¿L¡AÄ_Äq§ó»Ýnºë½T¬ã§P¶}«õ¤è¦V¡A¤~¯à¾¨³tÅãÅS¥¦ºë´ïªº¥»½è¡F¦P¼Ëªº¡A¸Ñª¼¼Æ¾Ú¥]²[¦U¤À²Õ¡B¦U±Ú¸s¡B¦UXXXXªº¤£¦P¸ê°T¡AIJ[¤F¦UºØ¦h¤¸¡B¦h¼h¦¸ªº°T®§¡F¦Ó§Ú̦b¤G¤ë¸Ñª¼«á¡AªÀ·|Áֽתmªm´´¡A¯E¹©ªº¥ë¦ñ̯ɯÉÂZÂZ¤¤¤´§NÀR¦Û«ù¡A¦b¤T¤ëºI½Z®É¶¡À£¤O¤U¡A¸g°Q½×¨M©w¤F¥Ø«e§Ú̦VASCO©Ò´£³øªº¤º®e¡C ¦ý¡A§ÚÌ©l²×¥¼°±¤î³o¨Ç¸Ñª¼¼Æ¾Úªº«áÄò©M¶i¤@¨B¤ÀªR¡A³o¨Ç¸ê®Æ¦³¨Ç¬O³°Äò§¹¦¨ªº¡AÁÙ¥¼¦V±M®a¤@¤@½T»{¡A©Ò¥H¤£«K¦b¤½¶}³õ¦Xµoªí¡F¦³¨Ç«h¬OÁÙ¦b¤ÀªR¤¤¡A¤]¦³¨Ç¬O§ÚÌpµe¦V¨ä¥¦°ê»Ú·|ij¤Î°ê»Ú´Á¥Z¥Ó½Ð³ø§i©Mµoªíªº¤£¦P½×¤å¡A¦ÛµM¤£«K°¨¤W´¦ÅS¡C¦ý¬O¡A¥un³o¨Ç¼Æ¾Ú©M®É¾÷¦¨¼ô¡A§Ṳ́´·|¤@¥»¹ï§ë¸ê¤H¸ê°T¤½¶}¡B³z©úªºì«h¡A¦b¦X¾A³õ¦X©M®É¾÷¤U´¦ÅS¡F¬Æ¦Ü§Ú̪º¤U¤@¨Bµo®ipµe¡A¨Ò¦p¥þ²y¤T´Á³Wµe¡A¦b¤º®e½T©w¥B¸g¼f®Ö³q¹L«á¡A§Ṳ́]¤@©w¦b²Ä¤@®É¶¡©M§ë¸ê¤H¤À¨É¡C ·sÃĬãµo¡A¤£¶È¬O¤@±øº©º©ªø¸ô¡A¥Bªu³~¯ð´Æº¡§G¡B¥Rº¡¬D¾Ô»P·ÀI¡F¦b¸g¹L¸Ñª¼«á¤@³s¦êÄY»Å¦ÒÅç¤U¨Ó¡A§Ú̧󪾹D¡GÁÙ¦³¤@³¡¤Àªº·ÀI¨Ó¦Û·¾³q¡A¤£¤î¬O¬ãµo¡B¬ì§Þ¡BºÞ²z¡Bªk³W¼h±ªº·¾³q¡A§ón»{¯u¬Ý«Ý»P§ë¸ê¤H¡B¬Æ¦Ü»PªÀ·|¤j²³ªº«ùÄò·¾³q¡F¬°¤F§ó¦³®Ä¡B§ó°ª«~½èªº·¾³q¡A§Ú̱N§óÄYÂÔ¥H¹ï¡A¦ýµ´¤£¦]¦¹©T¨B¦Û«Ê¡A©ñ±ó»P§ë¸ê¤H©MªÀ·|¤j²³ªº¹ï¸Ü¡C ¿Ë·Rªº§ë¸ê¤H¡AÁÂÁ±zÌ¥Hª½±µ¡B¶¡±µ¤è¦¡¡AÅý§Ú̪¾¹D±z̪º·P¨ü¡A¤]ÁÂÁ±z̪º®ï®ï¸ß°Ý©M½èºÃ¡A¦b¦b´£¿ô¤F§Ú̪º¤£©P©M«Ý§ï¶i¤§³B¡F§Ú̬۫H¡A¥unÄ@Á¾µêÀË°Q¡B¾Ç²ß¡A³o¨Ç¿i½m¡A³£¬O¬°¤F¦¨´N©ú¤é§ó¨ô¶Vªº¯E¹©©Ò¥²¸gªº¥\½Ò¡C³Ì«á ·q¯¬ºÝ¤È¨Î¸`´r§Ö ¥xÆW¯E¹©¥Í§Þ¸³¨Æªø ±i©À·O2016/6/8 |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/8 ¤U¤È 03:25:58²Ä 1913 ½g¦^À³
|
¯E§J¤j, ¦U¦ì¤j¤j: ¤£ª¾¬O§_¤è«K½Ð±Ð¹Ïªíªº¸ÑŪ: 1) Slide P12~17 ¤¤¹Ïªíªº³Ì¤U¤è³£¦³©M¾î¶b¬Û¹ïÀ³ªº¤H¼Æ. ½Ð°Ý§Ú¦b¸ÑŪ®É, ¦p¦ó±N³o¤H¼Æ±a¤J¹Ïªí¤¤¨Ó¬Ý ? Ä´¦pP13 ¦b32Ӥ몺®ÉÔ©|¥¼¹F50%, ¤U±ªº¼Æ¾Ú¬Oªí¥Ü¬I¥´822ªº¯f¤H©|¦³47, placebo ¦³22 ? ÁÙ¬O ¡K.??? ©Ò¦³ªº¸ê®Æ¨ìdate lockªº¤é¤l, ¨º¾î½u¤§«á¤U±¹ïÀ³ªº¼Æ¾Ú«ç»ò¬Ý ? P12~17 ¨C¤@¶¤U¤èªº¼Æ¾Ú³£¾A¥Î¦P¼Ëªº¸ÑŪ¤è¦¡¶Ü ? 2) ³¡¥÷¹Ï, ¦pP 12, 14, 16¦b¾î¶b§ÀºÝªº½u±ø·|¦³¤U¼Y²{¶H, ³o¤S¬O¤°»ò ? ¯u¦½ÃC, ¥i¯à¬OÄø°ÝÃD., ¦]¦bgoogle¤]¨S¬d¨ì¦p¦ó¾\Ū., ©PÃä¤]¨S¦³»{ÃѬÛÃö¥i¥H±Ð¾É§Úªº¿Ë¤Í. ©Ò¥H«pÃC½Ð±Ð. ½Ðª¾¹Dªº¤j¤j¤è«K®É«ü¾É¤@¤G., ·PÁ ·PÁ !! |
|
|
·|û¡GµL¦W10141903 µoªí®É¶¡:2016/6/8 ¤U¤È 03:19:57²Ä 1912 ½g¦^À³
|
¤Þ°_°aµM¤jªiªºASCO P18 ¦]¬° no. of sample too small It¡¦s just globo H,no global H(all of globo series) |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/6/8 ¤U¤È 03:19:16²Ä 1911 ½g¦^À³
|
µL¦W¤j: ÁÂÁ±z !! ¦¤W»°µÛ¶}¦·|,»°µÛ¥´¦rªí¹F¤£¦n,Åý±z¦A¸Ñ»¡¤@¦¸,ÁÂÁ !!! |
|
|
·|û¡GµL¦W10141903 µoªí®É¶¡:2016/6/8 ¤U¤È 03:05:28²Ä 1910 ½g¦^À³
|
KLH¬O¯S²§©Ê«Ü°ªªº¤j¤À¤l³J¥Õ½è¡A¥i¨ó§U¨ë¿E¨Åé§K¬Ì¤ÏÀ³²£¥Í¥i¿ëÃÑGH,SSEA3,SSEA4ªº¯S²§©Ê§ÜÅé(IgG,IgM) §ó¥¿¬° KLH¬O²§½è©Ê«Ü°ªªº¤j¤À¤l³J¥Õ½è¡A¥i¨ó§U¨ë¿E¨Åé§K¬Ì¤ÏÀ³²£¥Í¥i¿ëÃÑGH,SSEA3,SSEA4ªº¯S²§©Ê§ÜÅé(IgG,IgM) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/8 ¤U¤È 03:02:35²Ä 1909 ½g¦^À³
|
²q·Q¤j¤j¡G ¤£¦n·N«ä¡F§ó¥¿¤p§Ì¬Q©]ªº¶K¤å¡G ì¤å¡G¡u´NGHªº¥Í¦¨¦Ó¨¥¡A¦b¤ºÒÁÞªºSSEA-3ªº¥k±Û¥b¨Å¿}¡]D-galactose¡^ºÝ¥[¤W¤@Ó©¥Ä¦ÁÞ¡]Fucose¡^Åܦ¨¬°¤»ºÒÁÞªºGH¡A©Ò¥HSSEA-3¥i»¡¬O¦³GHªº¥À¿Ë¡C¡v §ó¥¿¡G¡u´NGHªº¥Í¦¨¦Ó¨¥¡A¦b¤ÁÞªºSSEA-3ªº¥k±Û¥b¨Å¿}¡]D-galactose¡^ºÝ¥[¤W¤@Ó¥ª±Û©¥Ä¦ÁÞ¡]L-Fucose¡^Åܦ¨¬°¤»ÁÞªºGH¡A©Ò¥HSSEA-3¥i»¡¬OGHªº¥À¿Ë¡C¡v ì¤å»~¥[¤F¤@Ó¡uºÒ¡v¦r¡AÅܱo¤£Û¤£Ãþ¡C¥y§À¤]¦h¤F¤@Ó¤¾¦r¡u¦³¡v¡C «ù¤[ªº¯E§J¤j¡G ¤j«v°Ý¡I ¦Ñ´¤j¡G §NÀR§NÀR¡KÁ@±z¤ß«æªº¡AIt¡¦s Globo H, not Global H¡C Tiger365¤j¡A±z¤]¤@¼Ë¡CJust Globo H, no Global H¡C¡]105/6/7 ±zªº²Ä 1834 ½g¦^À³¡^ |
|
|
·|û¡GµL¦W10141903 µoªí®É¶¡:2016/6/8 ¤U¤È 02:56:59²Ä 1908 ½g¦^À³
|
¤p¹xµ£¤j §d©v¯q»¡©ú¨ÅÀùÀù/·F²ÓM¤W¶W¹L98%¦Ü¤Ö§t¦³GH,SSEA3,SSEA4¨ä¤¤¤@ºØ§Üì (¸ê®Æ¨Ó·½1) ¤Wz¤TºØ§Üì¬O¯f±w¦ÛÅé²ÓM¯fÅܦ¨Àù²ÓM«á¡A¦b¨ä²ÓM½¤¥~§e²{ªºÁޯ׽è(§Üì) ¦ý¦]³o¤TºØ§Üì¬O¦ÛÅ饿±`²ÓM¯fÅܲ£¥Í¡A¦]¦¹¨Å餣·|²£¥Í§K¬Ì¤ÏÀ³(§_«h·|²£¥Í¦ÛÅé§K¬Ì¡AÄè·À¥¿±`²ÓM)¡A¤]´N¬O¤£·|²£¥Í¥i¿ëÃÑGH,SSEA3,SSEA4¤TºØ§Ü쪺¯S²§©Ê§ÜÅé(IgG,IgM) ¦p¦ó²£¥Í¥i¿ëÃÑÀù/²ÓM¤W§Üì(GH,SSEA3,SSEA4)ªº§ÜÅé? ¥´¤J822¡A822¥Ñ¤H¤u¦X¦¨ªºGHµ²¦XKLH¸üÅé KLH¬O¯S²§©Ê«Ü°ªªº¤j¤À¤l³J¥Õ½è¡A¥i¨ó§U¨ë¿E¨Åé§K¬Ì¤ÏÀ³²£¥Í¥i¿ëÃÑGH,SSEA3,SSEA4ªº¯S²§©Ê§ÜÅé(IgG,IgM) ª`·N¤F! ¯S²§©Ê§ÜÅéIgG,IgM¬O¥Ñ¥´¤Jªº822¨ë¿E²£¥Íªº »P¨ÅéÀù/·F²ÓM¤W±a¦h¤Ö±j«×ªºGH,SSEA3,SSEA4§Üì¡A§¹¥þµLÃö!!!§¹¥þµLÃö!!! ¦ý§ÜÅ饲¶·§ä¨ìÀù/·F²ÓM¤WGH,SSEA3,SSEA4§Üì¡A¤~¯à§ä¨ì¨ÃÄè·ÀÀù/·F²ÓM ¦Aª`·N¤F! §ÜÅé®Ä»ù°ª§C¡Bºû«ùªøµu »P ¯f±w¤WGH,SSEA3,SSEA4¤TºØ§Ü쪺ªí²{±j«×°ª§C ±N¨M©w822ªº¥DnÀø®Ä¡A¤]´N¬O²£¥Í§ÜÅé®Ä»ù°ª¡B«ùÄòªøªº¯f±w¡AY¨äGH,SSEA3,SSEA4§t¶qÁp¶°°ª¥Bªí²{±j ¨º¥LªºÀø®Ä¤]·|¸û¦n ¦³§ÜÅé¦ý§¹¥þµL§Üì¡A¦]§ä¤£¨ì¼Ä¤H©Ò¥H§¹¥þµLÀø®Ä¡C ¤Wz¬O822Àø®Äªº¾÷Âà(MOA)²z½× ¥H¤W¨Ñ°Ñ ¸ê®Æ¨Ó·½ 1 www.chinatimes.com/newspapers/20160301000389-260109 |
|
|
·|û¡G¦Ï«§«§10141876 µoªí®É¶¡:2016/6/8 ¤U¤È 02:21:39²Ä 1907 ½g¦^À³
|
·Å¬Gª¾·s....^^ ---------------------------------------- www.chinatimes.com/newspapers/20160301000389-260109 ¬°¯E¹©·sÃÄÄÀºÃ 2016¦~03¤ë01¤é 04:10 §d©v¯q¡þ¤¤¥¡¬ã¨s°|°ò¦]Åé¬ã¨s¤¤¤ß°Æ¬ã¨sû °w¹ï¶Q³øªÀ©ó2¤ë23¤é¥Z¸ü¥x¤j¯f²z¾Ç¬ì¾G¥Ã»Ê±Ð±ÂÃö©ó¡q¯E¹©·sÃĬ°¦ó¥¢±Ñ¡r¤@¤å¡A¥»¤H¨¬°¬ÛÃö§Þ³Nµo©ú¤H¡A¹ï¦¹¤å¸É¥R»¡©ú¦p¤U¡G ¾G±Ð±Â´£¨ì¡G¡u¤¤¬ã°|¥HGlobo-H¶i¦æ§K¬Ì¬V¦âªº¤åÄm¥iµo²{Globo-H¦bÀù¯g²Õ´¥u¦³14%¦Ü75%ªºÀù²ÓMªí²{¡A§Y¨Ï³o¨Ç²ÓM¥þ³Q±þ¦º¡AÁÙ¦³¤@¥bªº²ÓM¦s¬¡¡C¡v³o»P§Ú̪º¬ã¨s¬O¤£¬Û²Åªº¡Cº¥ý¯E¹©Á{§É¸ÕÅç¨Ï¥Îªº¬Ì]Globo-H KLH¨ä»¤µoªº§ÜÅé¡A¤£¶È¯à±þ¦º±a¦³Globo-HªºÀù²ÓM¡A¤]¯à±þ¦º±a¦³¬ÛÃöÁÞ¤À¤lSSEA3¤ÎSSEA4ªºÀù²ÓM¡]PNAS 2013¡^¡C ¦b§Ú̪º¥t¤@½g¬ã¨s¤¤¡A§Ú̵o²{¨ÅÀù¤Î¨ä¥L14ºØÀù²ÓM¤W¶W¹L98%¬Ò¦Ü¤Ö§t¦³¦¹¤TºØÁÞ¤À¤lªº¨ä¤¤¤@ºØ¡]PNAS 2014¡^¡A¦Ó¦b¨ÅÀù·F²ÓM¤W¡A§Ú̬Ʀܵo²{´X¥G100%¬Ò¦Ü¤Ö§t¦³¦¹¤TºØÁÞ¤À¤lªº¨ä¤¤¤@ºØ¡A¤]´N¬O»¡¦¹¬Ì]²£¥Íªº§ÜÅ馳¾÷·|±þ¦º¥þ¼ÆªºÀù²ÓM©ÎÀù·F²ÓM¡A¦Ó«D§@ªÌ©Òz³Ì¦h¶È¯à±þ¦º¤@¥b¡C ¤]¦]¬°¦¹¬Ì]ªº³oºØ¯S©Ê¡A¦b³]pÁ{§É¸ÕÅç®É¨Ã¥¼±N¯f¤HÀù²ÓM¤W¬O§_ªí²{Globo-H·í¦¨¦¬®×ªº¥²n±ø¥ó¡C¦b¼Æ¾Ú¸Ñª¼«á¡Aµ²ªG¥ç¤ä«ù¦¹¶µ½×ÃÒ¡C§Y¤£½×¥ô¦ó«¬ºAªº¨ÅÀù¯f±wª`®g¬Ì]«á¥un¯à²£¥Í¨¬°÷ªº§ÜÅé¡A¬Ò¯àÅã²{¨¬°÷ªºÀø®Ä¡C ³oÓ¬Ì]¬O¬ü°êOptimer¤½¥q§ÞÂà¦Û¬ü°êSloan KetterineÀù¯g¤¤¤ß¦Ó¨Ó¡A·í®É§ÞÂà®É¦¹¬Ì]¤w¦b¬ü°ê§¹¦¨¤@´ÁÁ{§É¸ÕÅç¡Aµ²ªGµo²{¦¹¬Ì]ªº¦w¥þ©ÊµL¸·¡A¥B¨ã¦³¤@©wªºÀø®Ä¤è¯à¶i¦æ«áÄòªº¤G¡B¤T´ÁÁ{§É¸ÕÅç¡C¦Ó¯E¹©ªºÁ{§É¸ÕÅç¬Ì]§÷®Æ¬Ò¥H§Ú̪º¦X¦¨§Þ³N´£¨Ñ¡A¥[¤WGlobo-Hªº¬ÛÃö¬ì¾Ç¤ÎÁ{§É«e¸ÕÅç¬Ò¤w¦³¬Û·íªº¬ã¨s¡A¥B§Ú̦bÁÞ¤À¤l»â°ì¨ã°ê»Ú»â¥ý¦a¦ì¬O¥@¬É¤W¤½»{ªº¡C ¥Ñ©óÁÞ¤À¤l¬Ì]¥Î©óÀù¯gªvÀøªºÁ{§É¸ÕÅç¦b¥xÆW¬O²Ä¤@¦¸¹Á¸Õ¡A¸Ñª¼µ²ªG¦p¥H¶Ç²ÎÃĪ«³]pÁö¥¼¯à¹F¨ì©Ò³]pªº¼Ð·Ç¡A¦ý±q¦³§K¬Ì¤ÏÀ³ªº¯f¤H¨Ó¬Ý¡A¦¹¬Ì]¤§¦³®Ä©Ê¤w¹F¨ì¡A¤]ÃÒ¹êÀù²ÓM¤W¯S®íÁÞ¤À¤l·í§@§Ü쪺¥i¦æ©Ê¡C |
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2016/6/8 ¤U¤È 02:08:18²Ä 1906 ½g¦^À³
|
°Ñ»P¸ÕÅ窺µÐÂĨì¥h¦~©³ªvÀø®É¶¡¶W¹L4¦~ªº¥u¦³47¦ì,©Ò¥H»¡4¦~¦s¬¡²v¦³78%,¬O¤£¬O¤£¤Ó¥¿½T? §Ú¤£¾å±oÁ{§É¸ÕÅçOSªº©w¸q,Á`ı±o©Ç©Çªº |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/8 ¤U¤È 01:33:31²Ä 1905 ½g¦^À³
|
¦Ñ´¤j ¯u¬O¹ê¨Æ¨D¬O ½T¹êhormone therapy¦bsubgroupªº¤ñ¨Ò«Ü«n ¼vÅT«Ü¤j ¦ý¬O ¦ý¬O ¦ý¬O Y¯E¹©¤½¥q½Ðªº¥Íª«²Îp¤½¥q ¤]«Ü±M·~ªº¸Ü ©w·|±Nhormone therapyµø¬°¨â²Õªº¦@ÅÜ¼Æ ¥[¥H²Îp±Æ°£¨ä¼vÅT ©Ò±oªº¨â²Õ®t²§²b®ÄªG ´N¬O¬Û·í¥i«HÅo ©Ò¥H¤p§Ì§Ú¤]²`¤Á´Á«Ý³oÃþ¸ê®Æ¥X²{ ˬO¶¶«K½Ð±Ð¦Ñ´¤j ¬O§_¬Ý¹L§K¬ÌªvÀøªk¬ã¨s¦³³ø§i¹L §C§K¬Ì¤ÏÀ³ªº±Ú¸s¬O§_¥X²{®û¼í²{¶H?ÁÂÁ§iª¾ |
|
|
·|û¡GBH56710142562 µoªí®É¶¡:2016/6/8 ¤U¤È 01:24:27²Ä 1904 ½g¦^À³
|
±wªÌ±µ¨ü²üº¸»XªvÀøªº¤ñ¨Ò¦b¹êÅç²Õ»P¹ï·Ó²Õ¬O±µªñªº, ¦ý¬O±q²Ó¶µ¨Ó¬Ý¨ä¤¤¤T³±©Ê±wªÌ¬Ý°_¨Ó822ªº®ÄªG¸û¨Î, ³o¥i¯à»P²üº¸»XÀøªk¹ï¤T³±©Ê±wªÌ¨S¤°»ò®ÄªG, ¦]¦¹¤T³±©Ê±wªÌ²Õ°ò¥»¤W¤£·|¥t¥~¦A±µ¨ü²üº¸»XÀøªk, ¤Ö±¼¤@Ó822¥H¥~¨ä¥¦¹ïªvÀø®ÄªG·|¦³¼vÅTªº¦]¯À, ©Ò¥H¤~·|¨Ï¤T³±©Ê±wªÌªº¼Æ¾Ú¬Ý¨Ó®ÄªG¤ñ¨ä¥¦¨âÃþ¦n¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/8 ¤U¤È 12:55:14²Ä 1903 ½g¦^À³
|
¦Ñ´¤j: ·P¨Ø±z¹ï¯u¬Ûªº°õµÛ¤Î¼ö±¡. ÁÂÁ±zªº¤À¨É, °²¤é¤S¦h¤F¤@¼Ë¥\½Ò, ©¯ºÖ ! ªÑªF·|ªº´£°Ý, À³¸Ó¬O¤£»Ýn¤F ? ½Ð«ü¥Ü |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/8 ¤U¤È 12:31:02²Ä 1902 ½g¦^À³
|
¸g»P®¦®v°Q½×קï«á,ÁÙ¬Oı±o¦³¥²n©M¦U¦ì¤À¨É!©ñ¤F120¸UÓ¤ß,OBI-822¥Ø«e¬Ý¬O«Ü¦³®Äªº!!! responder(112) placebo(124) Z score p-value ER(+),PR(+),HER2(-) 89(79.5%) 84(67.7%) 2.0328 p<0.05 Triple negative 12(10.7%) 17(13.7%) -0.6999 p=0.48392 HER2(+) 11(9.8%) 23(18.5%) -1.9064 p=0.05614 Global H negative 24(21.4%) 25(20.2%) 0.2397 p=0.81034 Global H positive 59(52.7%) 59(47.6%) 0.7821 p=0.4354 responder(112) non-responder(112) Z score p-value ER(+),PR(+),HER2(-) 89(79.5%) 72(64.3%) 2.5263 p<0.05 Triple negative 12(10.7%) 16(14.3%) -0.8081 p=0.41794 HER2(+) 11(9.8%) 24(21.4%) -2.3922 p<0.05 Global H negative 24(21.4%) 20(17.9%) 0.6727 p=0.50286 Global H positive 59(52.7%) 56(50%) 0.401 p=0.68916 ±qslide p-18ªº°T®§¦Ñ´ºâ¥X¨Ó¤F¨â²Õªº¼Ë¥»¤ñ¨Ò,¨ä¤¤ responder vs. placebo ¦³¤@¶µp<0.05 & responder vs. non-responder¦³¨â¶µp<0.05,¤]´N¬O»¡slide 18ªº³o¨â¶µªº µ²½×PFS, which one is better?¦³¤@¨Ç¦a¤è¬O¥i¥H«O¦u¬Ý«Ýªº----¤]³\°ª¦ô¤]¦³¥i¯à§C¦ô! responder vs. placebo¤¤ªºER(+),PR(+),HER2(-)¡Ap<0.05´N¬O»¡¨â²Õ¶¡¼Ë¥»¤H¼Æ¤ñ¨Ò¦³®t²§, ¨º¦¹slideªºµ²½×¨â²ÕªºPFS¨S¦³®t²§--------³o¼Ëªºµ²½×¥i¥H«O¦u¬Ý«Ý!!!¦]¬°¨â²Õ¶¡ªº¼Ë¥»¤H¼Æ¤ñ¨Ò¤£¹ïµ¥!!! *¦ý¬O¦]¬°¨â²Õ¶¡ªº¼Ë¥»°÷¤j,³£¶W¹L80Ó,©Ò¥HÀ³¸Ó¤£¦Ü©ó¼vÅTµ²ªG¤Ó¤j* *¨º¨ì©³¬Oresponder better or placebo better©O?-------¼Ë¥»¦A¤j¤@ÂI¦³¥i¯à¬Oresponder better!!!* responder vs. non-responder¤¤ªºER(+),PR(+),HER2(-) & HER2(+)¡Ap<0.05. ¦¹slideªºµ²½×ER(+),PR(+),HER2(-)³o¤@¶µ¨â²Õªº PFS responder better--------³o¼Ëªºµ²½×¤]¦³¥i¯à¦]¼Ë¥»¤H¼Æ¤ñ¨Ò¤£¹ïµ¥¤zÂZµ²ªG!! ¦]¬°¨â²Õ¶¡ªº¼Ë¥»¤H¼Æ¤ñ¨Òresponder 79.5%, non-responder 64.3%!!! *responder²Õªº¯f¤HER(+),PR(+),HER2(-)ªº¤ñ¸û¦h,PFS¤ñ¸û¦n*----¦pªG¨â²Õ³£¤@¼Ë¦hªº®ÉÔ·|¤£·|´N¨S¦³ ¤ñ¸û¦n©O?--------------ÁÙ¦³«ÝÆ[¹î,¦Ñ´»{¬°À³¸Ó¤£·|®t¤Ó¦h,n®t¤]¬O¤Ö¦n¤@ÂI¦Ó¤w! ¦¹slideªºµ²½×HER2(+)³o¤@¶µ¨â²Õªº PFS¨S¦³®t²§----³o¼Ëªºµ²½×¬O¥i¥H«O¦u¬Ý«Ýªº!!!¦]¬°¨â²Õ¶¡ªº¤H¼Æ¤ñ¨Ò¤£¹ïµ¥!!! responder²Õ¥u¦³11(9.8%);non-responder²Õ24(21.4%)¡Asample size¤Ó¤p,¤£¨ã°Ñ¦Ò»ùÈ!!! ¥H¤W³£¬O¸g¹LZ-score for 2 population protional testpºâ¥X¨Óªº!!!---¤µ¤Ñ¦Are-check¤@¹M,¿ùªº¦a¤è ¦³×¥¿¤F! ½Ð¹ï·Óslide-18 &slide-11¨Ó¬Ý,ªÅ®æ³£¸¹±¼¤F,p value«eªº´N¬OZ score! ´Á«ÝªºdataÁÙ¦³ ~~~¦~ÄÖ,ECOG,use of hormone therapy³o¨Çcharacteristicªºresponder²Õ,non-responder²Õ©Mplacebo²Õ¶¡ªº ¼Ë¥»¤H¼Æ¤ñ¨Ò~~~ ¤×¨ä¬Ouse of hormone therapy!!!---------³o¬Ophase I trial®Éªº¤£½T©w¦]¯À! ¤§«eªº·s»D¦³¼g¨ì¹êÅç²Õªº±µ¨ü¹Lhormone therapyªº°ª¹F62.5%©Ò¥Hobi-822¤~·|¦³®Ä-----³o¥y¬O©ñª¯§¾! ¦]¬°placebo²Õªº±µ¨ü¹Lhormone therapyªº¤]°ª¹F61.3%¡A¨â²Õªº±ø¥ó¬O¨S¦³®t²§ªº! ¤§«e¦³°ü²£¬ìÂå¬É¬Y¦Ñ¥X¨Ó©ñ¯¥»¡:scientific¦³®Äªº²Îp¤W¤£¤@©w¦³®Ä!!---¤£ª¾¬O°OªÌ¼g¿ùÁÙ¬O¸Ó¦ÑÁ¿¿ù À³¸Ón˹L¨ÓÁ¿,²Îp¤W¦³®Äªº,Á{§É©Î¬ì¾Ç¤W¤£¤@©w¦³®Ä!!! ¤£n§â²ÎpµL¤Wºõ,²Îp¥u¬O¤@Ó¤èªk,Á{§É©Î¬ì¾Ç¤W¦³®Ä¤~¬O³Ì«nªº!!! |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/6/8 ¤W¤È 10:19:20²Ä 1901 ½g¦^À³
|
Pie¤j ÁÂÁ±zºëÅPªº¤ÀªR!¤×¨ä±z²Îp¤è±ªº±M·~©Ò§@os¤ÀªR,§óÅý¤p§Ì©ñ¤ß³\¦h,·P®¦! °w¹ï±zªº¤ÀªR,¤p§Ì¦³´XÂI¬Ýªk»P±z°Q½×,Y»{ª¾¦³»~,½Ð±z¥H²Îp±M·~¤£§[«ü¥¿! 1Ãö©ó©µ¿ð¤ÏÀ³°ÝÃD¡A¤p§Ì¬Ý¹ÏªíÁöµM8©PigG>160ªº¥u¦³¬ù20%,¦ýigM>160¦³¬ù50%,Y¥HigM¥ý²£¥ÍÀø®Ä,ÀH®É¶¡¸g¹LigG¦Aµo´§Àø®Ä¡C±i¸³¥ý«eªk»¡¶È»¡©ú§ÜÅé4¿¯Ç¤J¦¬®×,¬O§_¬O¤£½×igG¤ÎigM¥un>160³£¥i¯Ç¤J? 2Y§â¹êÅç²Õ¤º°ª§ÜÅé¤ÏÀ³²Õ¤Î§C§ÜÅé¤ÏÀ³²Õ³z¹LÁ{§É³]p¿z¿ï¾÷¨î¤Î³Q§P©w°²©ÊPD¦]¯À±Æ°£(¬Ò¥i¥´§¹¤E°w),¨º»ò¦P¼Ë¹Ï§ÎP16,¦b¹ï·Ó²Õ¤£Åܱ¡§Î¤U,¬O§_°ª§C§ÜÅéPFS¦±½u·|¤j´T«×¦a©¹¥k¤W¤è²¾°Ê? 3¥t¦]¬°2/21,3/31,¤Î6/5¦¤È³õ¤p§Ì³£¦³°Ñ¥[,¥B¦³¤ÏÂÐÅ¥¿ýµÀÉ,¤p§Ì¤£§_»{±i¸³ªº½Í¸Ü¥i¯à·|±aµ¹§ë¸ê¤H¹L«×¼ÖÆ[ªº´Á«Ý,¦ý±i¸³©ó2/21ªk»¡¶È»¡¹ï©ó°Ñ»Pascoªº§â´¤«×¡A¥´¬Ì]¡A²£¥Í§ÜÅé¡A¦³Àø®Ä¬OÅå¤Hªº¡AYµLªk³Q±µ¨ü,¨º§Ú¤]¶^¯}²´Ãè¡A¥t·|«á±µ¨ü³X°Ý¡A¦³´£¨ì¤@¤Á·|¥[§Ö¡A¦ý±q¥¼´£asco¤§«e·|¦³±ÂÅv¡C ¥t3/31°w¹ïascoªº»¡©ú¬O~ Asco¥h¦~¶i¥habstrct¦³5800¦h½g,¿ý¨ú²v3.8%,,¤J¿ï¨ì¤fÀY³ø§iªº«D±`¤Ö¡A³o¹ï§Ú̱N¨ÓÁ{§É©¹«e¨«¦³¨S¦³¤°»òª½±µÃö«Y¡A¥i¥H»¡¦³¤@ÂIÂI°Ó·~»ùÈ¡A¦]¬°Ãn¥ú«×«D±`°ª¡A¦]¬°©Ò¦³¥un¦bÀù¯g¤è±¦³¿³½ìªº¤H³£·|°Ñ¥[¡A¤×¨ä¬O¤jÃļt¤§Ãþªº¡AÁÙ¦³¤@¨Ç¨ä¥Lªk³W³æ¦ìµ¥¡A¤@©w·|¥h°Ñ¥[ªº¡A©Ò¥H³oÓ¬O¦³À°§Uªº¡A¥i¬O§ÚÌ·íªì³]p³Ì¥Dn¥Øªº¤£¬O¥u¬O¦b¬Ý¥Lªº°Ó·~»ùÈ¡A¦Ó¬O¥xÆWªºÂåÃIJ£·~¡B¥Í§Þ²£·~¡A±q¨Ó¨S¦³¥D¾É¹L¤@Ó¥þ²yªº¤j«¬¤T´ÁÁ{§É¡A¤@Ó¤]¨S¦¨¥\¹L¡A¤]¨S¦³¦bascoµoªí¹L¡A§Ú̧Ʊ浥©ó»¡¹ï¥þ²y¥Í§Þ²£·~°µ¤@«Å»}¡A§ÚÌ¥xÆW¦³¯à¤O°µ¤T´ÁÁ{§É¡A³Ð·sªº¥þ²y·sÃÄ¡A¯à°÷¦basco¤W³Q»{¥i¡A¬O¤@Ó«D±`¦nªºµ²ªG¡A¹ï©ó¯f¤H¦³¯u¥¿À°§U¡C´Nµ¥©ó¥xÆW¨«¥X¨ì¥@¬É¥þ²yªº¥«³õ¥h¡A·íªì¬O³o¼Ëªº²z·Q¥h°µ¡A·íµM¹ï§Ṳ́½¥q¨ÓÁ¿¡A¥h¨ºÃäªí²{³Ì«áµ²ªG¥i¥H³Q¥þ²yªº·s»D¬É¡ACNN¤]¦nBBC¤]¦n¡A¯à°÷³øªº¸Ü¨º§ó¦n¡A³o¬O§Ú̧Ʊæ¬Ý¨ìªº¡A²{¦b§Ṳ́]¤£¯à°÷speculate¨ì®ÉÔ·|³y¦¨¦h¤j©Î¨S¦³¦h¤j¤pªº¤@¨ÇÅF°Ê¡A²{¦b¤£«K»¡©ú©Î¹w´ú¡C ·íµM¤p§Ì¤ß¤¤¬O«D±`´Á«Ý¦³¡A·j´M¹L«á¦³¤@½g¦]¨üascoª©ÅvµLªk¤½¶}¤º®e¡A¤£ª¾»Pasco¬ÛÃö³W©w¬O§_¦³Ãö¡A´Á«Ý¯Î°|ªø·|«á¯à®´¨Ó¦n®ø®§¡A¥H¤W¤p§Ì©å¨£¨Ñ±z°Ñ¦Ò! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤W¤È 10:17:03²Ä 1900 ½g¦^À³
|
¯«¯µªº 78% ¬O¥©¦X¶Ü? ²³¤j¤j ±q¹Ïªí11»P17¨â±i§ë¼v¤ùµo²{ 1 ¨ÅÀùOBI822¤@´ÁÁ{§É¸ÕÅçOS 4¦~¦s¬¡²v 78% (27¦ì¨ü¸Õ¦³21¦ì¦s¬¡) ³Ì«á°lÂÜ27¦ì¦³13¦ì(48%)¬¡¹L9¦Ü10¦~ 2 ¨ÅÀùOBI822¥xÆW¤T´ÁÁ{§É¸ÕÅçOS 4¦~¦s¬¡²v 78.05% (112¦ì¨ü¸Õ 87 ¦ì¦s¬¡) ²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) 3´Á¤¤Á`¦s¬¡´Á¡]·N¹ÏªvÀø±Ú¸s¡^4¦~Á`¦s¬¡69.3 %(224¦ì¨ü¸Õ¦³155¦ì¦s¬¡) ÁÙ«ùÄò°lÂܤ¤ (¦³²£¥Í¨¬°÷§ÜÅé»P¥¼¯à²£¥Í¨¬°÷224¦ì¨Ö¦b¤@°_¤ÀªR ) Àù¯g¯f±w»P®aÄݪº²z·QÃĪ«: °ª¥Í¬¡«~½è §C°Æ§@¥Î ¦³®Ä¯àªø´Á¦s¬¡ ¬I¥´¤è«K ·ÓÅU¤è«K °ª¶Q¤£¶QªºÃÄ»ù ¨ÅÀùOBI822 Á`¦s¬¡´ÁOS ¬Û·í¥O¤H´Á«Ý!!! ¥uµ¥³o¤@¶µ ²¢»eªºµ¥«Ý |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/8 ¤W¤È 09:47:58²Ä 1899 ½g¦^À³
|
¤p¹xµ£±z¦n. ³o´N¬O§Ú·Q´£¿ôªº, ¦pªG§Ú·Q¡¨¾É¦V¤@ÓÅý¦Û¤v¤£¶Ë¸£µ¬ªºµ²½×¡¨, SSEAªº³¡¤À§Ú¤]·|¶É¦V±zªº¸ÑÄÀ. ¦ý¬O^¤å¤W, ¯un¨º¼ËÁ¿ªº¸Ü, ª½±µ»¡ ¡§, most patients who have the expression of the similar carbohydrate antigens, SSEA3 and 4 also responded to the vaccine¡¨ ´N¦n°Õ, «ç»ò·|¥Î³o»ò©í¤fªº»¡ªk©O¡H ©Ò¥H³oÃä§Ú´£¿ô¦Û¤vªº, ©ÎªÌ»¡§Ú«Ü§x´bªº,¬O§Ú³Q¹L¥h¾Ç²ß¨ìªº 822ª¾ÃѨî¬ù¤F¡AÁÙ¬O§Ú³Q¹L¥h±µ¨ü¹LªºÄYÂÔ¤åªk°V½m¨î¬ù¤F¡H ¦Ü©ó^¤å¸Ì±ªº ¡§and¡¨, ¦bÄYÂÔ¤åªk¤W, and «e«áªºªF¦èÀ³¸Ón©Ó¸ü¬Ûªñªº¡¨¤ñ«¡¨. ³oÃä«e±ªºmajority,¡@§Ú¦³µ´¹ï§â´¤¡A¥u¬O¹ï©ó§ë¼v¤ù¤W72%¡@ªº¤@ӧήe, ¨S¦³¦AÄ~ÄòÄÄz¤Ï¬M¤ñ¨Ò¡D ¥t¥~¤@Ó§Ú¦³µ´¹ï§â´¤ªº, ¬ORugo ¦pªG¥h¦ÒGMATªº¸Ü, ¤åªk¤À¼Æ¤@©w«ÜÄê¡K. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/6/8 ¤W¤È 09:41:42²Ä 1898 ½g¦^À³
|
¦Ñ´¤j¡A ¤p§Ì·Qªk»Pcliff¤j¤@¼Ë¡A±z¬O¦h¼{¤F¡A³o¨ÇÀ³¸Ó¤£¬O°ÝÃD¡A¤½¥qn¼á²M¤]¤£Ãø ==================================================================== ¦U¦ì¤j¤j¡A ®¥³ß¤j®a¤S®¼¹L¥h¤F¡A¯u²z¶VÅG¶V©ú¡A¬Q¤Ñ1253+¤µ¤Ñ1209±i,°ò¥»¤W¤w¸g§â©P¤@3000±i½æ³æ®ø¤Æ±¼¤F (¦]¬°¦³¨Ç¤H¶^¯}500¤]¤£·Q½æ) ¦p¦P§Ú«e¨â¤Ñ»¡ªº¡A¶^°±®É½æ±o±¼ªº¤£n°ª¿³¤Ó¦¡A©¹©¹³£¬O¬Û¹ï§Cªº»ù¦ì¡A ¦]¬°¯E¹©¯uª÷¤£©È¤õ·Ò¡A¥¼¨Ó¬On¸òªÑ¤ý¤@¨M»Û¶¯ªºÁÞ¤k |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/8 ¤W¤È 09:13:23²Ä 1897 ½g¦^À³
|
¥´°w´N¬O¥´§Üì ³oÃä²£¥Íªº§ÜÅé´N¬O·|»{cancer cellªºSSEA3 SSEA4 Globo H Cancer cell¤Wªº³oÃþantigen ¥i¯à¶q¤£°÷¤Þµo§K¬Ì¤ÏÀ³ ©Î¬O B cellªºpool¤£°÷¤j ©Î¬O clonal selection³Æselect±¼¤F ¤£¹L³o¤£¤Ó«n «ÂI¬O ¦pªG±wªÌ¥»¨ªº§K¬Ì¨t²ÎÁÙºâOKªº¸Ü ²z½×¤W·|²£¥Í§ÜÅé |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/6/8 ¤W¤È 09:02:34²Ä 1896 ½g¦^À³
|
¤pªº¥H¬°: ¦h¼Æªº±a¦³GH§Üìªí²{ªº,¥H¤Îµ´¤j³¡¤À±a¦³SSEA3/4ªº±wªÌ ¥´¶i¬Ì],´N²£¯à§ÜÅé¤ÏÀ³ |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/6/8 ¤W¤È 08:56:04²Ä 1895 ½g¦^À³
|
°Ý°ÝÃD¤j¡G ÁÂÁ±zªº¤À¨É !!! ªº½T,¦pªG§Ú̳£ÁÙ·d¤£²M·¡³Ì°ò¥»ªºªF¦è,®£Äß´N·|½¯©µ,»¡ªº¦n ! ¤pªº¨S¦³Å¥¨ìH.Rugoªºìµ,¦ý´N±z¤À¨Éªº^¤å¦r¥y¤W¨Ó¬Ý,¤pªº»{¬°¦oªº·N«ä most¦b³o¸Ì¬O«üSSEA3,SSEA4§Ü쪺¯f¤H¸Ìµ´¤j³¡¤Àªº¤ñ¨Ò,¦Ó¤£¬O¾ãÓ¸s²Õªº¤ñ¨Ò. The majority of ¦b³o¸ÌÀ³¸Ó¤]¬O«ü²£¥ÍGHªº±wªÌ¤¤ªº¦h¼Æ ©Ò¥HÀ³¸Ó¨ä©Ò³zÅSªº·N«äÀ³¸Ó¤£¬OSSEA3 SSEA4ªº¤ñ¨Ò°ª©óGHªº¤ñ¨Ò magority ¤Îmost¤À§O¥Î¨Ó´yz¨äGH ¤ÎSSEA3/4¤À§O¸Ì±ªº¤ñ¨Ò ³o¬O¤pªº¬Ý±z¤À¨Éªº^¤å,«Üª½Ä±ªº·Qªk,¥i¯à§Ú¬O¿ùªº,Åwªï°Q½× ÁÂÁ±z |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/8 ¤W¤È 08:51:58²Ä 1894 ½g¦^À³
|
°Ý°ÝÃD¤j¤j ·PÁ±zºëªöªº¸Ñ»¡ ·P¿E±zº¡º¡ªº¼ö±¡ ÁÂÁ±z |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/8 ¤W¤È 08:45:05²Ä 1893 ½g¦^À³
|
Ä~Äò»¡©ú, ¦pªG¦]¬°^¤å¥ý¦æµü«ü¦V¤£©úªºÅܼƪº¸Ü, ·|¼vÅTªº¬O - ªí²{¥X¡@SSEA3/4 ªº¯f¤H, ¤ñªí²{¥XGlobo Hªº¦h ¨ä¥Lªº¤£ÅÜ. |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/8 ¤W¤È 08:37:49²Ä 1892 ½g¦^À³
|
¬°¨D¤£»s³y¥t¤@¤è¦Vªº¿ù»~¶Ç»¼, Ä~Äò»¡©ú: The majority of patients has some expression of Globo H, and most patients who have the expression of the similar carbohydrate antigens SSEA 3 and 4, which this vaccine generates immune response to as well. ³o¥y¦b¯Âºé^¤å¤WÅý§Ú·|«O¯dªº¬O, ³oÓ most patients who ªº³¡¤À, ¦]¬°¤f»y³t«×«D±`§Ö, ¤£ª¾¹Dì·N¸Ì±Rugo¤ß¸Ì¦b most patient ©M who ¤§¶¡, ¦³¨S¦³¤@Ó , ªº¦s¦b, ¦]¬°¥y¸q·|¤£¤@¼Ë. ¦]¬°SSEA3/4 ªºªí²{·|¦p¦¹¤§°ª, ¬O©M§Ú¤§«eªº»{ª¾¤£¤Ó¤@Pªº, ©Ò¥H§Ú³oÃä¤]¦A´£¥X¤@¦¸, as a disclaimer. |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/8 ¤W¤È 08:30:24²Ä 1891 ½g¦^À³
|
ÁöµM¬Q¤Ñ¤W¤È¦b(10140527 µoªí®É¶¡2016/6/7 ¤W¤È 12:59:24) §Ú¤w¸gPO¹L¤@¦¸¤F, ¦ýµo²{¤j®aÁÙ¦b°Q½×GloboH, SSAE3/4ªº°ÝÃD, ¨º»ò§Ú¦A¸Ô²Ó¤@ÂI»¡©ú. ¦bASCO presentation ¤W, ·íDr.Rugo Á¿¨ì˼ƲĤG±i§ë¼v¤ù®É, ¦o»¡ªº¬O: ¡§The treatment response, limited in the way I suggested appears to be independent of tumor biologic subtype and Globo H expression levels, but the numbers are quite small. The majority of patients has some expression of Globo H, and most patients who have the expression of the similar carbohydrate antigens SSEA 3 and 4, which this vaccine generates immune response to as well.¡¨ 1. ³o¬q^¤å«Ü²³æ, ©Ò¥H§Ú«Ü¦³§â´¤µ´¹ï¨S¦³Å¥¿ù 2. ^¤å¶W¯Å¦nªººô¤Í, ½Ð¤£nÃhºÃ, ¸Ì±¦³¤@¨Ç¦a¤è¬Ý°_¨Ó¤£¬O§¹¬ü/¥¿½Tªº¤åªk; ¨Æ¹ê¤WÅ¥§¹¾ãÓpresentation §t Q&A, ³o¼Ëªº¨Ò¤l¼h¥X¤£½a. ³o¨Ç¦Ñ¥~·Q¨ì¬Æ»ò»¡¬Æ»ò, ¦ý¬O§Ú¥Î³v¦r½Zªº¤è¦¡¥´¤U¨Ó, ©Ò¥H¤~·|¦³³o¼Ëªº²{¶H. ¦A¨Ó: - ¡§majority¡¨ ^¤å¬O ¡§¦h¼Æªº¡¨ - ¡§most¡¨ ^¤å¬O ¡§¤j³¡¤Àªº¡¨ - ©Ò¥H most > majority, °ò¥»¤W, ¥un¤j©ó50%, ^¤å´N¥i¥H»¡¬O majority, ¨Ò¦p¦pªG¬FÄÒ¿ïÁ|, ¥unŤF¤@²¼, ¤]·|Åܦ¨¦h¼ÆÄÒ (majority party). ¤Ï¹L¨Ó»¡, ¤@ÓªF¦èªº¤ñ¨Ò¦pªG¥u¦³51%, ^¤å¤£·|¥Îmost ¨Ó§Î®e. ©Ò¥H: - ¦b³o¦¸Á{§É, «Ü²M·¡ªº¨Ã¨S¦³§â Globo H ©M SSEA3/4 ²VºÙ - ªí²{¥X¡@SSEA3/4 ªº¯f¤H, ¤ñªí²{¥XGlobo Hªº¦h - ©Ò¥H¤@©w¦³¤£±aGlobo H, ¦ý¬O±a¦³ SSEA3/4 ªº¯f¤H, ¦]¬°³æGlobo H´N¤w¸g72%¤F - ·íµM¤]·|¦³ Globo H, SSEA3/4 ³q³q³£¨S¦³ªº¯f¤H - ©Ò¥H³Ì«áRugo »¡ªº³o¥y´N¬O: ¡§¦h¼Æªº¯f¤Hªí²{¤FGlobo H, ¦Ó¤j³¡¤Àªº¯f¤Hªí²{¤FÃþ¦üªºSSEA3, SSEA4§Üì, ¦Ó³oÓ¬Ì]¦P¼Ë¤]¹ï¥¦Ì²£¥Í§K¬Ì¤ÏÀ³. ¤j®a¼ö¯P°Q½×ªº¦P®É, §Ṳ́]¸Ó´£¿ô¦Û¤v, ¦pªG§Ú̳sRugo §¹¾ã»¡¤F¬Æ»ò³£ÁÙ¨S¦³§¹¥þ´x´¤¤§«e, ´N»{¯uªº°µ¤G¦¸¸àÄÀ/¤ÀªR, ¤T¦¸¸àÄÀ/¤ÀªR, ¦pªG°ò¥»°²³]¤£½T©w, «á±¥i¯àl¥Í¤Ó¤£½T©wªºµ²ªG. ¦Ó¦b³oÓ¹Lµ{¤¤, ¥i¯à¤£¦Ûıªº, §Ú̳£§êºt¤F´²¥¬®£Äߪº¨¤¦â. ³Ì«áÅ¥»¡¥«³õ¤W¦³Ó»¡ªk¬O, ·|«áªºQ&A ¤½¥q³Q´£°Ý¤H¹qÃz¤F, ³o¤]¬OJ»¡¤K¹D. ¤T¦ì´£°ÝªÌªº°ÝÃD, ³£¦b©ó¤F¸Ñ¾÷¨î, ¦³ªº¤H»y®ð¸û«ÈÆ[, ¦³¤@¦ì°ò©ó¹L¥h¸gÅç»y®ð¸û½èºÃ, ¦p¦¹¦Ó¤w. ¨C¤@Ó¦r§Ú³£Å¥¹L¤F, ©Ò¥H¨S¦³¬Æ»ò¹q¤£¹qªº¨Æ±¡, §OJ«ä¶Ã·Q¤F. |
|
|
·|û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2016/6/8 ¤W¤È 08:27:23²Ä 1890 ½g¦^À³
|
«ç»òÁÙ·|¦³¤H°Ý¡y¬°¦ó¨S¦³Globo-Hªí²{¤]¯à²£¥Í§ÜÅé¡zªº°ÝÃD¡C·|³o¼Ë°Ýªí¥ÜÁÙ¤£²M·¡822³oªF¦è¡A¦¹ª©¤w¸g¦³¤£¤Ö¤H»¡©ú 822 ¬O¬Ì]¡AYÁA¸Ñ¬Ì]ªºì²z¡A´N¤£·|°Ý¤Wzªº°ÝÃD¤F¡C ³o¬O°ò¥»¥\¡AY¤@¨Ç°ò¥»ªºª¾Ãѳ£¤£À´ªº¸Ü¡A´NµLªkÁA¸Ñ´CÅ黡ªº¬O¹ï¬O¿ù¡A·íµM¤]¥i¯à¬Ý¤£À´¤½¥q»¡ªº«°T¡A¦b³o¼Ëªºª¬ªp¤U¡A®e©ö¿ù»~ªº²z¸Ñ¥¿½Tªº¸ê°T¡C¤j®an¦h¥Î¥\¡A¤~¯à¥´±Ñ¸U´cªº´CÅé°Ú! ¥t¥~¡A§ÚªººÃ°Ý¸ò £~£~ ªº·Qªk¤@¼Ë¡A¬°¦ó¤£¤½§G NED ªº¤H¼Æ¡A¤@¦ý¤½§G¤§«á´N¯à®ø°£¼Æ¾Ú¤W¦³µLÀø®Äªº²q´ú¡C¥¼´Á¯f¤HÁÙ¯à NED ³o¬O¦óµ¥¾_¾Ñªº·s»D¡C |
|
|
·|û¡GFaFaFa10140966 µoªí®É¶¡:2016/6/8 ¤W¤È 07:36:52²Ä 1889 ½g¦^À³
|
¤£ª¾°¨°º ªºOBI-822 §Z±_Àù¤G´Á¬O§_¦³¹ïSSEA-3 & SSEA-4§ÜÅé°µ¤ÀªR. |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/8 ¤W¤È 07:22:59²Ä 1888 ½g¦^À³
|
¦Ñ´¤j ¤£¥Î«È®ð Åý¤j¤á¤H®aªº±z¦w¤ß §Ṳ́]¦w¤ß Leo¤j ²Îp®Ñ«Ü¦h §Ú¥H«e¬Ýªº³£¬O±Ð¬ì®Ñ ¬ì´¶ªº²Îp®Ñ ¤ñ¸û¦n¤J¤â®@ Cliff¤j «Ü·PÁ±z¬°¤j®a»¡¥X Globo H¤ÎSSEA3/4ªº¥À¤lÃö«Y ¥[±j¤j®a¹ï822Àø®Äªº«H¤ß ¦A¦¸½Ð±Ð±z ¬O§_¦³¨ä¥LÀù¯g§K¬ÌÀøªkªº¤åÄm ¥i¥H¬Ý¨ì§C§ÜÅé¤ÏÀ³¦ñÀH®û¼í±¡§Î¡H·P |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2016/6/8 ¤W¤È 07:14:19²Ä 1887 ½g¦^À³
|
¦¨¤Ñ¦b³o¨Ç¼Æ¾Ú¥´Âà¬O¨S¦³¥Îªº,«Ü²³æ´N¥i¥H¸Ñ¨Mªº¨Æ«ç»ò¤£°µ©O?³oÅý§Ú¦Ê«ä¤£¸Ñ°Ú?¤°»ò¨Æ©O?´N¬O:¥h´ú¨C¤@¦ì¨ü¸ÕªÌ¬Ý¬Ý¦³þ¨Ç¤HNED,§i¶D¥þ¥@¬ÉNEDªº¼Æ¾Ú,¤@¤Áªº¤@¤Á´Nªï¤b¦Ó¸Ñ¤F!«¢«¢«¢!³o»ò²³æªº¨Æ³£¤£°µ«ç»òºâ±M®a©O?±M®a´N¬O¤@°ïÁ¿±o¤fªj¾î¸,ÀY´ßÃa±¼ªº¤H°Õ!«¢«¢«¢«¢«¢! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/8 ¤W¤È 06:50:12²Ä 1886 ½g¦^À³
|
«D±`·PÁ Cliff¤j®¦®vªá®É¶¡»Pºë¯«¡A ¤Þ¸g¾Ú¨å¦a»¡©ú¤Î±À½×¡AÀ°¤p§Ì¸Ñ´b °£¤F·P¿E¤§¥~¡A¤´¬O·P¿E ¦³±z¯u©¯ºÖ ¦A¦¸ÁÂÁ±z ¤]ÁÂÁ¤j®a |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/6/8 ¤W¤È 01:20:57²Ä 1885 ½g¦^À³
|
Cliff¤j.. ·PÁ±zªº¸Ñ»¡,§Ú·|¦A·Q·Q.. °ò¥»±¹ê¤O¯uªº«Ü®t.. ~~~ ©Ò¥H¬Q¤Ñ§Ú¤~´£°Ý¡A¥¼¨Ó¤½¥q·|¤£·|´N§ÜSSEA-3©Î§ÜSSEA-4§ÜÅé°µ¦¸¸s¤ÀªR¡F¦]¬°GH©ÎSSEA-3©ÎSSEA-4ªºÁp¶°·|¶W¹L85%¡C ~~~ ©Ò¿×ªº85%? ¬O§_»P¯Î°|ªø²Ä¤@®É¶¡¦^À³°OªÌ©Ò»¡ªº,¦n¹³¬O.. ¨Ì¥L¬Ý¹L¸Ñª¼¼Æ¾Ú,¯¸¦b§K¬Ì¬Ì]¨¤«×,±q¥¼¬Ý¹L¦p¦¹¦nªº¼Æ¾Ú,¦³80%Àø®Ä. ³o¦³Ãö§_©O? ¬O§_´N¬O¤£¥u¬OGlobo-H,ÁÙ¦³SSEA-3©Î§ÜSSEA-4§ÜÅé,¤~¦³80%¥H¤WÀø®Ä ¥u¬O³o¤@¦¸ªk»¡·|,¥u«]¦b©ó½×¤å¤º®e©Ò¥Dn¨Ì¾ÚGlobo-Hªº50%Àø®Ä,³o¬O¤£§tSSEA-3©Î§ÜSSEA-4§ÜÅé©Ò²£¥ÍªºÀø®Ä.. Y¤TªÌ¥þ³¡¥[Á`¶i¨Ó,´N·|¦³±z©Ò»¡ªº85%¥H¤W ¾Ç¦p¦¹ºë²`¦Ó±M·~ªº°ò¥»±,±`±`¸£³U·|¥´µ²..¯u¬Oªº.. ¯u¤£¦p¬ÝK½u¹Ï,§Þ³N¤u¨ã¦p¦¹§Ö³t¤ÏÀ³.. «u§r..ÁÙ¬O¾Ç²ß¦A¾Ç²ß.. ¯E¹©ª©,¯u¬O»Ýn±z̳o¼Ëªº±M·~¤H¤~,¤£µM,ÁÙ¯uªºµLªkª¾¹D¤½¥q¦b·d¬Æ»ò©N©N.. «¢«¢.. ¯uªº·PÁ±z.. |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/6/8 ¤W¤È 01:01:13²Ä 1884 ½g¦^À³
|
QQ¤j ³oÓ°ÝÃD¦b¥ý«e¯Î°|ªø±µ¨ü³¯©y¥Á¥ß©eªº½è¸ß®É,¯Î°|ªø´¿¸g´£¹L¦b¤@´Á¹êÅ礤,¤w¸gÃÒ¹ê¬O¬Ì]ªº®ÄªG¦Ó«D¦õ¾¯ªº®ÄªG,¤£ª¾³o¬q¸Ü¦³µLÀ°§U ivod.ly.gov.tw/Play/VOD/87769/300K/Y,3-4¤ÀÄÁ¤§¶¡,¦b2002¤@´ÁPANS¤º¦³»¡©ú,¨Ñ°Ñ¦Ò! |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/8 ¤W¤È 12:33:47²Ä 1883 ½g¦^À³
|
Cliff¤j: ÁÂÁ±zªº¦^ÂÐ. ì¨Ó¯u¬O¡¨¦õ¾¯¡¨ , §Ú¦]¹ï³oÂI«Üª°ºÃ, ©Ò¥HµLªk½T»{. ÁÂÁ±z. ¥u¬O¬°¦ón°µ¦¹¤ñ¸û, ¯u¯Ç´e. ¯u¬O¾ÇµL¤î¹Ò, ¯E¹©¤§®üµL²P. ·PÁªu¸ô¦³±z ! ·PÁ²³¦h¯E¤Í¬Û¦ñ ! ¯E§J¤j: ÁÂÁ±zªº¼á²M»¡©ú, ÁöµLªk¥þµM²z¸Ñ, ¦ý«Ü²M·¡±zÅý¦Ñ´¤jªººÃ¼{¤Æ¸Ñ¤F. ¦Ñ´¤j: ±z¦Ñ¦n¦n¥ð®§§a ! ¥u¦³¦nªº¨Åé¤~¯à¦n¦nºÊ·þ³¦ñ¯E¹©ª½¨ì¥´¶i¥@¬É¬×, §OµÛ«æ, ¸ôÁ٫ܪø, ¯E¹©¤w¸g¨«¤F¤Q´X¦~º©º©ªø¸ô, ¦n¤£®e©öÀÆ¥úªì²{, ´NÅý§Ų́£ÃÒ¥Lªº¦¨ªø_§§§a. ¯¬±z©]©]¦n¯v ! «Øcc¤j: ¤£«È, ¥H«á³o´N³Ò¾r±z¤F. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/8 ¤W¤È 12:26:39²Ä 1882 ½g¦^À³
|
µL¤j¥S¡G §NÀR·Q¤@·Q¡u¬°¦ó¨S¦³Globo-Hªí²{¤]¯à²£¥Í§ÜÅé¡v¡H §ÜGHªº§ÜÅé¬O¦p¦ó³Q»¤µo¥X¨Óªº¡H----¦]¬°¥´¤J822¡A822§t¦³GH°Ú¡I³oGH»¤µo±wªÌ²£¥Í¹ï§ÜGHªº§ÜÅé¡C¡]³o§ÜÅé¨Ã«D¥Ñ±wªÌÅ餺Àù²ÓM¤WªºGH©Ò»¤µo¥X¨Óªº¡^ ©Ò¥H°ÝÃD¬O¦b«á±¡G³o¨Ç»¤µo¥X¨Óªº¹ï§ÜGHªº§ÜÅé¡A¦b±wªÌÅ餺§ä¤£¨ìªí²{GHªº¨ÅÀù²ÓM®É¡A·|¤£·|²£¥ÍÀø®Ä¡H§Ú»{¬°¡AY±wªÌÅ餺²£¥Í¹ï§ÜGHªº§ÜÅé®É¡A¤]²£¥Í¤F¹ï§ÜSSEA-3©Î¹ï§ÜSSEA-4§ÜÅé¡A¦Ó±wªÌÅ餺¨ÅÀù²ÓMÁö¤£ªí²{GH¡A¦ý«oªí²{SSEA-3©ÎSSEA-4¡A¨º½Ð°Ý±z·|¤£·|¦³Àø®Ä¡H ©Ò¥H¬Q¤Ñ§Ú¤~´£°Ý¡A¥¼¨Ó¤½¥q·|¤£·|´N§ÜSSEA-3©Î§ÜSSEA-4§ÜÅé°µ¦¸¸s¤ÀªR¡F¦]¬°GH©ÎSSEA-3©ÎSSEA-4ªºÁp¶°·|¶W¹L85%¡C |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/6/8 ¤W¤È 12:06:14²Ä 1881 ½g¦^À³
|
2. ¥HGlobo-H °µ¬°¿Eµo§ÜÅ骺¼ÐÃÑ¡A³o¬O822¦³Àø®ÄMOAªºÃöÁä¤@Àô¡C¤½¥q¤í¤@Ó»¡©ú¡G¬°¦ó¨S¦³Globo-Hªí²{¤]¯à²£¥Í§ÜÅé¡C(¦³¤H²q´ú¬O¦³SSEA-3/-4¡A¦ý°ß¤½¥q»¡ªk¬°·Ç¡^ ~~~~ ¤p§Ì¹ï¦p¦¹±M·~ªºÃöÁä°ÝÃD,¨Ã¤£¬O«ÜÀ´.. ¦ý§Ú¦³¤@Ӭݪk.. ·í¯Î°|ªø»¡,¥un¦³§K¬Ì¤ÏÀ³,´N¦³Àø®Ä¤§»y ·í¤¨l¼Ù·ù¥D»¡,YOBI-822ªºÃĦ¨¥\¨ú±oÃÄÃÒ,§Ú¤@©w²Ä¤@Ó¥ý¥´¤@°w. ¨S¦³Àù¯g¯fªº¤H,«ç¥i¥H¥´¤@°w©O? ¬O§_¬O,¨¤W¨S¦³Àù²ÓM©Î»¡Globo-H§Ü쪺¤H,¤]¥i¥H¥´(°£¤F¥¥°ü¥~) ¨º¦³¨S¦³Globo-Hªí²{¶q©Î»¡¶qªº¤j¤p,³o»POBI-822ªºÃÄ¥´¶i¥h,Åý¨Åé²£¥Í§ÜÅé,¨âªÌ¦³Ãö¶Ü? ²£¥Í§ÜÅé,À³¸Ó¥u¬OÅý¥¿±`²ÓM²£¥Í§ÜÅé,¦Ó¦¹§ÜÅ馳¥D°Ê»{ª¾Globo-HÀù²ÓMªº§@¥Î(¼Ð°O.¼Ð¹v), ¦Ó·|¥D°Ê¦a¥h´M§äÀù²ÓM,¶i¦Ó±þ¦ºÀù²ÓM.. ³o¸ò¥»¨Àù²ÓMªºªí²{¶q¤j¤pÀ³¸Ó®ÉµLÃöªº.. ¤p§Ì°ò¥»±«Ü®z..¤£ª¾³o¼Ë»¡..¹ï§_? §ó¦óªp..³o¥¼¨Ó¬O¬Ì],¬Ì]´N¬O¥i¥H¨Æ«e¹w¨¾,³o»PÅ餺¬O§_¦³Àù²ÓM¦h¹èµLÃö.. ¥u¬O¤@¥¹²£¥Í§ÜÅé,´N·|¥D°Ê´M§äÀù²ÓM¶i¦Ó±þ¦º.. °Ñ¦Ò |
|
|
·|û¡Gpeter12310135866 µoªí®É¶¡:2016/6/7 ¤U¤È 11:57:36²Ä 1880 ½g¦^À³
|
¦Ñ·¨¤j §Ú¤ä«ù§A |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/7 ¤U¤È 11:47:49²Ä 1879 ½g¦^À³
|
²q·Q¤j¤j¡G Q:¡u¦b¨S¦³Globo HªºÀù²ÓM¤W , ¬O§_´N¨S¦³SSEA-3¤ÎSSEA-4?ÁÙ¬O¤]¦³¥i¯à¦s¦b¨âªÌ©Î¨âªÌ¤§¤@?¡v A: SSEA-3³¡¤À¡G ´NGHªº¥Í¦¨¦Ó¨¥¡A¦b¤ºÒÁÞªºSSEA-3ªº¥k±Û¥b¨Å¿}¡]D-galactose¡^ºÝ¥[¤W¤@Ó©¥Ä¦ÁÞ¡]Fucose¡^Åܦ¨¬°¤»ºÒÁÞªºGH¡A©Ò¥HSSEA-3¥i»¡¬O¦³GHªº¥À¿Ë¡C¡]jmcb.oxfordjournals.org/content/early/2010/12/12/jmcb.mjq041/F1.large.jpg ¡^ ±µ¤U¨Ó½Ð¤U¸ü¡uwww.ncbi.nlm.nih.gov/pmc/articles/PMC2575305/bin/supp_105_33_11667__index.html¡v¡F¦A¬ÝùرªºFig.S2¡]¦bPage3 of 8¡^¡C Fig.S2 SSEA-3»PGH¦bìµo¨ÅÀù¤¤ªºªí²{²vªºÃöÁp©Ê¡C¨ú28¦ì¤HÃþìµo¨ÅÀù¼Ð¥»°µ¬y¦¡²ÓM»ö¤ÀªR¡AÅã¥ÜSSEA-3(+)²ÓM¼Æ/Total tumor cell»PGH(+)²ÓM¼Æ/Total tumor cell¡A¨âªÌ¦bPearson correlation coefficient analysis¤§¤U¡ASSEA-3»PGHªºªí²{²v§e²{ÅãµÛ¬ÛÃö©Ê¡C ©Ò¥Hì«h¤WÀ³¸Ó¦³SSEA-3ªº¨ÅÀù²Õ´´N§t¦³GH¡C¡]¬O«ü¨ÅÀù²ÓM¡A¤£¬O«ü¨ÅÀù·F²ÓM¡^ ¦A¨Ó¡A¬ÝTable.2¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC2575305/table/T2/ ¡^¡C ¦b11¥óGH(-)ªº¤HÃþ¨ÅÀù¼Ð¥»ùØ¡A¦³6¥ó¡]54.5%¡^¬OSSEA-3(+)¡F ¦b17¥óGH(+)ªº¤HÃþ¨ÅÀù¼Ð¥»ùØ¡A¦³16¥ó¡]94.1%¡^¬OSSEA-3(+)¡A¨Ã¥¼¹F100%¡C ©Ò¥H¯à¤£¯à»¡¡G¤£ªí²{GHªº¨ÅÀù²ÓM¡A¦³¥i¯à·|ªí²{SSEA-3¡H·|ªí²{GHªº¨ÅÀù²ÓM¡A´X¥G³£·|ªí²{SSEA-3¡H ³o¼Ë»¡ªºª¼ÂI¬O¥H¤Wªº¼Ë¥»¼Æ«Ü¤Ö¡FÁÙ¦³Àù²ÓM²Õ´¤Á¤ù©Ò§@ªº¬V¦â¤ÀªR¡A»PÀù¯g±wªÌ¬¡Åé¤Wªºªí²{¦³¨S¦³¸¨®t¡H¨Ñ±z°Ñ¦Ò¡C SSEA-4ªº³¡¤À¡G¯Ê¥F¬ã¨s¸ê®Æ¡AµLªkµû½×¡C QQ¤j¡G ¡u¡uAdditional studies are planned to further explore efficacy of OPT-822/821 in patients who generate a immune response.¡v³o¥y°á§¹¦oÄò±µ»¡¡uand compared those with seen in adjuvant alone.¡v §Úªº¬Ýªk¬O¡uÁÙ·|pµe¶i¤@¨B±´°Q¤ñ¸ûª`®gOPT-822/821¦Ó²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ»P¥u¥´¦õ¾¯ªº±wªÌªºÀø®Ä¡v ¦Ñ´¤j¡G 6/5»¡©ú·|¤¤´£¨ì¡A¤½¥q¤w°µ¥X«Ü¦h²Õªº¤ÀªR¡A¦]¬°Dr.Rugo¥u¬D¿ï¨ä¤¤ªº´X¶µ°µ¬°ASCO³ø§i¥Î¡A¥¼¨Ó¤½¥qÁÙ·|Ä~Äò°µ²Ó¶µªº¤ÀªR¡A¨ä¤¤¤]¥]§t§Ú©Ò´£°ÝªºSSEA-3 Ab¡BSSEA-4 Ab titer»PÀø®Äªº¤ÀªR¡C ¤p§Ì»{¬°goodness of fit¤£¬O°ÝÃD¡C±z¥ý¥ð®§§a¡A¨¯W¤F¡I ¡]www.cde.org.tw/Content/Files/Knowledge/b0801107-dd21-41ef-8c7d-4c6c2edf1bd7.pdf ¡^ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤U¤È 11:42:34²Ä 1878 ½g¦^À³
|
½Ñ¦ì¤j¤j«e½ú¡G ¤p§Ì¦b¦¹¸Û¼°ªº·PÁ¤j®a¡AÁÂÁÂ...¦AÁÂÁ¡C ·í¯E¹©ªºªÑªF¦bªÑ¥«¤W¯uªº¤]¬O³Ð·sªº§é¿i¡A¦b¦¹¾Ç²ßªñ¦~¤F¡I ½Ñ¦h¤j¤jªºµL¨p»PµLÀvªº©^Äm¡A¦p¦¹¤j·R¯u¤w¬O¥xÆW¤Ö¦³ªº©_ÂÝ¡A¤]»â¥ý¯E¹©ªº³Ð·s³Ð³y¤F¡I ·PÁ±zÌ¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤U¤È 11:33:36²Ä 1877 ½g¦^À³
|
¦Ñ´¦Ñ¤j¤j«e½ú¡G ±z¦Ñ´N®ø®ø®ð§a¡I ¤p§Ì¬O»{¦P±z½|ªº«Ü¦³¹D²z...¯E¹©¸gÀçºÞ²z¬O¦³«Ü¦h»Ýn¦A§V¤Oªº¦a¤è¡C ¸Ñ¹a¤]¬O²×»Ýô¹a¤H¡A³o¯E¹©½T¹ê¤]³dµL®Ç¶U¡C ¤½¥qªñ¤ë¥H¨Ó¡A¨Æ¹ê¤]¯un±¹ï³B²z¤Ó¦h¨Æ±¡¡C ¥H¤@®a¤pªº·s¤½¥qn¦P®É±¹ï³B²z¨º»ò¦h...·s¸IIJ¨ìªº·s¨Æ°È»P¸gÅç...¹Î¶¤³£¨Ó¦Û¥|¤èªº·s²Õ¦X¦bÀq«´¤W¡A¯u¤]µu®É¶¡¤W¤£¤Ó¥i¯à«´¦Xªº¤Ó§¹¬ü¡C ±z¦Ñ´N¥ý®ø®ø®ð¡A¦Aµ¹¥L̤@ÂI®É¶¡§a¡I |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/6/7 ¤U¤È 11:30:03²Ä 1876 ½g¦^À³
|
¦Ñ·¨¤j ªø´Á³B¦b¦åÀ£öt°ª±¡ªp ¹ï¨Å餣¤Ó¦n «¢«¢«¢ Y±z¦³·sµo²{ ¤p§Ì§ÖÀ°±zÂàµoµ¹¤½¥q ¤p§Ì¥´Âø¤u§@¤@§â¸n°Ú ¦U¦ì¤j¤jYµo²{¤½¥q¦³¨ÇºÃ¼{°ÝÃD ¦bÃÄ«~ÁÙ¨S¤W¥«®É°Q½×«á§Ö¥áµ¹¤½¥q ²¦³ºY¬O·sÃĤW¥««á¤~µo²{°ÝÃD »´ªº¼vÅTªº¥i¬O¤½¥qªº¸gÀ給²¤ ÄY«ªº¬O¼vÅT¤½¥qÄvª§¤O ²{¦b´N·í½m½m§L§a ¼vÅTªº¬O«H¤ß¸òªÑ»ùªºªi°Ê ¤½¥q³o2.3Ó¤ë±oÀ³¥I¥xÆW°¸é ÁÙ¥~¥[¦Û¤vªº¤@¨Ç²¨©¿ §O§Ñ¤F°ª¼h¥þ³Q¦C³Q§i(¶W§è) ¤½¥q°ª¼h¯h©ó©b©R ´N·í½m½m»L¤O§a~ QQ¤j ·PÁ«¢(¤p§Ì³£´À¦Ñ·¨¤j«æ¤F) |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/6/7 ¤U¤È 11:16:36²Ä 1875 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¤j§A¦n, ÁÂÁ§A ¦³§A¯u¦n ·PÁ ·PÁ ·PÁ |
|
|
·|û¡G¸Û¤ß10142309 µoªí®É¶¡:2016/6/7 ¤U¤È 11:10:35²Ä 1874 ½g¦^À³
|
¤p§Ì»{¦P¯E§J¤jªºÆ[ÂI |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/6/7 ¤U¤È 11:10:19²Ä 1873 ½g¦^À³
|
¦Ñ´¤j:¨¯W¤F!½Ð¦ÂI¥ð®§!6/27¤]¨S¨º»ò»·~©ñ§¹ºÝ¤Èªø°²´N«Ü±µªñ¤F!¥[ªo!!! |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/6/7 ¤U¤È 11:10:15²Ä 1872 ½g¦^À³
|
¯E§J¤j ¸Ñª¼¯u¬O¤@ªù¤j¾Ç°Ý ¤£ª¾§A¦³¤°»ò²Îp¾Çªº®Ñ±ÀÂ覆 ³oÓ²Îp¸ê®Æ¬O§_¥i¥Hª½±µ§ï¥Ñµ{¦¡¨Ó¶] ·PÁª©¤W½Ñ¦ì¯«¤H¦b³oÃä¥u¾É²³¤H |
|
|
·|û¡Gpeter12310135866 µoªí®É¶¡:2016/6/7 ¤U¤È 11:04:34²Ä 1871 ½g¦^À³
|
¦Ñ·¨¤j µ¹§A100ÓÆg |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/7 ¤U¤È 11:04:19²Ä 1870 ½g¦^À³
|
·PÁ¯E§J¤j,¤@¨¥Åå¿ô¹Ú¤¤¤H! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤U¤È 11:02:24²Ä 1869 ½g¦^À³
|
¦Ñ´¥S ¬°¤F¯E¹©¥¼¨Óªº¦¨ªø_§§,¥Î¤ß¨}W ¬°¤F¤½¥q¦n ³o¨â½g²Îp¤ÀªR À³±Hµ¹¤½¥q ¦Ü©ó¬O§_§R°£ ¦p¦Ñ´¥S¦³©ÒÅU¼{ ¼vÅTºÎ¯v ²¦³ººô¸ô¥@¬É ¸ê°T«Ü®e©ö¸¨¤J¦³¤ß¤H¤§¤â §R°£µL¥i«p«D |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/7 ¤U¤È 11:02:06²Ä 1868 ½g¦^À³
|
¦Ñ´¤j ©êºp ¥i¯ànÂI¿ô±zªº«ä¦Òª¼ÂI 1. responders²Õ¤£¬OÀH¾÷±q¹êÅç²Õ©â¨úªº¡A¬O¥ß·N¨ú¼Ëªº¡A¥»²Õ¥i¯à´N¤£¨ã¥À¸s¥Nªí©Ê¡A²Îp¤W¤£»ÝnÀËÅçresponders²Õ¸ò¹êÅç²Õ¬O§_¦P½è©Ê(Homogeneity)(±z»¡¾A¦X«×¤]¦æ)¡C 2. ¦ÒÅçresponders²Õ¸òPlacebo²Õ¤§Àø®Ä¡A¬O¥ÎCox model, ©Îproportional hazard model¦ÒÅç¡AÅãµÛ»P§_¡A¨äµ²ªG±À½×¥»¨Ó´N¤£À³¸ÓÂX¤j±À½×¨ì¥ß·N¨ú¼Ëªºresponders²Õ©ÒÄݪº¹êÅç²Õ¡A¥u¯à¤Î©ó²Å¦Xresponders²Õ°ò¥»¯S¼xªº¥À¸s¡C¥B¤wª¾¹êÅç²Õ¤£¬O¥þ¦³®ÄªG¡A®Ú¥»µL»Ý¦h¦¹¤@Á|¦ÒÅçresponders²Õ¬O§_¦P½è©Ê¡C 3. ÀËÅçresponders²Õ¸òPlacebo²Õ¤§HRÀø®Ä®t²§¬O§_¬°¯u¹ê¤£°²¡A¤£¬O¬Ý¼Ë¥»¬O§_²Å¦X±`ºA©Î¬Y±Ú¸sªº¯S¼x¡A¦Ó¬OnÀËÅç¼Ë¥»¯S©Ê©Î¼Æ¾Ú¯S©Ê¬O§_²Å¦XCox modelªº°²©w¡CCox model¦³³\¦h¤ÀÃþªº²Îp¼Æ²z¼Ò«¬¡A¤£¬O³£n±`ºA¤À¥¬©Î²Å¦X¬Y±Ú¸sªº¯S¼x¡C |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/6/7 ¤U¤È 09:03:09²Ä 1867 ½g¦^À³
|
§¹¥þ¦P·N§Þ³N¤j!~§Æ±æ¤j®a¦hµ¹¤½¥q¤@ÂI¹ªÀy,¤Ö¤@¨ÇV³d! ¥t¥~§â2/19¥H«á¤½¥q©Ò¦³ªº¦^À³©ñ¦b¤@°_¬Ý,µª®×¤£¬O¤w¸g«Ü²M·¡¤F¶Ü?6/5¸¹ªº¨â³õªk»¡·íµM«n,¦pªG¦A§â3¤ëªº§ë¸ê»¡©ú·|¤º®e©ñ¦b6/5«á±!µª®×´N¬O***´N¬O±µ¤U¨Ó¤@¤Á³£·|«Ü§Ö***!!! |
|
|
·|û¡G§Þ³N¤ÀªR¬£10139654 µoªí®É¶¡:2016/6/7 ¤U¤È 08:21:06²Ä 1866 ½g¦^À³
|
¦Ñ´¤j´£¨ì°ò¥»ªº²Îp°ÝÃD ¤p§Ì¤]»{¬°«Ü«n ¨S¦³³o¨Ç°ò¦«h«áÄò¬ã¨s¬OµL·N¸qªº ¦ý¤p§Ì¦³¥t¤@ºØ¬Ýªk ¤½¥q·|¤£·|»{¬°¥Ñ©ó³o¨Ç¬O°ò¥»ªº²Îp°²³] ©Ò¥H¨S¦³¦b±M®a·|ij¤¤§¹¾ã§e²{¥X¨Ó©O? ¤@¯ë§ë½Zconferenceªº¤å³¹ ³q±`·|¦³¶¼Æ½g´Tªº¨î Y¨S¦³§R°£°ò¥»ªº²Îp°²³]ÀË©wµ²ªG ¥ç©Î¬O±Nrobust test¬Ù²¤ «h¥i¯à·|¥e¥Î¤F쥻·Qªí¹Fªº¤º®e«ÂI ªp¥B³ø§i¥u¦³µuµu12¤ÀÄÁªº®É¶¡ «ç»òÁÙ·|¦³®É¶¡´£¨ì°ò¥»ªº²Îp¼Æ¾Ú©Î¥»¨Ó´N¸Ó²Å¦Xªº°²³]°ò¦? ´N¹³ªÑ¥«±`¥Îªº®É¶¡§Ç¦C¸ê®Æ¤@¼Ë ¤ÀªR¤§«e»Ý±´°Q¸ê®Æ¬O§_¬°©wºA(Stationary) ¦pªGª½±µ¶i¦æ«D©wºAÅܼưjÂk¤ÀªR ±N³y¦¨µê°²°jÂk(Spurious Regression)µo¥Í ©Ò¥H¥²»Ý¶i¦æ³æ®ÚÀË©w(Unit Root Test) ¦ý³o¼ËªºÀË©w¦b¬ã°Q·|ªºµoªí¤W³q±`¬O³Q¬Ù²¤ªº ¤p§Ì¤£²M·¡¬O¤£¬O³o¼Ëªºì¦]¦Ó¨Sªí¹F¦Ñ´¤j·Qª¾¹Dªº°ÝÃD ¦ý½Ð¦U¦ì¯E¤Í̦h¨Ç@¤ß ¤p§Ì»{¬°¦¹¦¸ªº¤U¶^¬O¸ê¥»¥«³õÀ³¦³ªº¤ÏÀ³ º¦¦h¦^Àɥ𮧦A¦ÛµM¤£¹L¤F ¤£¸Ó¹L«×²o³s¦Ó©Ç¸o©ó¯E¹©°ª¼h©Î±Ð¥D °£«D¤½¥q¯uªº¦³¸Û«H°ÝÃD ¤£µM¸ÓÁÙµ¹¯Eôªº¤½¹DÁÙ¬O·|¨Ó ¥u¬O®É¶¡ÁÙ¨S¨ì¦Ó¤w ¤j¹Ù¨à¥[ªo! |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/6/7 ¤U¤È 07:07:47²Ä 1865 ½g¦^À³
|
¤é¡@¡@´Á¡G2016¦~06¤ë07¤é ¤½¥q¦WºÙ¡G¯E¹© (4174) ¥D¡@¡@¦®¡G§ó¥¿¯E¹©105¦~6¤ë5¤éªk¤H»¡©ú·|²³ø¤º®e µo¨¥¤H¡G¶À¨q¬ü »¡¡@¡@©ú¡G 1.¨Æ¹êµo¥Í¤é:105/06/07 2.¤½¥q¦WºÙ:¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:§ó¥¿¥»¤½¥q105¦~6¤ë5¤éªk¤H»¡©ú·|²³ø¤º®e 6.§ó¥¿¸ê°T¶µ¥Ø/³øªí¦WºÙ:105¦~6¤ë5¤éªk¤H»¡©ú·|²³ø 7.§ó¥¿«eª÷ÃB/¤º®e/¶¦¸:ºKn»Pµ²½×¡GªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo H ªí²{¶qµLÃö/²Ä21¶¡C 8.§ó¥¿«áª÷ÃB/¤º®e/¶¦¸:ºKn»Pµ²½×¡GªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo H ªí²{¶q¨S¦³¬ÛÃö©Ê/²Ä21¶¡C 9.¦]À³±¹¬I:ì²³ø²Ä21¶¤º®e^¤å¡¨Independent¡¨À³Ä¶¬°¡¨¨S¦³¬ÛÃö©Ê¡¨¥HÁקK½Ñ¦h»~¸Ñ¡C ³¡¤À´CÅé¤Î³ø¾ÉÄY«»~¸Ñ¥»¤½¥qªvÀø©Ê¨ÅÀù¬Ì]OBI-822¬ã¨sµ²½×¡A«üªvÀø¤ÏÀ³»P±wªÌ Å餺Globo Hªºªí²{§¹¥þµLÃö¡A¨Æ¹ê¥¿¦n¬Û¤Ï¡COBI-822¬O¥HGlobo-H¬°¼ÐÃѧÜì³]pªº ¬Ì]¡A¸Ó¬ã¨s¤wµý¹ê¡AOBI-822ªºªvÀø¤ÏÀ³¡A»P¬O§_ªí²{Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê¡A¦ý¸g OBI-822ªvÀø«á¥i²£¥ÍGlobo-H§ÜÅé¡A¦Ó¦³§ÜÅé¡A´N¥i²£¥ÍÀø®Ä¡F¥B§ÜÅé¿@«×¶V°ª¡AÀø®Ä ´N¶V¦n¡C 10.¥LÀ³±Ô©ú¨Æ¶µ:µL ============ ¯E¹©§ó¥¿«á¡A½T¹ê¤ñ¸û®e©ö²z¸Ñ¤F¡C¤p§Ì¦³¨âÓ·P·Q¡G 1. ³y¦¨§ë¸ê¤Hªº»~¸Ñ¡A¬O¤½¥qªº¿ù¡I¤£¯à²o©ì´CÅé¡C§Æ±æ¤½¥q°O¨ú±Ð°V¡C 2. ¥HGlobo-H °µ¬°¿Eµo§ÜÅ骺¼ÐÃÑ¡A³o¬O822¦³Àø®ÄMOAªºÃöÁä¤@Àô¡C¤½¥q¤í¤@Ó»¡©ú¡G¬°¦ó¨S¦³Globo-Hªí²{¤]¯à²£¥Í§ÜÅé¡C(¦³¤H²q´ú¬O¦³SSEA-3/-4¡A¦ý°ß¤½¥q»¡ªk¬°·Ç¡^ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/7 ¤U¤È 05:30:07²Ä 1864 ½g¦^À³
|
«Øcc¤j: ¤w°e¥X. |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/6/7 ¤U¤È 05:13:03²Ä 1863 ½g¦^À³
|
·PÁÂQQ¤j ¬O§_¯à¥ý±N¦Ñ·¨¤jªº°ÝÃDµoµ¹¯E¹©µo°Ý¥¥x Åý¯E¹©´£¦¦]À³ §K±o6/27Á{®É´£°Ý ¯E¹©¦]À³¤£«æ~ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/7 ¤U¤È 05:09:17²Ä 1862 ½g¦^À³
|
¦Ñ´¤j: ¦¬¨ì !!! ±z´N¥ý±N¤ß©ñ¤U, §O®ð§O«æ¤F. µ¥¨ì®É¤@©w±N±zªº´£°Ý, ¤@¦r¤£º|´£¥X. |
|
|
·|û¡G¦p¤Û¼v10141583 µoªí®É¶¡:2016/6/7 ¤U¤È 05:06:01²Ä 1861 ½g¦^À³
|
¦Ñ´¤j¡G ±zªº´£°Ý¤Ó«n¤F¡A¥¿¦p±z©Ò»¡ªº¡u¤@ӳ̰ò¥»ªº²Îp°ÝÃD,¦ý¬O«o¥i¥H±À½©Ò¦³ªº¦¨ªG,©ÎªÌ¥´Áy©Ò¦³ªº½èºÃ!¡v¡C ¤p§Ìªº«Øij¡A³o»ò«nªº°ò¥»²Îp°ÝÃD¡A¦³³Ò±z¤j¤H¡A¬O§_ª½±µ¥Îemail ±Hµ¹¯E¹©±i¸³¨Æªø¥»¤H¡C¦pªG¦bªÑªF·|¤W´£¥X¨Ó¡A¦p¦^µª»¡¦A¬ã¨s¡A¨º«áªG¦p¦ó¡H¡H¡H¡H¡K¡K ¦n¤[¨Sµ¹±z½Ð¦w¤F¡A¯¬±zºÖ¼z¶êº¡ ªüÀ±ªû¦ò! |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/7 ¤U¤È 04:47:04²Ä 1860 ½g¦^À³
|
¦³¤H°Ý¦³Àø®Ä¬°¦óÁÙ·|¦º? ²¦³º¤£¬O¥P¤¦§r...... ¦Ü©ó¦Ñ´¤jªº°ÝÃD¯uªº¬O²Îp¾Ç¤W«Ü«nªº°ÝÃD subgroup¯à¤£¯à¥Nªí¾ãÓgroup |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤U¤È 04:28:23²Ä 1859 ½g¦^À³
|
¤p©_¤j«e½ú¡G ÁÂÁ±z...³o¯uªºÀ³ÃÒ¤F2/22¶ÀÁ`©Ò¨¥ªºPFS¬O¦³®Äªº¡K¤j®a¦bASCO´N¬Ý±o¨ì¡C ¬Û«H¤T´ÁÁ{§É³]p¥¿½T«á¡A¸Ñª¼®É´N¯u¤j®a¶}¤ß¡A¶}¶}¤ß¤F¡I ·PÁ±z¤]Ãh©À±z¡C |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/7 ¤U¤È 04:18:34²Ä 1858 ½g¦^À³
|
·PÁÂ¥xÁÞ¤j,¦V«e¤j,QQ¤j,²q·Q¤j,pie¤j¥H¤Î¦U¦ì¤j¤jªº·N¨£. ¥t,²q·Q¤j,¦Ñ´ªº°ÝÃD©|¥¼±o¨ì¸Ñµª,Global H¬O¤£¬OGlobal H series(¥]§tSSEA3,SSEA4)¨Ã¤£¬O¦Ñ´ªº°ÝÃD ½ÐQQ¤j°È¥²¥N°Ý:¤@ӳ̰ò¥»ªº²Îp°ÝÃD,¦ý¬O«o¥i¥H±À½©Ò¦³ªº¦¨ªG,©ÎªÌ¥´Áy©Ò¦³ªº½èºÃ! ¬Q¤Ñ¤Ó±ß¥´¶ßºÎ¼gªº,¤µ¤Ñ¦A«¼g²M·¡¤@¦¸,«á±·|¦A¸ÑÄÀ,¦³¿³½ìªº¤j¤jn¥J²Ó»{¯u¬Ý~~ °ÝÃD:¥H¤U´XÂI¦³¨S¦³°µgoodness of fit(¾A¦X«×ÀË©w) 1. ¥´§¹¤E°wªº¹êÅç²Õ104¤H©M¹ï·Ó²Õ124¤Hªº©Ò¦³ÄÝ©ÊÁÙ¦³¨S¦³©MP-11ªºbaseline characteristics ¤@¼Ë,§¹¥þ¨S¦³®t²§? 2. ¥´§¹¤E°wªº¹êÅç²Õ104¤H¯à¤£¯à¥Nªí¹êÅç²Õ224¤H?¦³¨S¦³°µgoodness of fit(¾A¦X«×ÀË©w)? 3. responderªº112¤H©M¹ï·Ó²Õ124¤Hªº©Ò¦³Äݩʦ³¨S¦³©MP-11ªºbaseline characteristics ¤@¼Ë,§¹¥þ¨S¦³®t²§? 4. responderªº112¤H¯à¤£¯à¥Nªí¹êÅç²Õ224¤H?¦³¨S¦³°µgoodness of fit(¾A¦X«×ÀË©w)? ¬°¤°»òn°Ý³o¨Ç°ÝÃD? ½Ð¦U¦ì¤j¦A¦n¦n¬Ýp-11ªºbaseline characteristics,©Ò¿×ªºRCT study´N¬O«OÃÒ¨â²Õ³Q¿ï¨ìªº¾÷²v¬O¤@¼Ëªº, ¦ý¬O¨Ã¤£¯à«OÃÒ,¨â²Õ¶¡©Ò¦³ªºÄݩʳ£·|«Ü±µªñ,OBI-822«Ü©¯¹B,¨â²ÕªºÄݩʳ£¨S¦³®t²§,³o¤@ÂI«D±`«n,¦] ¬°³o¥i¥H«OÃÒ±N¨Óªºµ²ªG¤£¨ü¥ô¦óÄݩʪº¤zÂZ!!!¤]´N¬O»¡,¦pªG¹êÅç²ÕªºPFS¤]¦n,OS¤]¦n,Àu©ó¹ï·Ó²Õ®É, ****¨Ã¤£¬O¦]¬°¥H¤UÄݩʪº¤H¦b¹êÅç²Õ¦û¤ñ¸û¦hªºÃö«Y***** ¤ñ¸û¦~»´ªº¯f¤H,±q¤p¦Y¤H°Ñªø¤jªºÁú°ê¤H,ECOG0ªº¯f¤H,stage I at initial Dx.ªº¤H, time from first Dx.&first meta. Dx. to day1ªº®É¶¡¸ûµu,n. of progression after metal Dx.¸û¤Ö, ¤T³±©Êªº¸û¤Ö,¥´¹Lhormone therapyªº¸û¦h,Global H positiveªº¸û¦h.....µ¥ ¦P¼Ëªº¹D²z,¦pªGn±q¤¤©â¬Y¤@Ósubgroup¥X¨Ó,¦pªG¹êÅç²ÕªºPFS¤]¦n,OS¤]¦n,Àu©ó¹ï·Ó²Õ®É,§A¥²¶·n¦A°µ ¤@¦¸subgroupªºÄݩʪºÀË©w,Áٯण¯à¥Nªíì¨Óªº224¤H©M¹ï·Ó²Õ¤@¼ËªºÄݩʨS¦³®t²§! n¨S¦³®t²§,©â¥X¨Óªºsubgroupªºµ²ªG¤~¬O¥i«Hªº,¨S¦³¤zÂZ¦]¯Àªº,¨S¦³°¾¨£ªº,¨S¦³¨è·Nªº!!!! ¦³´XÓÄݩʦ³®t²§¤]¨S¦³Ãö«Y,¦ý¬O¦bºâ¸Ósubgroup©M¹ï·Ó²ÕªºPFS&OS®É,¦³´XÓÄݩʦ³®t²§´Nn§â´XÓ¤]¦Ò ¼{¦¨¤zÂZ¦]¯À,¤@°_pºâ¥X¨Óªºµ²ªG¤~¬O¯u¥¿ªº¸Ósubgroup¬O§_Àu©ócontrol groupªºµ²ªG!!! ¤£nÅý¯E¹©¦A°jÁ׳oÓ°ÝÃD!¤£nÅý¯E¹©¦A°jÁ׳oÓ°ÝÃD!¤£nÅý¯E¹©¦A°jÁ׳oÓ°ÝÃD! ¤@ӳ̰ò¥»ªº²Îp°ÝÃD!¤@ӳ̰ò¥»ªº²Îp°ÝÃD!¤@ӳ̰ò¥»ªº²Îp°ÝÃD!---«o¥i¥H¸Ñ¨M©Ò¦³°ÝÃD!!! ¨S¦³³oÓµª®×,§A¤@¦AÁ¿¤°»ònon responder¸ÌÁÙ¦³1:80,1:40,only IgM,non IgG&IgM¤°»òªº,³£¨S¦³·N¸q! ¨S¦³³oÓµª®×,§A¤@¦AÁ¿¤°»ònon responder¸ÌÁÙ¦³1:80,1:40,only IgM,non IgG&IgM¤°»òªº,³£¨S¦³·N¸q! ¨S¦³³oÓµª®×,§A¤@¦AÁ¿¤°»ònon responder¸ÌÁÙ¦³1:80,1:40,only IgM,non IgG&IgM¤°»òªº,³£¨S¦³·N¸q! ¦pªG¦´N°µ¦n¤FÀË©w,³o»ò°ò¥»¤S³o»ò«nªº¤@±iªí¬°¤°»ò¤£¦bASCO¨q¥X¨Ó?¬°¤°»ò¤£¨q¥X¨Ó?¬°¤°»ò¤£¨q¥X¨Ó? ¬O¨S¦³°µ?¬O¨S¦³°µ?¬O¨S¦³°µ? ÁÙ¬O¤£´±¨q?ÁÙ¬O¤£´±¨q?ÁÙ¬O¤£´±¨q? No excuse!No excuse!No excuse! p-11ªºbaseline characteristics´N¬O±N¨Ó³o½g½×¤åµoªí®ÉªºTable1,°w¹ïRCT½×¤å,Âå¬É¦³©Ò¿×: ¤º¦æªº¬ÝM&M (§÷®Æ»P¤èªk)and table1´N¬O³o»ò¨Óªº! ¦A¦¸ÁÂÁÂpie¤jªº«ü¥¿,¬Q±ß¯uªº¤Ó²Ö¤F,¦Ñ¤H¥H«e³£¬O10ÂIºÎ,¶R¤F¯E¹©«á³£11:30ºÎ,¬Q¤ÑÁÙ¥¢¯v¤F,ü! ³o»ò¤jªº¤½¥q,Á¿Ó³ø§i·dªºº¡«°·«B,¯u¬Oªº! 5619¤j,P-18 forest plot(´ËªL¹Ï)¥u¦³¦P¤@Äݩʪº¨â²Õ¥ª¥k¤ñ(¦presponder better or non responder better) ¤£¥i¥H¤W¤U¤ñ(¦pGlobal H negative&Global H positive) ¦n¤ß¤j,§Aªº°ÝÃD¤]¦bp-11ªº¥k¤U¨¤:72% of those tested in study group and 70% of those tested in control group! |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/7 ¤U¤È 04:14:41²Ä 1857 ½g¦^À³
|
©IÀ³¹Ç§AÅó±ø±ø¤jªº»¡ªk ¤HÃþ¤Æ¾ÇÃÄ/³J¥Õ½èÃÄ/¤p¤À¤lÃĤw¸gµo®i¦h¦~¡A´X¥G¤w¸g¨ì¤F·¥ÁÞ¤À¤lÃıN±µÄò«á¨Óªºµo®i«¥ô-----¡Ö ²{¦b§ÜÃÄ©Ê«ÜÄY«¡A«Ü¦h«á½u§Ü¥Í¯Àªº§Ü¥Í¯À§ÜÃÄ©Ê°ò¦]¤@ª½¥X²{¡A¹ï©ó¯S§O¬O¦b°|¤º¥[Å@¯f©Ðªº«¯g¯f¤Hªº«Â¯Ù«Ü¤j¡A¤]¬O³y¦¨°|¤º·P¬VP¦ºªº«nì¦] ¦Ó§Ü¥Í¯Àªº¬ãµo ¤@ª½µLªk¦³¬ð¯}©Êªº¶i®i ´dÆ[ªÌ»{¬° µLÃÄ¥i¥Îªº®É¥N§Y±N¨ÓÁ{ ¦ý²Óµßªí±¨¤W ¤]¦³«Ü¦h¤HÃþ²ÓM¨S¦³ªºÁÞ¤À¤l³J¥Õ °w¹ï³o¨ÇÁÞ »s³y¥X ¦³®Äªº¬Ì]©Î§ÜÅé ³£¬O¸Ñ¨M§ÜÃÄ©Ê©Ò³y¦¨µLÃÄ¥i¥Îµ~¹Ò ³o¤]¬O¯E¹©¥HÁÞ¤À¤l¬Ì]§Þ³N¥t¤@Ó§Q°òÂI ©Ò¥H Àµ½Ð·|¥X®u6/27ªº¤j¤j °Ý¤@¤U¤½¥q¹ï³o¤è±¬O§_¦³µÛ¾¥©Î¬O³W¹º©O¡H sa.ylib.com/MagCont.aspx?Unit=featurearticles&id=2428 ¡½¥Ø«eÁÞÃþ¬ã¨s¤w©MÀù¯g¡B¬y·P¤Î§ÜÃĩʲӵߪº°»´ú»PªvÀø¦³Ãö¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤U¤È 04:14:37²Ä 1856 ½g¦^À³
|
¤p·s¤j slide ²Ä17¶MOS¤ÀªR,n¦Aµ¥¤@¬q®É¶¡,¦~©³¬O¤@ÓÆ[¹îÂI, MOS¦s¬¡¦±½u¥h¦~10¤ë©³¬ù¦b0.8ªþªñ ¦p¤p©_¤j©Ò¨¥¥i¯àn1¦Ü2¦~¼Æ¾Ú¤~·|¦¨¼ô¤U°¦Ü0.5 ,¬°¤F¥´±ÑÄvª§¹ï¤â, §ÚÄ@·N²¢»eµ¥«Ý§ó¤pªºpÈ ©¯¦n¬ü°êFDA¼fÃıM®a ¤]¤£¬O¤@©wnµ¥MOS¼Æ¾Ú¦¨¼ô¤~·|¤Uµ²½×,¼fÃıM®a·|¬ÝÁͶÕ(¦~©³¬O¤@ÓÆ[¹îÂI) ²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) p È ¦¤w¤p©ó0.05 ¦³§K¬Ì¤ÏÀ³»P¹ï·Ó²Õ p È= 0.0399 ¦³§K¬Ì¤ÏÀ³»P¨S¦³§K¬Ì¤ÏÀ³ pÈ = 0.0207 ¥t¥~¤]¦bµ¥´Á¤¤Á`¦s¬¡´Á¡]·N¹ÏªvÀø±Ú¸s¡^¤¤ ¹êÅç²Õ»P¹ï·Ó²ÕMOS¦s¬¡¦±½u ¦b8Ó¤ë«e¶}¤f¤wÂX¤j ¥Ø«epÈ = 0.289 ¨â²Õ¥Ø«e¬ù¦b30¦Ü32Ӥ뤧¶¡¹ï·Ó²ÕMOS¦s¬¡¦±½u§Ö¦¨¼ô¤F ¹êÅç²Õ¬ùn1¦Ü2¦~MOS¦s¬¡¦±½u¤~·|¦¨¼ô ¥H¤W¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡GĹ¥J10142318 µoªí®É¶¡:2016/6/7 ¤U¤È 03:48:53²Ä 1855 ½g¦^À³
|
¤@Ó«Ü¥®¸Xªº°ÝÃD,°ª§ÜÅ骺21¤H¬O¦]¦ó¦Ó¦º?¬O¨Ó¤£¤Î±Ï?¦³Àø®Ä¬°¦óÁÙ·|¦º?¤@ÂIºÃ°Ý |
|
|
·|û¡G¸Û¤ß10142309 µoªí®É¶¡:2016/6/7 ¤U¤È 03:47:35²Ä 1854 ½g¦^À³
|
pie¤j ¤p§Ì¦L¶H¤¤±i¸³¬O»¡¥´§¹4°w¨S¦³²£¥Í§K¬Ì¤ÏÀ³ªº·|½Ð¦oÂ÷¶}, ¦³¿ù½Ð«ü¥¿,ÁÂÁÂ! |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/6/7 ¤U¤È 03:43:59²Ä 1853 ½g¦^À³
|
slide ²Ä17¶OS¤ÀªR,§C§ÜÅé¹êÅç²Õ¦b²Ä25Ó¤ëOS¤w¶}©lĹ¹L¹ï·Ó²Õ,¥Nªí¦p¥xÁÞ¤j©Ò¨¥¥un¦Aµ¥¤@¬q®É¶¡(¤]³\¦~©³)¾ãÅ骺OS ²Ä13¶¦³¥i¯àÅܦ¨P¤p©ó0.05 ,°¨¤W¥i¥Ó½ÐFDAÃÄÃÒ,¨º®É´N¨S¦³¥ý¥´´X°w¶q§ÜÅé¤j©ó160 µ¥ª§Ä³¤F,¾A¥Î¹ï¶H±N¤j´TÂX¤j,¥un¥´°w´N¬O¤F,¦]¦³OS «OÃÒ ¦³»~½Ð«ü¥¿ ÁÂÁ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/6/7 ¤U¤È 03:37:24²Ä 1852 ½g¦^À³
|
¸ô¤H¥Ò¤j,pie¤j: §Ú»{¬°¥´§¹¤E°w¨Ó¤ñ¸û¬O¦³"¬ì¾Ç"¤Wªº·N¸q ¦]¬°ÁöµMPD¦b37¶g¥H¤W¡A¦ý¤]¥i¸ÑÄÀ¬°¹êÅç²Õªº¦n¾Ç¥Í¸ò¹ï·Ó²Õªº¦n¾Ç¥Í¨Ó¤ñ¸û ÅãµMªº¡A¹êÅç²Õªº¦n¾Ç¥ÍÁÙ¬O¤ñ¹ï·Ó²Õªº¦n¾Ç¥Í¦n¡AÃÒ©ú¹êÅç²Õ½T¹ê¬O¦³®ÄªG¾Ç¥Íªí²{§óÀu ¥t¦³Ãö¤T´Á³]p¡A±M®a°Q½×«á³]p·|§óºë·Ç¡A¥Ñ©ó³o¬O¥þ²y²Ä¤@¤ä¥HÁÞ§@¬°¥Dn§Ü쪺Á{§É¸ÕÅç ¦pªGÃÒ©ú¦³®Ä¡A¥¼¨Ó¹ï¤HÃþ¹ï§Ü¯e¯f(¤£¥u©óÀù¯g¡A¤d¦Ê¸UºØ¯e¯f)¥¼¨Ó³£·|¶}°_¬ãµoªº¤jªù «áÄòµo®iµL½a¡C¤HÃþ¤Æ¾ÇÃÄ/³J¥Õ½èÃÄ/¤p¤À¤lÃĤw¸gµo®i¦h¦~¡A´X¥G¤w¸g¨ì¤F·¥ ÁÞ¤À¤lÃıN±µÄò«á¨Óªºµo®i«¥ô ¦Ó822¨ì©³¦³¨S¦³®Ä¡A«Ü²³æªº»¡¡A¦³§ÜÅé´N¦³®Ä¡A©Ò¥H²³øÁ`µ²¤~·|»¡ ¤U¤@¨B¸ÕÅç³W¹º±N±´°Q822/821¹ï²£¥Í§K¬Ì¤ÏÀ³¯f±wªºÀø®Ä¥H¤Î¦p¦ó¼W±j¨ü¸ÕªÌªº§K¬Ì¤ÏÀ³ ¥¼¨Óȱo´Á«Ý¡A¨S¤Ó¤j¸êª÷À£¤Oªº¡A¤£¥²±þ¦b³Ì§CÂI¡A¯u¥¿ªº°ª¤sÁÙ¨S¬Ý¨ì ·s榳¤Ñ¤s¤]¦³¦R¾|µfºÚ¦a¡A¯àµn¤W¤Ñ¤sªº¡A¤£¥²«Ý¦b¦R¾|µfºÚ¦a |
|
|
·|û¡G¸ô¤H¥Ò10135334 µoªí®É¶¡:2016/6/7 ¤U¤È 03:21:54²Ä 1851 ½g¦^À³
|
pie ¤j «D±`¤¤ªÖªº¸Ñ»¡, ·PÁ±zÅý§ÚÌ´²¤á¯à§ó²`¤J¤F¸Ñ·N²[ |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/7 ¤U¤È 03:01:04²Ä 1850 ½g¦^À³
|
¦Ñ¶§¤j ¦³¥´§¹¤E°wªº±wªÌ, ¨äPD®É¶¡¦b37¶g¤§«á ¨S¥´§¹¤E°wªº±wªÌ, ¨äPD®É¶¡¦b37¶g¤§«e §â¥´§¹¤E°wªº¤@²Õ©M¨S¥´§¹¤E°wªº¤@²Õ®³¨Ó¤ñ¸û, ¬O¨S¦³·N¸qªº |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2016/6/7 ¤U¤È 02:54:57²Ä 1849 ½g¦^À³
|
¤p©_¤j¡A µo§¹¤å¤~¬Ý¨ì±zªº«ü¾É, ÁÂÁÂ! |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/7 ¤U¤È 02:51:48²Ä 1848 ½g¦^À³
|
²á²áÃö©óASCOªº¤@¨Ç·Qªk 1. §K¬Ì©µ¿ð¤ÏÀ³ slide 15Åã¥Ü¤F²£¥Í°ª§ÜÅ骺²Ö¿n¤H¼Æ, ¥i¥H¬Ý¥XIgGªº²£¥Í®É¶¡¸û±ß, ¦Ó¥BÅܲ§«Ü¤j. ²Ä5¶g, 9¶g, 13¶g, 17¶g, 25¶g³£¦³¤@©w¤ñ¨Òªº¤H¶}©l²£¥Í°ªIgG§ÜÅé. ¦pªG¤T´Á¥Î¥´§¹¥|°w, ²Ä¤E¶g¦³µL²£¥Í°ªIgG¨Ó¿z¿ï, ¤j¬ù¥u¦³20%±wªÌ¥i¤J¿ï¹êÅç²Õ, ¤£ª¾¹D¤½¥qn«ç»ò³B²z³oÓ°ÝÃD. 2. °ª§ÜÅé¤H¼Æ50% ¥Ñ©ó§K¬Ì©µ¿ð¤ÏÀ³, ¦³¨Ç±wªÌ¦b§ÜÅé¿@«×¹F°ª®p«e´NPD¤F, ¥t¥~¤]¦³¨Ç±wªÌ´£¦°h¥X¹êÅç, ©Ò¥H°ª§ÜÅé¤H¼ÆÀ³¸Ó°ª©ó50%¤£¤Ö. ¥Ñslide 15¨Ó¬Ý, ¥i¥H°µÓ±À´ú, ¦pªG°µ§¹¾ãÓÀøµ{, ¥i¥H²£¥Í°ª§ÜÅ骺¤ñ¨Ò¬ù¬O70%. ¦Ò¶qÀù¥½±wªÌªº¨Å骬ªp, 70%±wªÌ¯à²£¥Í°ª§ÜÅé¯uªº«Ü¤£¿ù. 3. OBI822¹ï§C§ÜÅé²Õ¦³®`? ³o¬O«Ü®e©ö±o¨ìªº¿ù»~µ²½×, ²¦³º§C§ÜÅé²ÕªºPFS¤ñ°_¹ï·Ó²Õ¯uªº®t«Ü¦h. §Ú¦b(2016/5/24 ¤U¤È 10:48:51)´£¹L¤@Ó·§©À, §K¬Ì©µ¿ð¤ÏÀ³»P¤À²Õ³y¦¨ªº²Îp°¾®t, ¹ï°ª/§C§ÜÅé²ÕªºPFSªí²{¼vÅT«Ü¤j. ³o¦¸³ø§i¤jP¦LÃÒ¤F³oÓ·Qªk. ¥J²Ó¬Ýslide 16, °ª/§C§ÜÅé²Õ»P¹ï·Ó²Õ²Ä¤@¦¸©úÅã©Ô¶}®t¶Z, ¬O¦b²Ä9¶g. ¦A¬Ýslide 12, ²Ä9¶g®É, ¹êÅç²ÕPD¤ñ²v¥u²¤°ª©ó¹ï·Ó²Õ¤@ÂI. ¦ý¬O¥Ñ©ó¤Wz²Îp°¾®t, ²Ä9¶g®ÉªºPD¤H¼Æ, ¤j³¡¤À³£Äé¨ì¤F§C§ÜÅé²Õ, ¨Ï±o¦b²Ä9¶g§C§ÜÅé²Õ¤U°«Ü¦h, ¦Ó°ª§ÜÅé²Õ«h¤U°«Ü¤Ö. ¦P¼Ëªº²{¶H, µo¥Í¦b²Ä17¶g»P²Ä25¶g, ¹êÅç²ÕPD¤H¼Æ, ¤j³¡¤À³£Äé¨ì¤F§C§ÜÅé²Õ, ©Ô¶}¤F§C§ÜÅé²Õ»P¹ï·Ó²Õªº®t¶Z. ¦¹²Îp°¾®t, ¦b¶V¦´Á¶VÄY«, ÀHµÛ§K¬Ì©µ¿ð¤ÏÀ³®ÄÀ³»¼´î, ¤]¸òµÛ´î½w. ¤]´N¬O»¡, slide 16§e²{ªº¤T±ø¦±½u, ¬O¥Rº¡²Îp°¾®tªº, »Ýn×¥¿. ×¥¿¹L«á, ¤jP¤W§C§ÜÅé²Õ·|©¹¤W©Ô, °ª§ÜÅé²Õ·|©¹¤U©Ô, ¤T±ø¦±½u®t²§·|ÁY¤p. §C§ÜÅé²Õ¨ä¹ê¨S¦³¨º»ò®t, °ª§ÜÅé²Õ¤]¨S¦³¨º»ò¦n. ¤½¥q¥Î°ª/§C§ÜÅé²Õ¨Ó¤ÀÃþ, ¬O¨ã¦³¬ì¾Ç¤Wªº·N¸q, ¦ý¬O¦ü¥G¨S¦³·NÃѨì¹ï²Îp¥¿½T©Êªº¼vÅT. ¾ãÅé¨Ó¬Ý, OBI822¦bPFSªºªí²{¤W, µL½×¬O¦]¬°°²©ÊPD©Î¨ä¥L¦]¯Àªº¼vÅT, §Y¨Ï¬O°ª§ÜÅé²Õ, ¬O¨S¦³¨º»òÅãµÛªº. 4. OBI-822ªºªvÀø¤ÏÀ³»P±wªÌÅ餺Globo-Hªºªí²{¶qµLÃö? ¦pªG³o¥y¸Ü¬O«üOBI-822ªºÀø®Ä©M±wªÌGlobo-Hªºªí²{µLÃö, §Ú»{¬°¬O¥¿½Tªº, ¤]¬O¹ï¤½¥q¦³§Qªº. ¥Ñslide 18¨Ó¬Ý, °ª§ÜÅé²Õ, ¬Û¹ï©ó§C§ÜÅé²Õ/¹ï·Ó²Õ, ¹ï©óGlobo-H positive¦³Àø®Ä, ¹ï©óGlobo-H negative¤]¦³Àø®Ä. ©Ò¥HµL½×±wªÌ¦³µLGlobo-Hªí²{, °ª§ÜÅé²Õ³£¦³Àø®Ä. 쥻OBI-822¥u¯à¹ï¬ù70%¦³Globo-Hªí²{ªÌ¦³Àø®Ä, ²{¦b¬O¹ï100%±wªÌ¦³Àø®Ä, ·íµM¬O¦n¨Æ¤@¥ó. ¦ý¬O³o¼Ë¤½¥q«ÜÃø¸ÑÄÀ, ±wªÌ¨S¦³Globo-Hªí²{¬°¤°»ò¤]¦³Àø®Ä. §Ú²qGlobo-H negative±wªÌªºÀø®Ä, ©MSSEA3, SSEA4ªí²{¦³Ãö. ¦ý¤½¥q¦ü¥GÁÙ¨S·Ç³Æ¨¬°÷ªº¸ê®Æ¨Ó»¡©ú³oÂI. ÆZ»{¦P¦Ñ¶§¤j, ©ú©ú¼Ë¥»¼Æ¤£°÷, ¤S¨S¦³¨¬°÷ªº¸ê®Æ¸ÑÄÀºÃÂI, ÁÙ©ñslide 18, ¯u¬O°Q¥´. ¥t¥~, slide 18¤@¼Ë¨ã¦³²Îp°¾®t, »Ýn×¥¿. 5. OS¤ÀªR slide 13Åã¥ÜOBI822¹ï©µªø±wªÌ¹Ø©R, º¥º¥¥i¬Ý¥XÅãµÛªºÀø®Ä. ¦A¹L¤@¨â¦~, ¼Æ¾Ú¦¨¼ô«á, À³¸Ó¦³¾÷·|¥Ó½ÐÃÄÃÒ. ³o¬O§Ú¬Ý§¹ASCO«á, ³Ì¤jªºÄ~Äò«ùªÑ«H¤ß¨Ó·½¤F. 6. ¤½¥qµo¨¥¤Ó¼ÖÆ[ 2/22§ë¸ê¤H»¡©ú·|, ±i¸³»¡ASCO«á, ¥i¯à·|¤Þ°_°ê¥~´CÅé, ¦pCNN, ªº¤j´T³ø¾É. ASCO«á, §Ú«Ü´Á«ÝªºGoogle¤F«Ü¦h¦¸, ³sÓ¼v¤l³£¨S¦³. ÁÙ»¡¸Ñª¼«á, ±ÂÅv¥u·|§ó¦n, ¥u·|¥[³t, ¥i¯à¦bASCO«e´N¦³¾÷·|½Í¦¨. ¤@¼Ë¨SÓ¼v¤l. ´Á«Ý¶V°ª, ¥¢±æ¶V¤j. ³o¦¸ªk»¡·|«ÜÂÔ·V, ¤£¬Û¤zªº¤£»¡, ÁÙ¨Sµo¥Íªº¤£»¡, ¤]¬O¦n¨Æ. §ÚÁÙÆZªY½à¤¤¸ÎªººÞ²z¶¥¼h, ¬Û¹ïµo¨¥¸ûÂÔ·V. |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2016/6/7 ¤U¤È 02:51:10²Ä 1847 ½g¦^À³
|
¤p´²¤á¤j,°Ñ¤@©@¤j, ·PÁ«ü¾É¡A¤p§Ì½T»{«á¤F¸Ñ¤F! §Ú·QÁÙ¬OÃÒ©ú¥XÀø®Ä»PGlobo Hªí²{¶q¦³¥¿¬ÛÃö·|¤ñ¸û¯à§ó¥[±j¤ÆMOAªº½T»{ §Æ±æ¤UÓ¸ÕÅç¥i¥H¦³¥¿±ªº¼Æ¾Ú¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/7 ¤U¤È 02:45:36²Ä 1846 ½g¦^À³
|
999¤j¡A ¡y§¹¦¨¤E°w104¤H¥ÎÃIJժº¤¤¦ìPFS 22.5Ó¤ë¡z ¥u¬O§i¶D§ÚÌ¡A¾ãÅé¹êÅç²Õ»P¹ï·Ó²ÕªºpÈÁö¨S¹LÃö¡A¦ý¬O«á¥b¬q¦³¥´§¹9°wªº©Ô¥X¨Ó°µ¤ñ¸û¡A¹êÅç²ÕÁÙ¬OÀu©ó¹ï·Ó²Õ¡A22.5Ó¤ë¤ñ18.1Ó¤ë¡A¦h¤F4.4Ó¤ë¡A¦]¦¸PFS¤£¬O¨S¦³®Ä¡C ½Ð±z§Ñ¤F¥H«eªº±Àºâ§a¡I ¥H«e±Àºâªº°²³]°ò¦»P¥Ø«e©Ò§e²{ªº¹ê»Ú±¡ªp®t¤Ó¦h¡A ASCO¤w¸g¤½¥¬¼Æ¾Ú©M¹Ï«¬¤F¡A ´N¥H²{¦bªº¼Æ¾Ú¹Ï«¬¨Ó²z¸Ñ822 ¥t¥~¡APFS¥i¥H¤Ö©ñÂI¤ß¤O¥h¬Ý Àø®Äªº«ÂI¦bP17ªºOS¤ÀªR ÁöµMOSªºKM¹Ï¥¼§¹¦¨ ¦ý¤w¸g¹w§i¹ï·Ó²ÕªºM OS½d³ò¦b30~36Ӥ뤧¶¡ P12»¡©ú¹ï·Ó²ÕªºM PFS=40 weeks=10Ó¤ë P17¹w§i¹ï·Ó²ÕªºM OS=30~36Ó¤ë »PIbranceªºÁ{§É¹êÅç¹ï·Ó²ÕM PFS=10.2Ó¤ë ¤ÎM OS=34Ó¤ë¡A¬O«Ü±µªñªº ¦Ü©ó822ªºResponse³o¤@²ÕªºOS¯uªº¶ZÂ÷¦¨¼ôÁÙ¦³¤@¤j¬q¶ZÂ÷ ¬Ý¨ÓÁÙn¤@¨â¦~¥H¤Wªº®É¶¡¤~¥i¯à¥X²{M OS¡C ¯Q¾~¤j¡G 348¤H¤¤¥u¦³243¤H¦³´úGlobo H¡A¤£¬O©Ò¦³¤H³£¦³ÀËÅé¤Á¤ù¡C |
|
|
·|û¡G°Ñ¤@©@10141487 µoªí®É¶¡:2016/6/7 ¤U¤È 02:42:06²Ä 1845 ½g¦^À³
|
¦n¤ß¯Q¾~¤j¡A¤½¥q¦³»¡³o¦¸¨S¦³¥þ³¡³£¦³´úGlobal Hªí²{ªºIHC´ú¸Õ¡A¥u¦³240¦h¦ì¦³¼Æ¾Ú¦Ó¤w¡C ½Ð¬Ýwww.youtube.com/watch?v=_znW_DxOkRI ±q1:03:30¥ª¥k¬Ý´N¦³¦^µª¤F¡C |
|
|
·|û¡G¤p´²¤á10134411 µoªí®É¶¡:2016/6/7 ¤U¤È 02:39:00²Ä 1844 ½g¦^À³
|
¦n¤ßªº¯Q¾~¤j¡A ¯u°ª¿³§AÁÙ¦b¡C§Æ±æ¥¼¨Ó¦pªGÁÙ¦³¤j®a¹L«×¼ÖÆ[ªº±¡ªpµo¥Íªº¸Ü¡AÁÙ¯àÅ¥¨ì±zªºÄµ¥ÜÁn¡C ±z»¡ªº¤H¼Æ¹ï¤£°_¨Óªº°ÝÃD¡A§Ú¾Ì¤£¤Ó¦nªº°O¾Ðµ¹±z¤@Ó¥i¯àªºµª®×¡C ¦L¹³¤¤¡Aªk»¡·|¤¤¡A§E³Õ¤h¦³´£¨ì¡A¨Ã¨S¦³ÀËÅç©Ò¦³¯f¤Hªºglobo-hªºexpression¡C ¦]¦¹¡AÀËÅç¤H¼Æ¦ÛµM¬O¤p©óÁ{§É¤H¼Æªº¡C §Æ±æ±z¯à¦A¦Û¤wcheck¤@¤U§Ú»¡ªº¬O¤£¬O¹ïªº¡C |
|
|
·|û¡GPT10139061 µoªí®É¶¡:2016/6/7 ¤U¤È 02:29:46²Ä 1843 ½g¦^À³
|
¥H«á·ù¥D¥i¥H·dÓ¹³®½¦å¤¤¤ß²Õ´¬[ºcªº°òª÷·| Ä@·N®½³¡¤À§ÜÅ骺¤H,¥i¥H§K¶O¥´822/833¹w¨¾Àù¯g ¥i¯à·|¤ñ®½¦åÁÙÀ½¯}ÀY,ÁÙ±o´ú¸Õ¬Ý½Ö²£¥Í§ÜÅé³Ì¦³®Ä²v. Æg!! |
|
|
·|û¡GĹ¥J10142318 µoªí®É¶¡:2016/6/7 ¤U¤È 02:07:09²Ä 1842 ½g¦^À³
|
¥¿±`¤H²£¥Íªº§ÜÅé¥i¥H´£·Ò¨Ã¨ÑÀ³µ¹µL§K¬Ì¤ÏÀ³ªº¤H,YµL±Æ¥¸ªº¸Ü,©Ò¦³±aglobe-h¨t¦CªºÀù¯g,´N¥i±o¨ìªvÀø¤F,asco µû½×®aªºµ²»y´N¥i¥H±o¨ì¸Ñµª. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/6/7 ¤U¤È 01:46:33²Ä 1841 ½g¦^À³
|
Ãö©óGHªí²{»PÀø®Ä¡A§Úªº¸ÑŪ¬O: 1.Àø®Ä³ò¶¦b§ÜÅéIgG®Ä»ù1:160¦³µ´¹ï©ú½TÃö«Y¡A°ª§ÜÅé»P¹ï·Ó²Õ©Î°ª§ÜÅé»P§C§ÜÅéPFS, OS PÈ¥i¥H¬Ý¨ì ²³øPAGE 16 & PAGE 17 2.GHªí²{¶q»P§ÜÅé²£¥Í¶q(Àø®Ä)µLÃöÁp¬O¦X²zªº¡A§ÜÅé²£¥Í¬O¦]¬°¥´822³oÓGH¥[¤FÓKLHÁÙ¦³821¦õ¾¯²£¥Íªº ¤£¬Oì¨Ó±wªÌ¨¤WªºGH¦h¤Ö¨Ó¨M©wªº 3.·|«á¦³¤H°Ý§E³Õ¤h¨ä¥L°ÝÃD¡A§E³Õ¤h¦³´£¨ìB«¬¨xª¢¬Ì]¦³¤H¦A«ç¥´¤]¤£·|²£¥Í§ÜÅé 822¤]·|¦³³oºØ±¡§Î¡A´N¬O¥´¤F¤~·|ª¾¹D¦³¨S¦³®Ä¡A¦ý¦³50%ªº¤H·|«Ü¦³®Ä 4.è¤~¦³·Q¨ì¤@Ó°ÝÃD¡A³o¦¸¥Î§ÜÅé®Ä»ù1:160, ¦pªG§ä1:320ªº¤S·|¬O¦p¦ó? ·íµM©Î³\¼Ë¥»¼Æ·|¤Ö¨Ç¡A¦ýÀø®Ä·|§óÅå¤H 5.¬Q¤Ñ¤w»¡¹L¥´822¡A§ÜÅé°ªÀø®Ä¦n¡A¨S§ÜÅé¤]¤£·|§ó®t¡A¥BµL°Æ§@¥Î¡A¦¨¥\¤w¬O¥²µM¡A¥unµyµ¥¤@¨Ç®É¶¡§Y¥i ¥H¤WY¦³ÂÕ»~¡A·Ð½Ð«ü¥¿ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/7 ¤U¤È 01:36:03²Ä 1840 ½g¦^À³
|
¶Â½ü§B¤j ÁÂÁ±z¸ÔºÉªº¸ÑÄÀ ¯u°ª¤H¤]! |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2016/6/7 ¤U¤È 01:32:27²Ä 1839 ½g¦^À³
|
¤j®a¦n¤[¤£¨£ ¦]¬°²³¦h¦]¯À¤p§Ì«Ü¤[¨Sµo¨¥ ¤p§Ìªº·Qªk¬O¥Ø«e¹ï¤½¥qªº§ë¸ê¦Ò¶q§¹¥þ¥u¨Ì¾Ú®Ñ±ÃҾڥկȶ¦rªºªF¦è¨Ó§PÂ_ ³Ìªñ²×©ó¦³¤ñ¸û¥¿¦¡ªº¥Õ¯È¶Â¦rªºªF¦è¡A©Ò¥H¯S¨Ó°Q½×¡C ¦b¬Ý§¹ASCO³ø§i«á¡A¤p§Ì¦³¤@°ÝÃD¨D±Ð: ¦bslide 18¤¤¡Aresponder¦@112¤H, Globo H expression negative¦³24¤H, positiveªº¦³59¤H, 24+59= 83¤H, 112¤H¤¤¬°¦ó¥u¦³83¤H¦³Globo H ªº¸ê®Æ? ¨ä¥L29¤H¬O¨S¦³´ú¸ÕÁÙ¬OGlobo Hªº´ú¸Õ¦³¤@¨Ç§Þ³N¤Wªº°ÝÃDµLªk§JªA©Ò¥HµLªk¨ú±o¸ê®Æ? ¨ä¹ê¦bplacebo 124¤H¤¤¤]¥u¦³ 25+59= 84¤H¦³Globo H¸ê®Æ, Non-responder 112¤H¤¤¥u¦³20+56= 76¤H¦³Globo H¸ê®Æ, ¬°¦ó¦³³oºØÁ`¤H¼Æ°Â¤£°_¨Óªº±¡§Î? ¹ê¦b·Q¤£³z¡A·q½Ð½ç±Ð¡C |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/7 ¤U¤È 01:28:18²Ä 1838 ½g¦^À³
|
¤p§Ì©IÀ³©Ó¤Ñ¤j©Ò»¡ §Ú²q¤½¥q¤@ª½·Qªí¹F¤@¥ó¨Æ §ÜÅ骺²£¥Í »P »P²ÓMªí²{GHªº¶qµLÃö ¥Î¨ÓÃÒ¹ê822¤ÞµoӮקÜÅ骺¯à¤O ¨Ó©IÀ³³o¦¸³Ì«nªºµo²{ ´N¬O ¥un¦³§ÜÅé ´N·|¦³ Àø®Ä §ÜÅé¶V¦h Àø®Ä¶VÅãµÛ ³o§ÜÅé ¤]¶¡±µÃÒ©ú¤F888ªº®ÄªG ¥un°µ¥X³oÓ§ÜÅé §Y¨ÏӮקK¬Ì¨t²Î¤£¦n ÁÙ¬O¥i¥H¦³«Ü¦nªºÀø®Ä ¤p§Ì²L¨£ ½Ð²³¤j«ü¥¿.. |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/7 ¤U¤È 01:19:20²Ä 1837 ½g¦^À³
|
¤p§Ì¸ÕµÛ¦^´_²q·Q¤jªº°ÝÃD 1.¦b¨S¦³Globo HªºÀù²ÓM¤W , ¬O§_´N¨S¦³SSEA-3¤ÎSSEA-4? ÁÙ¬O¤]¦³¥i¯à¦s¦b¨âªÌ©Î¨âªÌ¤§£¸? ¥¼§¹¦¨¤À¤Æªº¨ÅÀù²ÓMªº½T¦³¥i¯à¨S¦³Globo H ¦ý ¤]·|¦³«Ü¤jªº¾÷²v¦³SSEA-3¤ÎSSEA-4ªºBIOMARKER ²³æ¨Ó»¡ ¤£¦P¤À¤Æ®É´Áªº²ÓM ¨ä²ÓMªí±ªº¼Ð°O·|¦³¤£¦P ¤]¦³¥i¯à³£¦³ ¦ý¦b²ÓMªí±ªº¼Æ¶q¤£¤@¼Ë ¦A¥Î§ó²LÅ㪺¨Ò¤l Y±N¥ÕÀY¾vµø¬°GLOB H ¶ÂÀY¾v©ÎL¤òµø¬°SSEA-3¤ÎSSEA-4 ¤£¦P¦~¬ö ¥LªºÀY¾vºCºC¥Ñ¶ÂÅÜ¥Õ ¸U¤@²ÓM¬ðÅÜ Åܦ¨¨rÀY ´N¨S¦³GLOBE H.... ¥t¥~822 ªº¸ÕÅç , Globo HªºÀË´ú¬O¥Î¿Ã¥ú¬V¦â(?)ÁÙ¬O¥Î½èÃлö§PŪ? ¤½¥q¬O»¡¥ÎIHC ´N¬O©Ò¿×ªº§K¬Ì¿Ã¥ú¬V¦â ³o¤èªk ¾A¦X©w©Ê ¦Ó½èÃлö¾A¦X©w¶q ¨â¤èªk¦U¦³§Q¹ú ¥H§¹¾ãªº¹êÅç¨Ó»¡ «Øij¨âºØDATA³£§e²{¬°³Ì¨Î ¤p§Ì²L¨£ ¦³¿ù½Ð«ü¥¿.. |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/7 ¤U¤È 01:17:45²Ä 1836 ½g¦^À³
|
¥LÌn´ú¶qªº§ÜÅé¬Oconjugate¦bcarrier protein ªºGlobo H ¤£¬OÀù²ÓMªºGlobo H¤Þµoªº ·íµMµLÃö ´N¦n¹³¥´¬y·P¬Ì] §Ú¨S±o¬y·P ¦ý¦]¬°¬Ì]·|²£¥Í§Ü¬y·P§ÜÅé ©Ò¥H¦b§Ú±o¬y·P«á ³o¨Ç§ÜÅé·|¹ï§Ü¯f¬r |
|
|
·|û¡GĹ¥J10142318 µoªí®É¶¡:2016/6/7 ¤U¤È 01:17:14²Ä 1835 ½g¦^À³
|
Ó¤H¨£¸Ñ,obi-822¥´»s¤HÅ餺´N¥i²£¥Í§ÜÅé,¥un¦³§K¬Ì¤ÏÀ³,»P§AÅ餺¬O§_¦³globe -h ©Îs3 & s4µLÃö,©Ò¥H¥¿±`¤H¥´¤F¤]·|²£¥Í§ÜÅé,³o¨Ç§ÜÅé«o¥iªvÀø±aglobe-h;s3;s4ªºÀù²ÓM. |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/6/7 ¤U¤È 01:09:05²Ä 1834 ½g¦^À³
|
§ë¼v¤ù-21¬O³o»ò¼gªº¡GªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶qµLÃö¡C±i¸³¦^µª¦¶Âå®vªº´£°Ý¡A¦^µª»¡¡§¨S¦³Globo Hªí²{¤]·|²£¥Í§ÜÅ顨¡C¯u¥s¤H¤@ÀYÃú¤ô¡C¡§¨S¦³Globo Hªí²{¤]·|²£¥Í§ÜÅ顨±i¸³³o¥y¸Ü¤£´Nªí¥Ü¡GªvÀø¤ÏÀ³Åã¥Ü»PGlobo Hªí²{¤§¦³µL¬OµLÃöªº¡H¨º»ò¡§ªí²{¶q¡¨©M¡§ªí²{¡¨¨âªÌµü¸q¦bÅÞ¿è¤W¦³¦ó°Ï§O¡H¬Q±ß¤½¥qµoªº¼á²M½Z¡A¤p§ÌÁÙ¬O²z¤£²M¨ºÓ¥Õ¸Ü¤å¡Aü¡C¦³ª©¤Í°ª¤H¥HSSEA-3/-4¸ÑÄÀ¡A¤p§Ìı±o³o©MÀø®Ä¦³¬ÛÃö¡A¦ýÅÞ¿è¤W¨º¬O¨â½X¨Æ¡C ¤¤¤È¦Y¶º®É·Q¤F·Q¡A³o¸Ì¸ÕµÛ±À²z¦p¤U¡C §ë¼v¤ù-18¡A²M·¡Åã¥Ü¡AResponder vs Placebo¥H¤ÎResponder vs Non-Responder¨âÓ¤ñ¸û¡AGlobe-H ªí²{ Negative ªºHR¡]ªvÀø¤ÏÀ³¡^³£³Ó¹L Globe-H ªí²{ Positiveªº¡Cª`·N¡AªvÀø¤ÏÀ³¤£¤î¬O©MGlobo Hªí²{¶qµLÃö¡AGlobo Hªí²{Negativeªº¡A¨äÀø®ÄÁÙ²¤³ÓGlobo Hªí²{Positiveªº¡C¦ý¬O¼Ë¥»¦³¡AÁÙ¬O¥i»¡¡§ªvÀø¤ÏÀ³©MGlobo Hªí²{¶qµLÃö¡¨¡C¬°¤°»ò¡H¤p§ÌªºJ¶Ã¸ÑÄÀ¬O¡G 822¬Ì]©Ò¿Eµoªº§ÜÅé¬On¥h±þ¦³§Üìªí²{ªºÀù²ÓM¡A¥HGlobo H¬°¼ÐÃÑ¡C©w©Ê¨Ó¬Ý¡AGlobo Hªí¶q°ªªº¡A¯f±¡¸û«¡]¤£¥²µM¡^¡A¼ÐÃѦh¡A¿Eµoªº§ÜÅé¤]´N¦h¡CGlobo Hªí¶q§Cªº¡A¯f±¡¸û»´¡]¤£¥²µM¡^¡A¼ÐÃѤ֡A¿Eµoªº§ÜÅé¤]´N¤Ö¡C¦p¦¹³o¯ë¥¿Å¤§¤U¡A´N¦³¡§ªvÀø¤ÏÀ³©MGlobo Hªí²{¶qµLÃö¡¨ªºµ²ªG¡C¥H¤WÅÞ¿è¬O±Æ°£SSEA-3/-4¦]¯Àªº¡C ½Ð¤j¤jÌ´§Ã@§åµû¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤U¤È 12:58:37²Ä 1833 ½g¦^À³
|
¤p©_¤j«e½ú¡G ½Ð±Ð±z«ç»ò¬Ý³o§¹¦¨¤E°w104¤H¥ÎÃIJժº¤¤¦ìPFS 22.5Ó¤ë¡H ³oÓ¥ÎÃIJդ¤¦ì¼Æ22.5Ӥ몺±Àºâ...µS°O±z¦´N±Àºâ¥X¨Ó§i¶D²³¤j¤jµª®×¤F¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/7 ¤U¤È 12:50:46²Ä 1832 ½g¦^À³
|
BH¤j ¤Ó·PÁ¤F ³o¼Ë¤p§Ì´N¨S¦³ºÃ¼{¤F ¦Ñ´¤j±Ð±ÂªººÃ°Ý¤]Àò±o¸Ñµª ¦A¦¸·PÁ |
|
|
·|û¡GBH56710142562 µoªí®É¶¡:2016/6/7 ¤U¤È 12:43:39²Ä 1831 ½g¦^À³
|
¥H«e§d©v¯q(¤¤¥¡¬ã¨s°|°ò¦]Åé¬ã¨s¤¤¤ß°Æ¬ã¨sû)¤£¬O´N¦³§ë®ÑÁ¿¸Ñ¹L¤F¡C www.chinatimes.com/newspapers/20160301000389-260109 [...º¥ý¯E¹©Á{§É¸ÕÅç¨Ï¥Îªº¬Ì]Globo-H KLH¨ä»¤µoªº§ÜÅé¡A¤£¶È¯à±þ¦º±a¦³Globo-HªºÀù²ÓM¡A¤]¯à±þ¦º±a¦³¬ÛÃöÁÞ¤À¤lSSEA3¤ÎSSEA4ªºÀù²ÓM¡]PNAS 2013¡^¡C ¦b§Ú̪º¥t¤@½g¬ã¨s¤¤¡A§Ú̵o²{¨ÅÀù¤Î¨ä¥L14ºØÀù²ÓM¤W¶W¹L98%¬Ò¦Ü¤Ö§t¦³¦¹¤TºØÁÞ¤À¤lªº¨ä¤¤¤@ºØ¡]PNAS 2014¡^¡A¦Ó¦b¨ÅÀù·F²ÓM¤W¡A§Ú̬Ʀܵo²{´X¥G100%¬Ò¦Ü¤Ö§t¦³¦¹¤TºØÁÞ¤À¤lªº¨ä¤¤¤@ºØ....] ----------------------------------------------------- ±wªÌ´Nºâ¨S¦³Globo-H¤]ÁÙ¥i¥H°w¹ïSSEA3¤ÎSSEA4²£¥Í®ÄªG, ¤½¥q¬Q¤ÑªºÁn©ú¹ê¦b¼gªº¤£°÷²M·¡¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/7 ¤U¤È 12:31:40²Ä 1830 ½g¦^À³
|
²³¤j¦w ¤p§Ì·Q½Ð±Ð¥Í¤Æ¤è±ªº±M®a¤j¤j ¦b ¤¤¬ã°| ´å¥¿³Õ ¦Ñ®v¹êÅç«ÇªºÂ²¤¶¤¤ http://icob.sinica.edu.tw/lab.php?id=25 ´£¤Î [ 1. ¥HÁÞ¬ì¾ÇªºÆ[ÂI¨ÓåªR¤HÃþFL·F²ÓM»P¸~½F²ÓM §Ú̧Q¥ÎÁÞÃì½èÃФÎÁÞ³J¥Õ½èÃФÀªRªk¨Ó¤ÀªR¤HÃþFL·F²ÓMªºÁÞ³J¥Õ»PÁÞÃ쪺®Ö¤ßºc³y¡C ¨ä¤¤µo²{¡A¦³7Ó·s¿oªº¤HÃþFL·F²ÓMªí±ÁÞ³J¥Õ¤]·|°ª«×ªí²{¦b¨ÅÀù¸~½F·F²ÓM¤º¡C §Ú̬۫H³o¨Ç¦s¦b©ó¤HÃþFL·F²ÓMªº·s¿oÁÞÃì±N¯à§@¬°¸~½F±M¤@©Ê°»´ú¼Ðªº¤]¯à§@¬°¨ÅÀùªºÁÞÃì¼Ð¹vªvÀø¡C ¹L¥hªº¬ã¨sµo²{SSEA-3¨ã¦³5Ó¦hÁÞµ²ºc(2Gal£]1¡÷ 3GalNAc£]1¡÷ 3Gal¡÷ 4Gal£]1¡÷ 4Glc£]1)¥B¬°Globo Hªº«eÅXª«¡C SSEA-4«h¬OSSEA-3ªº³è²G»Ä¤Æ(sialylated)l¥Íª«(NeuNAca2 -SSEA-3)¡C¥t¤@¤è±¡AGlobo H¬O¤wª¾ªº¸~½F¥Íª«¼Ð°O¡A ¤]·|¯S²§©Êªº°ª«×ªí²{¦b¤HÃþFL·F²ÓM¤W¦ÓGlobo Hªº§ÜÅé«h¦P®É·|»PGlobo H©MSSEA-3²£¥Í¤ÏÀ³¡C ©Ò¥H¡A³o¨Ç¤HÃþFL·F²ÓMªº¥Íª«¼Ð°O¤]³\¥i§@¬°Àù¯gªº¼Ð¹vªvÀø¡C §Ṳ́]¥H¨t²Î¤Æªº°ò½è»²§U¹p®g²æªþ´åÂ÷ªk-½èÃлö(MALDI-MS)¤Î¦êÁp¦¡½èÃÐ(MS/MS)¤ÀªR±oª¾ ¦b³o¨Ç¤HÃþFL·F²ÓM³vº¥¤À¤ÆªøFLÅél¥Í²ÓM¡A¯«¸g«eÅX²ÓM©Î¤ºF¼h²ÓMªº¹Lµ{¤¤¡A Áޯ׽誺®Ö¤ßµ²ºcglobo- ©M lacto-¨t¦CÁޯ׽è·|©úÅã¦aÂ૬¦¨¥t¤@®Ö¤ßµ²ºc¡A ¥Ñ¦¹±À´ú¤HÃþFL·F²ÓM¤À¤Æ¯S©wªº²ÓMÃШt»PÁޯ׽誺®Ö¤ßµ²ºc¦³°ª«×ªº¬ÛÃö©Ê¡C ¦b¤À¤Æ¦¨¤ºF¼h²ÓM¹Lµ{¤¤¡AÁޯ׽誺«¬ºA§¹¥þ¤£¦P©ó¤À¤Æ¦¨FLÅél¥Í²ÓM©Î¯«¸g«eÅX²ÓMªºÁޯ׽諬ºA¡C ¦b¤ºF¼h²ÓM¤¤¡A³z¹L°ò½è»²§U¹p®g²æªþ´åÂ÷ªk-½èÃлö¤Î¦êÁp¦¡½èÃФÀªR±oª¾³Ì¬ð¥XªºÁޯ׽è®Ö¤ßµ²ºc¬OGb4Cer¡A ¦Ó¦b½èÃФW§¹¥þ¨S¦³Æ[¹î¨ìSSEA-3©M4§Üì©ÎGD3¡CªoµM¦Óª¾¡A§Ú̵۫ªº½×ÂI¦b©ó²ÓM¶i¦æ§K¬Ì¬V¦âªº¹Lµ{¤¤¡A ¥«°âªº§ÜÅé·|¹ïÁޯ׽貣¥Í¥æ¤e¤ÏÀ³¦Ó¾ÉP§PŪ¿ù»~¡A¦]¦¹¦b¤HÃþFL·F²ÓM¤Î¨äl¥Íªº²ÓMÃШt¤¤¡A ¹ï©ó²ÓMªí±ªºÁޯ׽è©ÎÁÞÃìµ²¦Xª«ªºªí²{±N¤´µM»Ýn¨Ì¿à½èÃлö¨Ó¶i¦æºë½Tªº§PŪ¡C] ¤p§Ìªº°ÝÃD¬O ¦b¨S¦³Globo HªºÀù²ÓM¤W , ¬O§_´N¨S¦³SSEA-3¤ÎSSEA-4? ÁÙ¬O¤]¦³¥i¯à¦s¦b¨âªÌ©Î¨âªÌ¤§£¸? ¥t¥~822 ªº¸ÕÅç , Globo HªºÀË´ú¬O¥Î¿Ã¥ú¬V¦â(?)ÁÙ¬O¥Î½èÃлö§PŪ? ½Ðª¾¹Dªº¤j¤j¤£§[«ü¾É¦p¦ó ÁÂÁ¤j®a! |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤U¤È 12:24:12²Ä 1829 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡A½Ñ¦ì¯E¤Í¤j¤j¡G ¤p§Ì¥H쨤«×... ÁÙì¤j®a·íªì¥HPFS¬°Á{§Éªº³]pªº¦¨±Ñ·í«ü¼Ð°ò¦¡C ¥Ø«e¥ÎÃIJժº¼Æ¾Ú¬O104¤H¤¤¦ì¼Æ¬O22.5Ó¤ë......µM«á«p§À®ÄÀ³¤´«ùÄò¤¤...¨º¨ì©³ÃĬO¤£¬O¦³®Ä...¦¨¥\¤F¶Ü¡H ¦pªG¦A¥[¤W¦]«I¼í¤ÏÀ³»~§PPDªº±wªÌ¡A¦pªG¬O¦ª¾¹D§K¬ÌÀøªk¯S©Ê¦Ó«ùÄò¥´¤U¥h...¨º¼Ë¥»¼Æ·|¼W¥[¦h¤Ö¡H ½Ð±Ð½Ñ¦ì¤j¤j...¥Î³oÓ¨¤«×«ä¦Ò¬O§_¦³»~¡H¡H¡H ¦³»~¬Oº|¤F«ä¦Ò¤°»ò¡H ·P®¦½ç±Ð¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/7 ¤U¤È 12:07:48²Ä 1828 ½g¦^À³
|
¬Ì]©Ò¿Eµoªº§ÜÅé¬On¥h±þ¦³§Üìªí²{ªºÀù²ÓM¡C¨S¦³§Ü쪺Àù²ÓMÀ³¸Ó¬O±þ¤£¦ºªº¡C ¤½¥qªº»¡ªk½T¹ê¤£°÷²M·¡¡C¤¸´Iªº³ø§iÁÙ¦³ÂIÅÞ¿è¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/7 ¤W¤È 11:54:25²Ä 1827 ½g¦^À³
|
Tiger ¤j: ¶i¤@¨B«ä¯Á¤F±zªº°ÝÃD. §Úªº¤ß±o¬O³o¼Ë¤lªº: 1) 822¬O¬Ì]¦Ó«D§ÜÅéÃĪ«. 2) ¯f¤H쥻¬O§_±a¦³GH¥»¨Ó´NÃö«Y¤£ÅãµÛ. «ÂI¦b©ó822¥´¤U¥h«á, ¬O§_¯à¦b¯f¤H¨¤Winduce¦Ó²£¥Í§Üì(§K¬Ìì©Ê)±q¦Ó¿Eµo¥X¤@³s¦êªº§K¬Ì¤ÏÀ³ (¨£slide P5)²£¥Í§ÜÅé¦Ó¦³Àø®Ä. 3) 822ªºMOA´N¬O¤W±²Ä2)ÂI±o¨ì¬ì¾Ç¤ÎÁ{§É¤WªºÃÒ¹ê. ©Ò¥H¤½¥qªº»¡ªk¬O µL¸·ªº. ·|³y¦¨³o²V¶ÃÀ³¬O¦b©ó²V²c¤F¬Ì]»P§ÜÅ骺MOA¬O¤£¦Pªº. ¥H¤WY¦³»~, ¤]Àµ½Ðª©¤W¤j¤j«ü¥¿. ·PÁÂ. ¦Ñ´¤j: ¬Ý±o¥X¨Ó±z¹ï¯E¹©·R¤§²`, ³d¤§¤Áªº´£°Ý., Áöª¾±z¤´¦b®ðÀY¤W, ¦ý¤]¹ê¦b§Ô¤£¦í¥Õ¥Ø¤@¤U»¡ ¡§±z¤Ó¥i·R¤F!!¡¨ ¤ÏÂЫôŪ±zªº°ÝÃD, ³o¨Ç°ÝÃD³£«Ü´Î, ¦bªÑªF·|¤W, ·|¥N¬°´£°Ý, ¦ý§Ú¹ï²Îp¹ê¦b¤£¦æ, ¤½¥qY¦^µª, ¸ÑŪ¤è±¥u¦³«ô½Ð¤p©_¤j, ¯E§J¤j, ¤Ñ©R¤jµ¥²Îp°ª¤â¤F. §Ú²q·Q, ¦]¬°ÁÙ¦b¸Ñª¼¶i¦æ¤¤, ³o¨Ç¤½¥qÀ³¸Ó³£·|°µ¤ÀªR©ÎªÌ¤w¸g¦³¼Æ¾Ú¤F. ¦ý¨ü©óASCOªº³W©w©Ò¥H©Î³\¤£¯à¦bASCO½×¤å«e¥ýµoªí. ±i¸³¹ï³o¤è±¦³«D±`¥¿±ªº¦^À³, ½Ð¬Ý¥H¤Uµø°T¦Û1:09:33¶}©l¬ù5¤ÀÄÁªø«×. www.youtube.com/watch?v=_znW_DxOkRI&feature=youtu.be ASCO¬O¥HDr. Hope Rugo¬°ºtÁ¿¤H, slide¤]¬OHopeªº, ©Ò¥H¦³¥i¯à¬OHope¬D¿ï¥X¦o©Ònªº¤º®e¥h°µ¬°¬ì¾Ç¤W¤ÎÁ{§É¤Wªº±´°Q, ¦Óªk»¡¤S¨ü©ó³o¨Çslide, ©Ò¥H¡K. |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/7 ¤W¤È 11:02:09²Ä 1826 ½g¦^À³
|
¦U¦ì¤j¤j: ½Ð°Ýþ¸Ì¯à°÷§ä¨ì Dr. Rugo ªº³ø§iÀÉ (»yµ©Î¼v¹³)¡H ¦hÁ¡I |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/7 ¤W¤È 10:06:25²Ä 1825 ½g¦^À³
|
Cliff ¤j: ·PÁÂ. ¤pªº¥i¥HºCºCµ¥, ±z¦ó®É¤è«K§Y¥i. Y¹ê¦b¤£«K, ½Ð©ñ¤U¤ÅÖñê. Tiger 365¤j: ±zªº°ÝÃD¥i¦A«Å¥¤@¦¸ªk»¡¤¤¿à³Õ©ó21:30¶}©lªºÁ¿ªk©Î³\·|§ó²M·¡¨Ç. www.youtube.com/watch?v=_znW_DxOkRI&feature=youtu.be ¤HÅé§K¬Ì¨t²Î¹ï©ó¯S©w§Üì¯à°÷²£¥Í§K¬Ì¤ÏÀ³¡A«hºÙ¨ä¦³§K¬Ìì©Ê¡C immunogenicity¬°§K¬Ìì©Ê¡A«ü§Üì¤À¤l¯à»¤¾É§K¬Ì¨t²Îµo¥Í§K¬Ì¤ÏÀ³¡A²£¥Í¬ÛÀ³§ÜÅé©Î®ÄÀ³T²O¤Ú²ÓMªº¯à¤O¡F¬°§Üì¤À¤lªº¯S©Ê¤§£¸ biokin.itis.org.tw/news/P2_FreeNewsFocusDetail.aspx?fcs_id=498009088&fname1=%E7%9F%A5%E8%AD%98%E8%BE%AD%E5%85%B8&fname2=%E5%B0%88%E6%A5%AD%E5%90%8D%E7%A8%B1 |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/6/7 ¤W¤È 09:51:44²Ä 1824 ½g¦^À³
|
¤½¥q´£¦W¤F¤TÓ¿W¸³ ¤@Ó¬O¤ý®õ©÷³Õ¤h ¥x¤j·|p¨t±Ð±Â |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2016/6/7 ¤W¤È 09:44:18²Ä 1823 ½g¦^À³
|
¥Ñ¦¹¥i¨£³oÓªÀ·|¯uªº¬O¤Hµ½³Q¤H´Û Ãø¹D³£¨S¦³¤Hªvªº¤F³o¨Ç¨rÆN¶Ü¡H |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/7 ¤W¤È 09:40:52²Ä 1822 ½g¦^À³
|
Ó¤Hı±o´N¬On½Ð¤@Ó±Mªù¦³¸gÅ窺¥Íª«²ÎpÅU°Ý ±Mªùµo¨¥ ¤½¥q¤]¤£¬O¨S¿ú ¸³¨ÆªøÁ`¸g²zµo¨¥¤H³£¤£¾A¦X§@³o¼Ëªº¨Æ±¡ ¬Ý¤F¦n´X¦¸³o¼ËªºÄ±±o³o¼Ë¤@ª½¦YÁ««Ü²Â |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2016/6/7 ¤W¤È 08:28:17²Ä 1821 ½g¦^À³
|
¦U¦ì¤j¤j ½Ð¥¿µø¦Ñ´¤j¤§¬Ýªk§a |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤W¤È 08:21:38²Ä 1820 ½g¦^À³
|
·j´M ¯E¹©¸Ñª¼¼Æ¾Ú¥L³o¼Ë¬Ý ¤µ¦¬Ý¨ìªº·s»D¡AÁ`ºâ¦³¤@¦ìªø©°¦¶¥D¥ôªº»{¦P»P¥¿±¬Ý«Ý822Á{§Éµ²ªG¡C |
|
|
·|û¡Gtiger36510142526 µoªí®É¶¡:2016/6/7 ¤W¤È 08:18:17²Ä 1819 ½g¦^À³
|
¦hÁ¤j®a³o»ò§Öªº¦^À³... §Úı±o¯E¹©n¼g²M·¡¤@ÂI ¤£µM ¤j®a³£¤@ÀYÃú¤ô....XD |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤W¤È 08:03:42²Ä 1818 ½g¦^À³
|
4 ¥»¦¸¥xÆW¤T´ÁÁ{§É¸ÕÅç 72% (¨ü¸ÕªÌ) ¨ãGlobo H ªí²{, ¤]´N¬O¬ù¦³28%¬O¨S¦³Globo H ªí²{ ³o¨Ç28%¬O¨S¦³Globo H ªí²{ªº¨ü¸Õ¥´¤FOBI 822 ¤]·|²£¥Í§ÜÅé , Ó¤H»{¬°¦³«Ü¤j¥i¯à¬O¦]¬° ¨ãSSEA-3 SSEA-4 ªí²{, Á`¦@¦³¤TÓÁÞ¤À¤l¼Ð¹v(§Üì) Globo H SSEA-3 SSEA-4 ¥H¤W4ÂI ¤À¨É ¶È¨Ñ°Ñ¦Ò ¦³¿ù½Ð«ü¥¿ ¦Ñ´¥S¦¦w: §A´£¨ìªº°ÝÃD«Ü¦³²`«×, ±i¸³¦bªk·|¦³»¡ ASCO ½×¤åµoªí¥u¦³12¤ÀÄÁ ,¥u¯à§â³Ì«n¤ÀªR¼Æ¾Ú¥ý§e²{, ¥H«áÁÙ·|¤½§i§ó²Óªº¤ÀªR, ¤j®a@¤ßµ¥«Ý¤F ( ¦n¹³¦³´£¨ì¤Q´XºØ¼Æ¾Ú) |
|
|
·|û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2016/6/7 ¤W¤È 07:57:46²Ä 1817 ½g¦^À³
|
to tiger365: 822 ¬O¬Ì]ªº§ÎºA¡A¥un¥´¤JÅ餺²z½×¤W´N·|²£¥Í§ÜÅé¡A¤§«á§K¬Ì¨t²Î·|¥h§ä±a¦³ GLOBAL-H §Ü쪺Àù²ÓM¡A¦ý§ÜÅé¸ò¯f¤HÅ餺¦³¨S¦³§Üì(GLOBAL-H )¨S¦³Ãö«Y¡C©Ò¥H¤½¥q»¡¡A¯f¤HÅ餺ªº¦³¨S¦³GLOBAL-H ³£·|²£¤W§ÜÅ骺·N«ä¬O³o¼Ë¡C ¦³µLÀø®Ä¸ò GLOBAL-H ªí²{¡y¶q¡zµLÃö¡C·N«ä¬O¤´¶·n¦³ GLOBAL-H ¤~¦³Àø®Ä¡AÀø®Äªº±j®z¸ò§ÜÅé¿@«×§e¥¿¬ÛÃö¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤W¤È 07:48:22²Ä 1816 ½g¦^À³
|
1¥xÆW¯E¹©¬Q¤Ñ¦b¤½¶}¸ê°TÆ[´ú¯¸¤½§i :µL§K¬Ì¤ÏÀ³±Ú¸s(§ÜÅé®Ä»ù<1:160)¡A¤½¥q¤w»¡©úÁÙ¥i²Ó¤À¬°¦Ü¤Ö¥|Ó±Ú¸s¡A§Y a§ÜÅé®Ä»ù1:40 b§ÜÅé®Ä»ù1:80¡B c¥u²£¥ÍIgM§ÜÅéªÌ¡A d¬J¥¼²£¥ÍIgG¡B¤]¥¼²£¥ÍIgMªº¨ü¸ÕªÌ¡C ¨Æ¹ê¤W¡A«e¤TÓ¦¸¤À²Õ¦b¥»¸ÕÅ礤¤]³£¬Ý¨ì¤Fª`®gOBI-822¤§«á©Ò²£¥ÍªºÀø®Ä¡A¦Lµý¥ý«e¦³§ÜÅé§Y¦³Àø®Äªº»¡ªk e ¶È¥¼²£¥ÍIgG©ÎIgM§ÜÅ骺¨ü¸ÕªÌ¥¼¨£Àø®Ä¡C 2¥»¦¸¥xÆW¤T´ÁÁ{§É¸ÕÅç 72% (¨ü¸ÕªÌ) ¨ãGlobo H ªí²{ ±i¸³¦bªk»¡³Ì«á¦^µª´£¨ì Globo H ªí²{¶V°ª §ÜÅé¶q¶V°ª Àø®Ä·|¶V¦n 3 ºKn»Pµ²½×: ªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo H ªí²{¶qµLÃö¡C(¸~½F¥Íª«¼Ð°O¦¸±Ú¸sªº¼Ë¥»¼Æ¤Ó¤Ö) ³oӤϦӬO»¡©ú ¤TºØ¨È«¬¨ÅÀùªºªvÀø¤ÏÀ³¤£·|¦]¬°Globo Hªí²{¶q°ª§C¨à¦³©Ò¤£¦P (¤TºØ¨È«¬¨ÅÀù³£¦³®Ä) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/7 ¤W¤È 07:25:15²Ä 1815 ½g¦^À³
|
·PÁ°ݰÝÃD¤j¤j!! QQ¤j¡A±zªº°ÝÃD²{¦b¥H¤â¾÷Ãø¥´¦r¡C |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/6/7 ¤W¤È 06:53:24²Ä 1814 ½g¦^À³
|
¤½¥q ªí²{¶qµLÃö ´CÅé ªí²{µLÃö ¤Ö¤F¤@Ó¦r ·N¸q¤£¦P |
|
|
·|û¡Gtiger36510142526 µoªí®É¶¡:2016/6/7 ¤W¤È 06:40:57²Ä 1813 ½g¦^À³
|
Hello ¤j®a¦n, ¸ò¤j®a½Ð±Ð¤@Ó°ÝÃD, ¨Ì·Ó¯E¹©¤½¥qªº¤½§i... (2)OBI-822ªºªvÀø¤ÏÀ³»P±wªÌÅ餺Globo-Hªºªí²{¶qµLÃö¤§³ø¾É¡G³¡¤À³ø¾ÉÄY«»~¸Ñ¸Ó ¬ã¨sµ²½×¡A«üªvÀø¤ÏÀ³»P±wªÌÅ餺Globo Hªºªí²{µLÃö¡A¨Æ¹ê¥¿¦n¬Û¤Ï¡COBI-822¬O¥H Globo-H¬°¼ÐÃѧÜì³]pªº¬Ì]¡A¸Ó¬ã¨s¤wµý¹ê¡A¥HOBI-822ªvÀø«á²£¥Í§ÜÅé»P§_¡A»P¬O §_±a¦³Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê¡F¥ç§Y¨S¦³Globo-H§ÜìªÌ¡A¸gOBI-822ªvÀø«á¥ç¯à²£¥Í §ÜÅé¡A¦Ó¦³§ÜÅé¡A´N¥i²£¥ÍÀø®Ä¡F¥B§ÜÅé¿@«×¶V°ª¡AÀø®Ä´N¶V¦n¡C ±³o¤@¬q¸Ü ¥HOBI-822ªvÀø«á²£¥Í§ÜÅé»P§_¡A»P¬O §_±a¦³Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê¡F¥ç§Y¨S¦³Globo-H§ÜìªÌ¡A¸gOBI-822ªvÀø«á¥ç¯à²£¥Í §ÜÅé¡A¦Ó¦³§ÜÅé¡A´N¥i²£¥ÍÀø®Ä¡F¥B§ÜÅé¿@«×¶V°ª¡AÀø®Ä´N¶V¦n ¨S¦³GLOBAL-H§Üì--->¤]¥i²£¥Í§ÜÅé ©Ò¥H GLOBAL-H§Üì ¸ò¦³µL²£¥Í§ÜÅéµLÃö ²£¥Í§ÜÅé´N¦³Àø®Ä ¨Ì·Ó¤W¥y¤@°_±À½× -----> ¦³µLÀø®Ä ¸ò GLOBAL-H §Üìªí²{µLÃö ³o¤£¬O¸ò§O¤H½èºÃ¯E¹©ªºµ²½×¤@¼Ë???? ¬O§Úªº°ê¤å¤Ó®t¶Ü??? §Ú«ç»ò¬Ý³£Ä±±o¯E¹©ªº¼á²M´N¬O»¡ ¦³µLÀø®Ä ¸ò GLOBAL-H §Üìªí²{µLÃö ??? ´N¬O¸ò§O¤H½èºÃ¥LªºÂIµ²½×¤@¼Ë ¯à§_ ½Ðºô¤W¯à¤HÄÀºÃ¤@¤U ¤j·PÁÂ.. |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/7 ¤W¤È 01:41:35²Ä 1812 ½g¦^À³
|
Cliff ¤j, °Ý°ÝÃD¤j: ¤j¤j·PÁ¨â¦ìµL¨p´£¨Ñ¬Ã¶Q¸ê®Æ !! Cliff ¤j: ¡K.. ¡uAdditional studies are planned to further explore efficacy of OPT-822/821 in patients who generate a immune response.¡v ³o¥y°á§¹¦oÄò±µ»¡¡uand compared those with seen in adjuvant alone.¡v ¡K¡K ¯à§_½Ð±z±N¦oÄò±µ»¡ªº¨º´XÓ¦r©M«ez¤å¦r¦X¦b¤@°_½Ķ¤@¤U ? §Ú¹ê¦b°Â¤£¥X¨Ó. ³Â·Ð±z³Ò¾r±z¤F, please please please ¡K.. |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/7 ¤W¤È 01:25:41²Ä 1811 ½g¦^À³
|
1. ¹êÅç²Õ¨S¦³¥´º¡¤E°wªº120Ó¯f¤H©M¹ï·Ó²Õ¨S¦³¥´º¡¤E°wªº50Ó¯f¤H¤]¥i¥Hºâ¥X¨Ó¤ñ¤ñ¬Ý~~ p-18 ¦U¦Û¤p©ó30Ósample sizeªº³£¤£n¨q¥X¨Ó,¨S¦³·N¸qªºªF¦è¨q¥X¨Óµ¹½Ö¬Ý?·íµM³Q¤Hµh®_°Õ! ¦presponder vs. non-responder----Global H 1+2+3+¨C¤@Ó¨S¦³·N¸q,¦ý¬O3Ó¥[°_¨Ó¦U§O³£¶W¹L50Ó¯f¤H sample size°÷¤F,®t²§´N¥X¨Ó¤F!¦U50´XӼ˥»ºâ¤j¶Ü?---------¤£ºâ! ¦P²z,responder vs. placebo-------¦U50´XӼ˥»ºâ¤j¶Ü?---------¤£ºâ! Gobal H negativeªºresponder vs. non-responder----responder better Gobal H negativeªºresponder vs. placebo-------´N§Öresponder better¤F,¥H¤W³£¦]sample size¤Ó¤p, ¨º´N¤£n©ñ¥X¨ÓÀ~¤H¹À!!! n¤£µM¦p¦óµ²½×?------¤£ºÞGlobal H negative,¥unresponder,PFS is better????¨ìÀY¨Ó,¦Û¥´¼L¤Ú,©M Global Hªºªí²{µLÃö???????·Q±À½¹êÅ窺®Ú¥»ªì°J??????? sample size³o»ò¤p,§AÁ¿³oÓ·F¤°»ò!!!Why are you so stupid! |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/7 ¤W¤È 01:07:26²Ä 1810 ½g¦^À³
|
¤j³¡¤Àªº°ÝÃD¸ê²`ªº¦U¦ì¤j³£¤w»¡§¹¤F,¦Ñ´¤µ¤Ñ¬Ý¨ì¥_ºa°ü¬ì¬Y¦Ñ¤]¦b³oºØ®ÉÔ¥X¨Ó§è«á»L,¤ß¤¤¤£³Ó¼N®D, 륻¨Î¤H,©`¦ó¥Ì¬°¨rÆN¨«ª¯?Áö»¡ªº«Üªo±ø,³oºØ®ÉÔ¥X¨Ó©ñ¤°»ò§¾? ¦Ñ´´£¥X´XÂI¬Ýªk,·|¥h°Ñ¥[¤U¦¸ªÑªF·|ªº¤j¤j,¥i§_¥N¬°´£°Ý? ITT analysisÀ³¸Ón§â¨C¤@ºØ²Õ¦Xªºsubgroup³£ºâ¥X¨Óµ¹¤j®a¬Ý! 1. ¹êÅç²Õ¨S¦³¥´º¡¤E°wªº120Ó¯f¤H©M¹ï·Ó²Õ¦³¥´º¡¤E°wªº50Ó¯f¤H¤]¥i¥Hºâ¥X¨Ó¤ñ¤ñ¬Ý~~ 2. ¬JµM·Qªº¨ìppt p-18¤ñresponder vs. placebo & non-responder vs. responderªºPFS,¬°¤°»ò´N¨S¦³ ·Q¨ì¤ñ¤@¤U: - ¥´§¹¤E°wªº¹êÅç²Õ104 vs. ¨S¦³¥´§¹¤E°wªº¹êÅç²Õ120ªºcharecteristic(¤£¶È¬Obiological subtype&Global H)(p-11) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ ¦b²Îp¤W³oÓ¥s°µgoodness of fit(¾A¦X«×ÀË©w),¥un¨âªÌªº©Ò¦³Äݩʳ£¨S¦³®t²§,´N¥Nªí104¤H¥i¥H§¹¥þ ¥Nªí224¤H,Y¦³®t²§ªºÅܶµ´Nn©ñ¤Jcovariate·íconfounder¤~¤£·|³Q¤H¸á¯f¬U¤l¥u¬D³nªº¦Y!!! ¿ï¦¸±Ú¸s¥u¿ï§ÜÅ馳ªí²{ªº·íµM¥R¥¸µÛ«Ü¦h¦]¯Àªº¤zÂZ,´N¨S¦³»¡ªA¤O¤F!!! ¬Æ¦Ü³o¨Ç³£n¤ñ - ¥´§¹¤E°wªº¹êÅç²Õ104 vs. ¹êÅç²Õ224ªºcharecteristic(p-11) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ - responderªº112 vs. non-responder112ªºcharecteristic(p-11) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ ¯E¹©§r¯E¹©,¯uªº·Ç³Æ¦nn¥´°ê»Ú¬×¤F¶Ü?nµo«°Tn¥ý·Ç³Æ¦n¦p¦óDenfense§r!¦Ñ¬O®Á¥´,Xªº,®`¦Ñ¤H³£¥¢¯v ¤F! |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/7 ¤W¤È 12:59:24²Ä 1809 ½g¦^À³
|
˼ƲĤG±i§ë¼v¤ù: The treatment response, limited the way I suggested appears to be independent of tumor biologic subtype and Globo H expression levels, but the numbers are quite small. The majority of patients has some expression of Globo H, and most patients who have the expression of the similar carbohydrate antigens SSEA3 and 4, which this vaccine generates immune response to as well. |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤W¤È 12:49:14²Ä 1808 ½g¦^À³
|
ºa®¦¤j¤j¡G ÁÂÁ±zªº´£¿ô¡I §Ú¦A«·s¥J²Ó¬Ý¬Ý¡K ·P®¦³á¡I ¤µ¤Ñ¤½¥qªº·s»D½Z±j¦Ó¦³¤O¡A¤£¦AÁ¾¨õ§Ô@¡K¯uªº´ÀªÑªFÌ¥X¤F¤@¤f®ð ®¥³ß¤j®a¡I |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/6/7 ¤W¤È 12:43:46²Ä 1807 ½g¦^À³
|
²Ä17¶µo²{OS§C§ÜÅ骺¹êÅç²Õ¬ù¦b²Ä25Ó¤ë¶}©l»P¹ï·Ó²Õ©Ô¶}¤F(Ĺ¹L¤F),³o¬O§_¤]¦³«¤j·N¸q |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤W¤È 12:37:34²Ä 1806 ½g¦^À³
|
«e«h¶K¤å¨Ì§Ç§ó¥¿¦p¤U¤~¹ï =1:160 >1:160 >=1:160 |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/7 ¤W¤È 12:28:38²Ä 1805 ½g¦^À³
|
To Cliff ¥S: ¨º¥y¬O: Future studies, as well as perhaps one you will hear about a little bit later, should explore the amplification of the immune response and tumor specific effects potentially with combination therapy ¥H¤W³v¦r½Z, CI=99%, P<0.00001, ¨Ñ±z°Ñ¦Ò. ^^ |
|
|
·|û¡Gºa®¦10139955 µoªí®É¶¡:2016/6/7 ¤W¤È 12:26:02²Ä 1804 ½g¦^À³
|
999¤j ¸ÕµÛ¦^µª ¨Ñ±z°Ñ¦Ò ½Ð±Ð±z̹êÅç²Õ224¤H¤¤¡A¦³50% 112¤H¦³²£¥Í§K¬Ì¤ÏÀ³¡A³o¬O«ü112¤H³£¦³¬Û·í¦nªºÀø®Ä¶Ü¡H -> a.·Ó²zn¦³¸û¦nªºÀø®Ä, ¦ý¤]n¬Ý¨ü¸ÕªÌ¥»¨¬O¤£¬O¦³±aglobal H ²Ä17¶¤¤OS 78%¬O§_¬O«üÁÙ¦³87¤H«ùÄò¦³«p§À®ÄÀ³¶Ü¡H -> ¨ä¹êÁÙn¬Ý¨ü´úªÌ¬OþӮɶ¡ÂI¶i¤J¸ÕÅ窺¤~ª¾¬O¤£¬O¯uªº«Ü«p, ¦ý¬Ý°_¨Ó«p§ÀÁͶդw¸g¥X¨Ó¤F ¤p§ÌÁÙ¦³¤@ÂI·Q¤£³qªº¬O¹êÅç²Õ112¤H¦³²£¥Í§K¬Ì¤ÏÀ³¡A¦ý¥´§¹9°wªº«o¥u¦³104¤H¡H ¤£¬O²£¥Í§ÜÅé1>160´N¦³Àø®Ä¡H¨º¬°¦ó«o¥u¦³104¤H¥´§¹9°w¡H -> ¦³«Ü¦h¥i¯à, ¨ä¤¤¤@Ó§Ú²q´N¬O¡¨Áö¦³¦n¤ÏÀ³¦ý¤w¨Ó¤£¤Î¤F¡¨¡Kevent: 21. ÁÙ¬O»¡¥u¦³104¤Hªº50%¦³«D±`¦nªºÀø®Ä¡H -> ³o§AÀ³¸Ó§Ë¿ù¤F.. ³oÀ³¸Ó¬O112¤H¦³«Ü¦nªºÀø®Ä¡HÁÙ¬O52¤H¦³«Ü¦nªºÀø®Ä¡H -> ¦Pa. |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2016/6/7 ¤W¤È 12:18:57²Ä 1803 ½g¦^À³
|
½Ð±Ð«e½ú OS ¼Æ¾Ú¬O§_¥²¶·µ¥«Ý 5 ¦~ data ¡A¤~¥i§e²{¡C(·Ó¤½¥qÁ{§Éªº³W¹º¦n¹³¬O5¦~) ¦pªG2011 ¦~¶}©lºâ¡A¤¦~®É¶¡ÂI·|¸¨¦b¦ó®É©O? 2016 ¦~¦~©³? |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/7 ¤W¤È 12:13:06²Ä 1802 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡G ÁÂÁ±z¡K·PÁ±z¶O¤ßªº«ü¾É¡I «z¡I¡I¡I³oÃĮĤӴΤF¡I ¯E¹©¥[ªo¡K²³¤j¤j¥[ªo¡K |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/7 ¤W¤È 12:03:43²Ä 1801 ½g¦^À³
|
¸É¥R ¨Ì¾Ú¬ü°êÀù¯g¨ó·|American Cancer Society ³Ì·s²ÎpÂàºÃ©Ê¨ÅÀù5¦~¦s¬¡²v22% OBI822 ¥|¦~¦s¬¡²v survival 78.05% Total Events 21 18.75% °Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù¤j©óµ¥©ó1:160 ªº¤H¼Æ¦³112¤H¡Aª½¨ì¥h¦~10¤ë©³ ¦º¤`¤H¼Æ¶È¦³21¤H Àø®Ä¦p¦ó ¦Û¦³±M·~µû»ù ¼Æ¾Úªº¦nÃa³Ì«á¥òµôªÌ§Ú»{¬°¬O 1°ê»Ú¨ÅÀù±M®aªºµû½× 2°ê»Ú¤jÃļtÄ@·N¥H²Å¦X°ê»Ú±ÂÅv¦æ±¡¶i¦æ±ÂÅv 3¬ü°êFDA¨Ì¾ÚÁ{§É¼Æ¾ÚÄ@·Nµ¹¤©ÃÄÃÒ®Öã¡A¤£½×¬Oª½±µµ¹¤©©Îµ¹¤©¯S§OºÞ¹D¦p ¥[³t¼f¬d¡A®Öã¬ð¯}©ÊªvÀø Àu¥ý¼f¬d«á¦A®Öã¡C 4¥xÆWTFDA³q¹LÃÄÃÒ¼f¬d 5-year relative survival rates for Metastatic, or stage IV breast cancers Breast cancers that have spread to other parts of the body are more difficult to treat and tend to have a poorer outlook. Metastatic, or stage IV breast cancers, have a 5-year relative survival rate of about 22% www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage 999¤j 1±µ¨ü¬Ì]¥B¦bªvÀø´Á¶¡´¿¥X²{¹ï OPT-822²£¥ÍIgG§ÜÅé®Ä»ù>=160 ªº¹êÅç²Õ¯f±w (112¤H) ¨äPFSÀu©ó¹êÅç²Õ¥¼²£¥Í§K¬Ì¤ÏÀ³ªº¯f±w(112¤H) »P ¹ï·Ó²Õ(124¤H) ¬°¤F¹êÅç²Õ²Õ¤º¤ñ¸û Åý¨â²Õ¤H¼Æ¬Û¦P¦U112¤H §ì¨ì²Ä112¤H³Ì§CIgG§ÜÅé®Ä»ù=160 ¤]¦³IgG§ÜÅé®Ä»ù>160 ¨Ò¦p 200 240 280 320 360 400 440 480 520 560 600 640 1280 2560 2 ¹êÅç²Õ112¤H¦³²£¥Í§K¬Ì¤ÏÀ³¡A¦ý¥´§¹9°wªº«o¥u¦³104¤H¡H ¦³¨Ç¯f±w¥´7°w 8°w ¨S¦³¥´¨ì9°w ¤]¥i¯à²£¥ÍIgG§ÜÅé®Ä»ù>=160 §¹¦¨¥þµ{¤E¦¸ª`®gªº¯f±w¹êÅç²Õ¬O104¤H 3 224¤H¤¤¦³²£¥ÍIgG§ÜÅé®Ä»ù>=160ªº«e±50%¬O112¤H ³o112¤H¦³«Ü¦nªºÀø®Ä |
|
|
·|û¡GAlien10142514 µoªí®É¶¡:2016/6/6 ¤U¤È 11:40:59²Ä 1800 ½g¦^À³
|
¦U¦ì¤j¤j ¬°¤°»ò¹ï·Ó²ÕªºMPFS ·|³o»ò¦n©O ¤£¬O¤j·§8-9 Ó¤ë ? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/6 ¤U¤È 11:39:05²Ä 1799 ½g¦^À³
|
¿ò¯]¡G˼ƲĤG±islide ¡uSummary and Conclusions (cont) Treatment response appears to be independent of tumor biologic subtype and Globo H expression levels --Numbers are to small to allow comparison within biologic subsets¡v ³o¥yRugo°á§¹«áÄò»¡¡umost patient have expression of similar carbohydrate antigen SSEA-3 and -4 which this vaccine generates immune response too as well¡v¡]¡K¥i¯à§ÚÅ¥¿ù¤F´XÓ¦r¡K¡^ ¡uAdditional studies are planned to further explore efficacy of OPT-822/821 in patients who generate a immune response.¡v ³o¥y°á§¹¦oÄò±µ»¡¡uand compared those with seen in adjuvant alone.¡v ¡u--Future studies should explore amplification of immune response. ¡v ³Ì«á³o¤@¥y¦o¬O»¡¡uFuture studies as well as perhaps one year you hear about a little bit later should explore amplification of immune response and tumor specific effects potentially with combine therapy.¡vÁp¦XªvÀø³á¡K ¥H¤WÄÝ©ó¤£t³d¥ô±Ôz¡A½Ð§O»{¯u¦a¥hÂà°Ý¤½¥q¬Æ»ò¤@¦~«á¦p¦ó¤ª¤ª¡K¡A¨ìÀY¨ÓÅ¥¿ùªº¬O§Ú¡A³Q¤½¥qÅF¦^¨Óªº¥i¬O±z¦Û¤v³á¡I§O»¡¬O§Ú»¡ªº¡F§Ún»¡ªº´N¬O¡Aťť´N¦n¡A¦o¤£¯à¥Nªí¤½¥q¡A¤p§Ì§ó¤£¬O¡I¤×¨ä¦oªº»¡¸Ü³t«×¤§§Ö¡K§ÚºÉ¤O¤F¡K ·|«áªº°Q½×¡A¬ù5¤À10¬í¡A¦³¤T¦ì´£°Ý¤F¥|Ó¡]?¡^°ÝÃD´Nµ²§ô¡A®ÇÃ䪺¨â½g³ø§iªÌ¶È¯à³§¤¡A¨S¤Hn°Ý¦oÌ¡A©Ò¥HAmy¸g²z©Ò¨¥¬Ò¬O¡C ¦³°ê¤º´CÅ黡¥~´C§N²M¡K¡A¦pªG³õ¤lùثܼö©O? ¥H¤U¨ÌµM¬O¤£t³d¥ô±Ôz¡G ²Ä¤@¦ì°Ý¦bresponder¡Bnon-responder»Pplacebo¶¡ªº§ÜÅé®Ä»ù®t¶Z¡A¡umay simply be a reflection mode¡]?¡^of time bias?¡v¡ARugo°±¤F¼Æ¬í¡A·b·b»ó»¡¤F¤@¨Ç¡A³Ì«á»¡¦o¤]¤£ª¾¹D¡I ²Ä¤G¦ì°Ý¤F¨âÃD§a¡H¬O±´°Q¬O§_¦³§ÜKLH Abªº°ÝÃD¡K¤p§Ì¤O¦³¤£¶e¡KRugo¸Ø»¡¬OÓ¡uexcellent question¡v¡C ²Ä¤T¦ì¬O¨Ó¸Ø¼úªº¡A¼K¼K¡AÅ¥µL¡C ¬Q¤Ñªº»¡©ú·|¡A±i¸³»¡¬O¶Â¥Õªº¡A¤£¬O¤C±mªº¡A§Úı±on¸É¤W¤@¥y¡A¡uÁö¤£¬O¤C±m¡A¦ý¤]¤£¬O±~ºGªº¡v¡C¥«³õ/´CÅ骺¸ÑŪ¡AÃø§K¦U»¡¦U¸Ü¡A¤H¤H¬O±M®a¡AÓÓ¨S§â´¤¡A½Ñ¦ì½Ð¦Û¤v¬ÝµÛ¿ì¡I ·PÁÂCaster¤j¤jµL¨p¨ó§U¡I |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/6 ¤U¤È 10:50:39²Ä 1798 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡A½Ñ¦ì¤j¤j«e½ú¡G ½Ð±Ð±z̹êÅç²Õ224¤H¤¤¡A¦³50% 112¤H¦³²£¥Í§K¬Ì¤ÏÀ³¡A³o¬O«ü112¤H³£¦³¬Û·í¦nªºÀø®Ä¶Ü¡H ²Ä17¶¤¤OS 78%¬O§_¬O«üÁÙ¦³87¤H«ùÄò¦³«p§À®ÄÀ³¶Ü¡H ¤p§ÌÁÙ¦³¤@ÂI·Q¤£³qªº¬O¹êÅç²Õ112¤H¦³²£¥Í§K¬Ì¤ÏÀ³¡A¦ý¥´§¹9°wªº«o¥u¦³104¤H¡H ¤£¬O²£¥Í§ÜÅé1>160´N¦³Àø®Ä¡H¨º¬°¦ó«o¥u¦³104¤H¥´§¹9°w¡H ÁÙ¬O»¡¥u¦³104¤Hªº50%¦³«D±`¦nªºÀø®Ä¡H ³oÀ³¸Ó¬O112¤H¦³«Ü¦nªºÀø®Ä¡HÁÙ¬O52¤H¦³«Ü¦nªºÀø®Ä¡H ÁÂÁ«ô°U«ü¾É¡C ¬Ý¹Ïªí¬Ýªº¦³ÂIÃú·Ù·Ù¡K |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/6 ¤U¤È 10:47:25²Ä 1797 ½g¦^À³
|
§ó¥¿¿ù»~ 2 ¹êÅç²Õ²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û (²Õ¤º¤ñ¸û) ¥|¦~ survival 78.05% Total Events 21 18.75% °Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù¤j©óµ¥©ó1:160 ªº¤H¼Æ¦³112¤H¡A¦º¤`¤H¼Æ¶È¦³21¤H¡A±q2011¦~¨ì¥h¦~10¤ë©³¤w¸gªñ¤¦~¡A81.25% ¨ü¸Õ¨Ì·Ó¦s¬¡ ,³oÓÃĦn¤£¦n¡A¹Ïªí³N¦r·|»¡¸Ü |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/6 ¤U¤È 10:37:14²Ä 1796 ½g¦^À³
|
²³¤j¤j±ß¦w A¥h¦~11¤ëMSCI¤½¥¬³Ì·s¥b¦~«×¥xÆW«ü¼Æ¦¨¤ÀªÑ½Õ¾ã¡A·sÃļt¯E¹© (4174) ¬O°ß¤@·s¼WªºÓªÑ èèwalker ¤j ´£¨Ñ«n¸ê°T ¯u¯«©_, ¯E¹©©~µM¦b 5/21 ³Q¥[¤J FTSE ¥þ²y«ü¼Æ Âù³ßÁ{ªù Obi Pharma Inc (4174) Key Developments OBI Pharma, Inc.(GTSM:4174) added to FTSE All-World Index (USD) Mar 21 16 B ±i¸³ªk»¡·|¦³´£¨ì¥¼¨Ó·|ºÉ§Ö§ä¨ì¦nªº®É¾÷¤½§i§ó²Óªº¾Ú¤ÀªR ,¤]·|°Ñ®aASCO meeting »Pµoªí©ó«n´Á¥Z,²{¦b¤w¸g¦b·Ç³Æ¤¤ 6¤ë5¤é¤U¤ªk»¡·|¼vµÀɦhÅ¥´X¦¸´N¤£·|³¡¥÷³Q´CÅé»~¾É C ¨ÅÀùOBI 822¦w¥þ©Ê¤è±: OPT-822/821°£¤F§K¬ÌÀøªk¯S©Ê³y¦¨¥DnÀø®Ä«ü¼ÐµL´c¤Æ¦s¬¡´Á¡]PFS¡^¥¼¹F¨ìÅãµÛ®t²§¥~@¨ü©Ê¨}¦n¡A¶È¦³²Ä1¨ì2¯Åªºµo¼ö©Mª`®g³¡¦ì¤ÏÀ³¡C(³o¤@Ó@¨ü©Ê¨}¦nªº¨Æ¹ê¤w±j±j¯P»¡©ú»P¤Ï»é´CÅ餣¹ê½×z: ¥xÆW¯E¹©¤µ¤Ñ¦b¤½¶}¸ê°TÆ[´ú¯¸¤½§i: ©Ò¦³¨ü¸ÕªÌ¤£½×¨ºÓ¸s²Õ¡A¦b¾ãÓ¸ÕÅçÆ[¹î´Á¤¤¡A°£¤Fµo¥Íª`®g³¡¦ìªº¬õ¸~¼öµh¤§¥~¡A±q¥¼¨£ÄY«°Æ§@¥Î¡A¹N½×¹ï¨ü¸ÕªÌ¦³®`?³¡¤À´CÅé¤Þ¥Î§ëÅU¤ÀªR®v¤§¤£¹êµû½×¡A»z«üOBI-822¹ï³¡¤À±wªÌ¦³®`¡A¤£¶ÈÄY«ÂÕ»~¡A¥B«YµL¤¤¥Í¦³¡C D ¨ÅÀùOBI 822Àø®Ä¤è±: 1¸ÕÅç²Õ¡B§Y±µ¨üOBI-822ª`®gªÌ¡AY²£¥Í§K¬Ì¤ÏÀ³ (¹ïGlobo H©Ò²£¥Íªº§ÜÅé®Ä»ù¡Ù1:160)ªÌ¡A¨äµL´c¤Æ¦s¬¡´Á(PFS)»PÁ`¦s¬¡´Á(OS)µL½×»PµL§K¬Ì¤ÏÀ³ªÌ (§ÜÅé®Ä»ù<1:160)¡B©Î¹ï·Ó²Õ¬Û¤ñ¡A§¡§e²{©úÅã®t²§¡C ¦pªG¥ÎIgG²£¥Í¶q«e50%ªº¸ÕÅç²Õ¯f¤H¡A¸ò¹ï·Ó²Õ©Ò¦³¯f¤H¦A¤ñ¤@¦¸¡A´N¹F¨ì¤FÀø®ÄÅãµÛ©Ê PFS¡AHR = 0.71 [95%CI 0.52-0.97]¡Ap= 0.029¡F OS¡AHR=0.57 [95%CI 0.33-0.97]¡Ap = 0.04 2¹êÅç²Õ²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û (²Õ¤º¤ñ¸û) PFS¡AHR = 0.52 [95% CI 0.37-0.71]¡Ap< 0.0001¡F(PFS ¹F¨ì«D±`ÅãµÛ®t²§) OS¡AHR = 0.52 [95% CI 0.29-0.92]¡Ap= 0.025 (OS ÁÙ¦bÆ[¹î¤¤¤w¹FSignificant¹w´Á©¹«á·|³v¨B©Ô¤j®t²§ ¦í¬O«D±`¥¿±ªºµo®i ¦pªGOS ¼Æ¾Ú¤w¦¨¼ô ¤£»Ý¦AÆ[¹î¤Ï¦Ó¤£¬O¦n®ø®§ ¶V±ß¤½§Gªí¥ÜOS·|¶Vªø, ¬¡ªº¶V¤[ ¡]µ²ªG¸g°ò¦¯e¯fª¬ºA/²üº¸»XÀøªk¨Ï¥Î±¡ªp®Õ¥¿)¡C Ó¤H¤H¬° ¯E¹©ªº¨ÅÀùÃĦ³¨S¦³®Ä¥J²Ó¬Ý§ë¼v¤ù²£¥Í§K¬Ì¤ÏÀ³¯f±wªº´Á¤¤Á`¦s¬¡´Á (interim OS) ¡]°Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù ≥1:160) ¥|¦~ survival 78.05% Total Events 21 18.5% °Ñ»P¸ÕÅç«á´¿¥X²{IgG§ÜÅé®Ä»ù¤j©óµ¥©ó1:160 ªº¤H¼Æ¦³112¤H¡A¦º¤`¤H¼Æ¶È¦³21¤H¡A±q2011¦~¨ì²{¦b¤w¸g¤¦~¥b¡A81.5% ¨ü¸Õ¨Ì·Ó¦s¬¡ ,³oÓÃĦn¤£¦n¡A¹Ïªí·|»¡¸Ü 3µL§K¬Ì¤ÏÀ³±Ú¸s(§ÜÅé®Ä»ù<1:160)¡A¤½¥q¤w»¡©úÁÙ¥i²Ó¤À¬°¦Ü¤Ö¥|Ó±Ú¸s¡A§Y a§ÜÅé®Ä»ù1:40 b§ÜÅé®Ä»ù1:80¡B c¥u²£¥ÍIgM§ÜÅéªÌ¡A d¬J¥¼²£¥ÍIgG¡B¤]¥¼²£¥ÍIgMªº¨ü¸ÕªÌ¡C ¨Æ¹ê¤W¡A«e¤TÓ¦¸¤À²Õ¦b¥»¸ÕÅ礤¤]³£¬Ý¨ì¤Fª`®gOBI-822¤§«á©Ò²£¥ÍªºÀø®Ä¡A¦Lµý¥ý«e¦³§ÜÅé§Y¦³Àø®Äªº»¡ªk e¶È¥¼²£¥ÍIgG©ÎIgM§ÜÅ骺¨ü¸ÕªÌ¥¼¨£Àø®Ä¡C (¥xÆW¯E¹©¤µ¤Ñ¦b¤½¶}¸ê°TÆ[´ú¯¸¤½§i) 4 ¨ÅÀùOBI-822ªvÀø«á²£¥Í§ÜÅé»P§_¡A»P¬O§_±a¦³Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê: OBI-822ªºªvÀø¤ÏÀ³»P±wªÌÅ餺Globo-Hªºªí²{¶qµLÃö¤§³ø¾É¡G³¡¤À³ø¾ÉÄY«»~¸Ñ¸Ó¬ã¨sµ²½×«üªvÀø¤ÏÀ³»P±wªÌÅ餺Globo Hªºªí²{µLÃö¡A¨Æ¹ê¥¿¦n¬Û¤Ï¡COBI-822¬O¥HGlobo-H¬°¼ÐÃѧÜì³]pªº¬Ì]¡A¸Ó¬ã¨s¤wµý¹ê¡A¥HOBI-822ªvÀø«á²£¥Í§ÜÅé»P§_¡A»P¬O§_±a¦³Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê¡F¥ç§Y¨S¦³Globo-H§ÜìªÌ¡A¸gOBI-822ªvÀø«á¥ç¯à²£¥Í§ÜÅé¡A¦Ó¦³§ÜÅé¡A´N¥i²£¥ÍÀø®Ä¡F¥B§ÜÅé¿@«×¶V°ª¡AÀø®Ä´N¶V¦n¡C(¥xÆW¯E¹©¤µ¤Ñ¦b¤½¶}¸ê°TÆ[´ú¯¸¤½§i) E ¨ÅÀùOBI-822»PÄvª§¹ï¤â¬Û®t10Ӥ뤧³ø¾É¡G ¸Ó¸ÕÅ礤§¹¦¨¤E¦¸OBI-822ª`®gªº104¦W±wªÌ¤¤¡A¨äµL´c¤Æ¦s¬¡´Á(PFS)¤¤¦ì¼Æ¬°22.5Ó¤ë¡A»P¹ï·Ó²Õ(64¤H)18.1Ó¤ë¡A¬Û®t4.4Ó¤ë¡C¦³³ø¾É±N¦¹¤@µ²ªG»P¥t¤@¤p¤À¤l¨ÅÀù¼Ð¹vÃĪ«IbranceªvÀø»P¹ï·Ó²Õ¬Û®t10Ӥ뵲ªG¬Û¤ñ¡A»{¬°OBI-822»P¤§¤´¦³¤@¬q®t¶Z¡A¥¼¨Ó¦b²üº¸»X¨üÅ鶧©Ê±Ú¸sªº¨ÅÀùªvÀø¥«³õ¤W±N¨ü¨ì¬D¾Ô¡C¨Æ¹ê¤W¡AIbrance»POBI-822ÃĪ«Äݩʤ£¦P¡AªvÀø¹ï¶H¡B¾÷Âà¤]~²§¡A¥BOBI-822´XµL°Æ§@¥Î¡A»PIbrance·|¤Þ°_¥Õ¦å²y´î¤Ö¤Î·P¬Vµ¥ÄY«°Æ§@¥Î¬Û¤ñ¡A¤GªÌ®t²§¬Æ¤j¡C¥BOBI-822¥¼¨Ó¬Æ¦Ü¥i¯à»PIbrance¨Ö¥Î¡A©¼¦¹¦bÀø¤W¬Û»²¬Û¦¨¡A¦Ó«D¦b¥«³õ¤¬¥¸©ÎÄvª§¡C(¥xÆW¯E¹©¤µ¤Ñ¦b¤½¶}¸ê°TÆ[´ú¯¸¤½§i) Ó¤H¬Ýªk : 1¦X§@±ÂÅv¹ï¶H·|¬OPfizer½÷·ç¤jÃļt ? 2 Ibrance µL´c¤Æ¦s¬¡´Á(PFS)¤¤¦ì¼Æ20.2Ó¤ë ,§¹¦¨¤E¦¸OBI-822ª`®gªº104¦W±wªÌ¤¤¡A¨äµL´c¤Æ¦s¬¡´Á(PFS)¤¤¦ì¼Æ¬°22.5Ó¤ë ¤ñIbrance ¦n2.3Ó¤ë³o¤~¬OµJÂI«ÂI ,©ú©ú¬O§Q¦h³Q»¡¦¨§QªÅ ¯u¨S¤Ñ²z F ASCO½×¤åºKn»Pµ²½× • OPT-822/821¬Ì]°µ¬°Âಾ©Ê¨ÅÀùªººû«ùÀøªk - ¥DnÀø®Ä«ü¼ÐµL´c¤Æ¦s¬¡´Á¡]PFS¡^¥¼¹F¨ìÅãµÛ®t²§¡C •@¨ü©Ê¨}¦n¡A¶È¦³²Ä1¨ì2¯Åªºµo¼ö©Mª`®g³¡¦ì¤ÏÀ³¡C • ±µ¨ü¬Ì]¥B¦bªvÀø´Á¶¡´¿¥X²{¹ï OPT-822²£¥ÍIgG§ÜÅé®Ä»ù>160 ªº¯f±w¡G - ¨äPFSÀu©ó¦w¼¢¾¯²Õ¥H¤Î¥¼²£¥Í§K¬Ì¤ÏÀ³ªº¯f±w • ±µ¨ü¬Ì]ª`®g¥B¥¼¦³§K¬Ì¤ÏÀ³ªº¯f±w¡A¹w«á¤£¦n¡C • §¹¦¨OPT-822/821¥þµ{¤E¦¸ª`®gªº¯f±w¡A¬Û¹ï©ó¦w |
|
|
·|û¡G¦Ï«§«§10141876 µoªí®É¶¡:2016/6/6 ¤U¤È 09:04:22²Ä 1795 ½g¦^À³
|
123¤j¡AÁÂÁ¤ήÉPO¤å¡A¤½¥q¯à¤Î®É¼á²M¤]«Ü¦n¡A¬Ý¨Ó¤½¥q²{¶¥¬q¯uªº¦³Ãø¨¥¤§Áô¡AÁÙ¦³³\¦h¥¼¤½¶}¸ê®Æ¬Oȱo´Á«Ýªº¡A¥Ø«e¥u¯àÀR«Ý¨Îµ¤F¡C^^ |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/6/6 ¤U¤È 08:35:14²Ä 1794 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:105/06/06 2.¤½¥q¦WºÙ:¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.¶Ç¼½´CÅé¦WºÙ:¥xÆWÄ«ªG¤é³øºô¡B¹d¦ëºô 6.³ø¾É¤º®e:(1)¥xÆWÄ«ªG¤é³øºô¡Gªk¤H»{¬°¡A¤Wz¼Æ¾Ú·t¥Ü¡AOBI-822¹ï¬Y¨Ç±wªÌ¦³¯q¡A ¡u¥ç¹ï¬Y¨Ç±wªÌ¦³®`¡v¡A°ò©ó¦¹¤@¥Ù¬Þªºª¬ªp¡A¬ü°êFDA¤£¥i¯à±µ¨ü¤½¥q¦¥ý´£¥Xªº¿z ¿ï¼Ð·Ç¡A¦¹¥~¡A¥»¦¸ASCO¸ê®ÆÅã¥Ü¡uOBI-822ªºªvÀø¤ÏÀ³»P±wªÌÅ餺Globo-Hªºªí²{¶q µLÃö¡v¡A¦¹µ²½×®£·|¨ÏFDAn¨D¶i¦æ§ó¦h¸ÕÅç¡A¤]¤£§Qproof-of-conceptªºÃÒ©ú¡C (2)¹d¦ëºô¡G·sÃļt¯E¹©(4174-TW)¬Q¤Ñ¤½¥¬¨ÅÀù·sÃÄOBI-822¸Ô²Ó¼Æ¾Ú¡A¥~¸êªí¥Ü¡A ¯E¹©¤´¦³2¤jÃö¥dn¹L¡A¥]¬A¹êÅç²Õ»P¹ï·Ó²ÕªºµL·ÀI¦s¬¡´Á¬Û®t¬ù4.4Ó¤ë¡A¡u»PÄvª§ ¹ï¤â¬Û®t10Ó¤ë¡v¡A¥t¥~¡AOBI-822¹ï¤£·|²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¦³®`¡A¦]¦¹¿z¿ïªvÀø±Ú ¸sªº¼Ð·Ç±N§ó§ï¡C 7.µo¥Í½t¥Ñ:¥»¤½¥qÄY¥¿µoªíÁn©ú¡A«ü½Ñ¦h´CÅé¹ï©ó¥»¤½¥qªvÀø©Ê¨ÅÀù¬Ì]OBI-822 ½×¤åªº³ø¾É§¡µo¥ÍÄY«ÂÕ»~¡AÄY«»~¾ÉªÀ·|¤j²³»P§ë¸ê¤H¡A¥»¤½¥q¼á²M¬ÛÃöOBI-822¬ã ¨s«nµ²ªG¦p¤U¡G (1)¹ï¬Y¨Ç±wªÌ¦³®`¤§³ø¾É¡G¸ÕÅç²Õ¡B§Y±µ¨üOBI-822ª`®gªÌ¡AY²£¥Í§K¬Ì¤ÏÀ³ (¹ïGlobo H©Ò²£¥Íªº§ÜÅé®Ä»ù¡Ù1:160)ªÌ¡A¨äµL´c¤Æ¦s¬¡´Á(PFS)»PÁ`¦s¬¡´Á(OS)µL½× »PµL§K¬Ì¤ÏÀ³ªÌ(§ÜÅé®Ä»ù<1:160)¡B©Î¹ï·Ó²Õ¬Û¤ñ¡A§¡§e²{©úÅã®t²§¡C ³o¸Ì©ÒºÙªºµL§K¬Ì¤ÏÀ³±Ú¸s(§ÜÅé®Ä»ù<1:160)¡A¨ä¹êÁÙ¥i²Ó¤À¬°¦Ü¤Ö¥|Ó±Ú¸s¡A§Y§Ü Åé®Ä»ù1:40¡B1:80¡B¥u²£¥ÍIgM§ÜÅéªÌ¡A¤Î¬J¥¼²£¥ÍIgG¡B¤]¥¼²£¥ÍIgMªº¨ü¸ÕªÌ¡C ¨Æ¹ê¤W¡A«e¤TÓ¦¸¤À²Õ¦b¥»¸ÕÅ礤¤]³£¬Ý¨ì¤Fª`®gOBI-822¤§«á©Ò²£¥ÍªºÀø®Ä¡A¦Lµý¥ý «e¦³§ÜÅé§Y¦³Àø®Äªº»¡ªk¡A¶È¥¼²£¥ÍIgG©ÎIgM§ÜÅ骺¨ü¸ÕªÌ¥¼¨£Àø®Ä¡C¦Ó©Ò¦³¨ü¸ÕªÌ¤£ ½×¨ºÓ¸s²Õ¡A¦b¾ãÓ¸ÕÅçÆ[¹î´Á¤¤¡A°£¤Fµo¥Íª`®g³¡¦ìªº¬õ¸~¼öµh¤§¥~¡A±q¥¼¨£ÄY«°Æ §@¥Î¡A¹N½×¹ï¨ü¸ÕªÌ¦³®`?³¡¤À´CÅé¤Þ¥Î§ëÅU¤ÀªR®v¤§¤£¹êµû½×¡A»z«üOBI-822¹ï³¡¤À±w ªÌ¦³®`¡A¤£¶ÈÄY«ÂÕ»~¡A¥B«YµL¤¤¥Í¦³¡C (2)OBI-822ªºªvÀø¤ÏÀ³»P±wªÌÅ餺Globo-Hªºªí²{¶qµLÃö¤§³ø¾É¡G³¡¤À³ø¾ÉÄY«»~¸Ñ¸Ó ¬ã¨sµ²½×¡A«üªvÀø¤ÏÀ³»P±wªÌÅ餺Globo Hªºªí²{µLÃö¡A¨Æ¹ê¥¿¦n¬Û¤Ï¡COBI-822¬O¥H Globo-H¬°¼ÐÃѧÜì³]pªº¬Ì]¡A¸Ó¬ã¨s¤wµý¹ê¡A¥HOBI-822ªvÀø«á²£¥Í§ÜÅé»P§_¡A»P¬O §_±a¦³Globo-H¨S¦³ÅãµÛ¬ÛÃö©Ê¡F¥ç§Y¨S¦³Globo-H§ÜìªÌ¡A¸gOBI-822ªvÀø«á¥ç¯à²£¥Í §ÜÅé¡A¦Ó¦³§ÜÅé¡A´N¥i²£¥ÍÀø®Ä¡F¥B§ÜÅé¿@«×¶V°ª¡AÀø®Ä´N¶V¦n¡C (3)»PÄvª§¹ï¤â¬Û®t10Ӥ뤧³ø¾É¡G¸Ó¸ÕÅ礤§¹¦¨¤E¦¸OBI-822ª`®gªº104¦W±wªÌ¤¤¡A¨ä µL´c¤Æ¦s¬¡´Á(PFS)¤¤¦ì¼Æ¬°22.5Ó¤ë¡A»P¹ï·Ó²Õ(64¤H)18.1Ó¤ë¡A¬Û®t4.4Ó¤ë¡C ¦³³ø¾É±N¦¹¤@µ²ªG»P¥t¤@¤p¤À¤l¨ÅÀù¼Ð¹vÃĪ«IbranceªvÀø»P¹ï·Ó²Õ¬Û®t10Ӥ뵲ªG¬Û ¤ñ¡A»{¬°OBI-822»P¤§¤´¦³¤@¬q®t¶Z¡A¥¼¨Ó¦b²üº¸»X¨üÅ鶧©Ê±Ú¸sªº¨ÅÀùªvÀø¥«³õ¤W±N ¨ü¨ì¬D¾Ô¡C¨Æ¹ê¤W¡AIbrance»POBI-822ÃĪ«Äݩʤ£¦P¡AªvÀø¹ï¶H¡B¾÷Âà¤]~²§¡A¥B OBI-822´XµL°Æ§@¥Î¡A»PIbrance·|¤Þ°_¥Õ¦å²y´î¤Ö¤Î·P¬Vµ¥ÄY«°Æ§@¥Î¬Û¤ñ¡A¤GªÌ®t²§ ¬Æ¤j¡C¥BOBI-822¥¼¨Ó¬Æ¦Ü¥i¯à»PIbrance¨Ö¥Î¡A©¼¦¹¦bÀø¤W¬Û»²¬Û¦¨¡A¦Ó«D¦b¥«³õ¤¬¥¸ ©ÎÄvª§¡C 8.¦]À³±¹¬I:µL 9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:³æ¤@Á{§É¸ÕÅçµ²ªG¡A¨Ã¤£¨¬¥H¥R¤À¤Ï¬M¥¼¨Ó·sÃĶ}µo¤W¥«¤§¦¨±Ñ¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡Gºa®¦10139955 µoªí®É¶¡:2016/6/6 ¤U¤È 07:52:57²Ä 1793 ½g¦^À³
|
5619¤j OBI-822¬O¥D°Ê§K¬Ì, ªvÀø¤ÏÀ³À³¸Ó»P¤Hªº§K¬Ì¨t²Î¹ï©ó¥´¤Jªº822¯à²£¥Í¦h¤Ö§ÜÅé(§Úx)¦³Ãö, »P¦h¤ÖGlobal H(¼Äx)µLÃö, ¥B¥un²£¥Í§ÜÅé, ¤S§ä¨ì±a¦³Global Hªº¸~½F´N¦³Àø®Ä..³o¨âx¹ï¾Ô, ®t§O¥u¬O¤jxÀ£°}®ø·À¼Ä¤HÁÙ¬O¹s¬P¬¶¤õµL·l¼Äx¾Ô¤O. ©Ò¥H§Úı±o§ë¼v¤ù¨S¼g¿ù°Õ¡A¤£¹L§Ú¬O¤@Ó¤£¥Î¥\ªº§ë¸ê¤H..¦pªG»¡¿ù, ½Ð¦U¦ì¤j¥Î¤OÃ@ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/6/6 ¤U¤È 06:54:50²Ä 1792 ½g¦^À³
|
5619¤j ü... ¤½¥q»¡±o§¹¥þ¥¿½T§r¡I ¡u§ë¼v¤ù-21¬O³o»ò¼gªº¡GªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶qµLÃö¡v «ÂI¦b¡u¶q¡v³oÓ¦r¡I·íµMµLÃö§r¡I ü..... ¤p§Ì¥»¨Ó·QÁ¿«Ü¦h¸Ü...·Q·Q¡A§@½}¡I ¬Û«H¤½¥qªº¯E¤ÍÌ¡AÁÂÁ¤j®aªº§V¤O¡A¤@°_¥[ªo¡I mouth¤j ¤p§ÌªY½à±z¡AÆg¡I |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/6/6 ¤U¤È 06:24:42²Ä 1791 ½g¦^À³
|
§ë¼v¤ù-21¬O³o»ò¼gªº¡GªvÀø¤ÏÀ³Åã¥Ü»P¸~½F¥Íª«¼Ð°O¨È«¬¤ÎGlobo Hªí²{¶qµLÃö¡C±i¸³¦^µª¦¶Âå®vªº´£°Ý¡A¦^µª»¡¡§¨S¦³Globo Hªí²{¤]·|²£¥Í§ÜÅ顨¡C¯u¥s¤H¤@ÀYÃú¤ô¡A¤£¯à©Ç§ë¸ê¤H¡§»~¸Ñ¡¨¡A§ë¼v¤ù¤W¤½¥qªº©x¤è¼gªk®£©È¬O¡§»~¼g¡¨¡A¦Ü¤Ö¡§¸Ó¸ÑÄÀ¦Ó¥¼¸ÑÄÀ¡¨¡C¦pªGªvÀø¤ÏÀ³»PGlobo Hªí²{¶qµLÃö¡A¨º»ò©Ò¿×ªºMOA´N¤£ª¾©Ò¥H¤F¡C¤p§Ì¬Ý¤Fyoutubeªk»¡·|¡A«Ü¥¢±æ¡C¤£¬O¹ï822ªºÀø®Ä¥¢±æ¡A¦Ó¬O¹ï¤½¥qªk»¡·|ªººt¥X¥¢±æ¡A¯u¤@°Æ¯fìæì檺¼Ë¤l¡C«ë¦Û¤v¦³³oºØ·Pı¡A¦ý´N¬O³o¼Ë¡C |
|
|
·|û¡GRudy10141433 µoªí®É¶¡:2016/6/6 ¤U¤È 04:16:03²Ä 1790 ½g¦^À³
|
¥´§¹¤E°wªº±Ú¸s¡A¬°¤°»ò¤£¦A¿z¿ï¸Ì±¦³§ÜÅ骺¡H §ÚÓ¤Hªº¸ÑŪ¬O¡A·|¥X²{³oÓ¥´§¹¤E°wªº¦¸±Ú¸s¡A´N¬O¬°¤Fn¸ÑÄÀ§ÜÅé¿@«×§Cªº¤H¡Aªí²{¤ñ¹ï·Ó²Õ®tªº°ÝÃD¡C ¦]¬°§ÜÅé¿@«×°ª-->Àø®Ä¦n¡A§ÜÅé¿@«×§C-->Àø®Ä®t¡A §Ú¤]¥i¥H»¡¬O¡A§ÜÅé¦hªº¤H¥Nªí¨Åé¦n¡A¥»¨Ó´NÀ³¸Ó¬¡ªº¤ñ¸û¤[¡A¦¨ÁZ¤ñ¸û¦n°Ú¡C ©Ò¥Hn¬D¤@Ó¡A¹êÅç²Õ¹ï·Ó²Õ³£¤½¥ªº±ø¥ó¡A¦A°µ¤@¦¸¤ñ¸û¡AÃÒ©úÃĬO¯uªº¦³Àø®Ä¡C ¦Ü©ó§ÜÅé¿@«× 1:160 °Ï¤À¥X¨Óªº¨âÓ¦¸±Ú¸s¡A §Úı±o¨âÓ±Ú¸sªº¼Æ¾Ú¡A¨ü¨ì¨Åé°·±dµ{«×ªº¼vÅTÁÙ¬OÆZ¤jªº¡A¼Æ¾Ú¥X¨Ó¤]¨ü¨ì¤F¤@¨Ç½èºÃ¡C ³o³¡¤À´N¥æµ¹¤½¥qªº±M®a¥h¸Ñ¨M§a¡C |
|
|
·|û¡Gªü¤É10141781 µoªí®É¶¡:2016/6/6 ¤U¤È 02:55:17²Ä 1789 ½g¦^À³
|
¦³¤@ÂI¤pºÃ°Ý¡A ¥´§¹¤E°wªº¹êÅç²Õ¥u¦³104Ó¤H¡A ¦³²£¥Í§ÜÅ骺¹êÅç²Õ«o¦³112Ó¤H(¨S¦³²£¥Í§ÜÅé¤]112¤H)¡A ©Ò¥H104Ó¤H¸Ì±¤]¥]§t¨S¦³²£¥Í§ÜÅ骺¡A ¬°¤°»ò¤£¿z¿ï¥X³o104Ó¤H¸Ì±¦³²£¥Í§ÜÅ骺? ³o¼Ë¤~¬O³Ì¦³°Ñ¦Ò»ùȪº¤@¸s¤H¤£¬O¶Ü?(¥´§¹9°w¡B¥i¥H²£¥Í§ÜÅé) ¦³³oӼƾڶÜ? ²£¥Í ¨S²£¥Í ¤p°O ¥´§¹ ___¤H ___¤H 104¤H ¨S¥´§¹ ___¤H ___¤H 120¤H ¤p°O 112¤H 112¤H |
|
|
·|û¡G¥ú¼v10031538 µoªí®É¶¡:2016/6/6 ¤W¤È 11:57:26²Ä 1788 ½g¦^À³
|
¤£¥Î°²³]¤F¡A·x·x¤j¡A§Ú¥i¥H§i¶D§A¡AOBI822ªº³Ì·s³ø§i¡A¤w¸g¦b¯f¤Í°é³y¦¨ÅF°Ê¡C ¥Ø«e¥L̳£¦b¤¬¬Û¸ß°Ý¥xÆW¹Ò¤º¬O§_¦³Ãþ¦ü°ê¥~S¤p©jªº¬ÛÃö¸gÅç©M«ç»ò°Ñ¥[·sªºÁ{§É¹êÅç... ü¡A«Ü¥i±¤¡A³o¨Ç¤H§¹¥þ¨S¦³ºÞ¹D¡A¤½¥q¤]¨S¦³«Å¶Ç¡AÀù¤Į́CÓ³£¹³µLÀY»aÃǶðÝ. §Ú»¡¹L²{¦bªº¤H«H©^¦³¹Ï¦³¯u¬Û¡AY¬Q¤Ñ°OªÌ·|¦³²³S¤p©jÄ@·N¤@°_¥X±¤O®¼¯E¹©¡A¯E¹©ÁÙ»Ýn³o»ò´d±¡¶Ü! §Ú¤£¤ÓÀ´... ¬°¤°»ò¤£¯à¥X±¤O®¼¯E¹©¡A¯E¹©³Q·d±o¯Q·Ï¿`®ð¡A¹ïÀù¤Í¦³¬Æ»ò¦n³B? ¤@Ó¥i¥H±Ï¥L̵´¯gªº§®ÃijQ¥´À£¦¨³o¼Ë¡A¥LÌ«ç»ò³£Àq¤£§\Án~ |
|
|
·|û¡Gªü°]10134057 µoªí®É¶¡:2016/6/6 ¤W¤È 11:27:06²Ä 1787 ½g¦^À³
|
Cliff¤j¡A ÁÂÁ±z¦^ÂСI ¤]¥u¯à@¤ßµ¥¯E¹©ªº¤½§i¤F¡I |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/6/6 ¤W¤È 11:03:09²Ä 1786 ½g¦^À³
|
°µÓ°²³]©Êªº¤p°Ý¨÷:¬Ý§¹ASCO¼Æ¾Ú¤§«á,¦pªG¿Ë¤Í¦³¬ÛÃöÀù¯g¯e¯f,½Ð°ÝÄ@¤£Ä@·N¦ÛÄ@©Î±ÀÂ˿ˤͰѥ[¥i¯àµo¥Íªº3´Á¸ÕÅç? ¥ý»¡¤p§Ìªºµª®×,¦pªG¬O§Ú¥»¤H,¤@©w³s©]¸÷¨D¦WÃB! PS:°µ§¹³oÃD°²³]©Êªº°Ý¨÷:§A´Nª¾¹D°Ñ¥[ASCO¤§«á¦³¦h«Â¤F! |
|
|
·|û¡Gmetrostar10141472 µoªí®É¶¡:2016/6/6 ¤W¤È 10:58:22²Ä 1785 ½g¦^À³
|
TO °]¥S Y¶i¤J¥þ²y¤T´Á¥i¯à´N¬O¸ò¤¤¸Î¤@¼Ë,Á{§É¸ÕÅç³]p¬Oopen label¨Ã«DÂùª¼´ú¸Õ ¤£·|¦³¹ï·Ó²Õ©M¹êÅç²Õ, ¦¬®×«e¥ý¥´¥|°w,¦³²£¥Í§ÜÅé´N¦¬,Y¨S¦³§ÜÅé½Ð¥LÂ÷¶}, ´M¨D¨ä¥LªvÀø¤è¦¡,¹ï±wªÌ¤~¦³«O»Ù |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/6 ¤W¤È 10:17:47²Ä 1784 ½g¦^À³
|
°]¥S¡A¤j«v°Ý! ³oÓ°ÝÃD¤@ª½¬O¤j®a©ÒÃö¤ßªºÄ³ÃD¡A¦ý¬Q¤Ñªº»¡©ú·|¤´¥¼»¡¥X¨ãÅé¤è¦¡¡A¥u¯à¦A@¤ßµ¥¤½¥q³W¹º¦n«á¦A¬Ý¤½§i¡C §Ú·Q³Ìªñ¤½¥q¤´¬O¬Û·í¦£¸L¡A©ó¤º©ó¥~À³¸Ó³£«Ü¦£¡C µy¦wÅo¡C |
|
|
·|û¡Gªü°]10134057 µoªí®É¶¡:2016/6/6 ¤W¤È 08:29:54²Ä 1783 ½g¦^À³
|
Cliff¤j¡A ¤p§Ì¦³¨ÇºÃ´b¡A 1. ¦pªG822n«·s³]p¶i¤JÁ{§É¤T´Á¡A¨º»ò¹êÅç²Õ/¹ï·Ó²Õn¦p¦ó¿z¿ï¡A¤~¯àÁקK³o¦¸ªºÁ{§É¼Æ¾Ú°ÝÃD¡H ¿z¿ïªº§Þ³N»P½d³ò³]p¦³¤F¶Ü¡H¥B²Å¦X²Îp»Pªk³Wªº³W½d¶Ü¡H ÁÂÁ¡I |
|
|
·|û¡Gbellad10142239 µoªí®É¶¡:2016/6/5 ¤U¤È 12:29:36²Ä 1782 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j: Á`¦s¬¡´Á¡]OS¡^¥Ø«e¼Æ¾Ú©|¥¼¦¨¼ô ³oÓ©|¥¼¦¨¼ô¬O«ü®É¶¡¤£°÷ªø? »P¹ï·Ó²Õ¨S©úÅã®t²§? ÁÙ¬O¤°»ò·N«ä? |
|
|
·|û¡G¤p¤á10140918 µoªí®É¶¡:2016/6/5 ¤W¤È 10:09:25²Ä 1781 ½g¦^À³
|
¸ÛªÌ¤j, §A»¡ªº¬O¹ïªº. ¤p§Ì½¿ù·N«ä¤F. ¤£¹L¤p§Ì§Æ±æ¹ï©Ò¦³±Ú¸s³£¦³®Ä~~ |
|
|
·|û¡G¸ÛªÌ10142612 µoªí®É¶¡:2016/6/5 ¤W¤È 10:06:11²Ä 1780 ½g¦^À³
|
¤p¤á¤j ³Ì«á¤@¥y§Ú·Q¡]½Ķ¡^¬O ¡]§K¬Ì¡^¤ÏÀ³©M¥Íª«¦¸±Ú¸s,GloboHªí²{ ¤§¶¡¨S¦³¬ÛÃö©Ê ¸ÑŪ¬O¥Ñ²Îp¸ê®Æ¥u¯à»¡ÁÙµLªkª¾¹D¬O¨º¨Ç ±Ú¸s¬O·|¦³§K¬Ì¤ÏÀ³ªº |
|
|
·|û¡G¤p¤á10140918 µoªí®É¶¡:2016/6/5 ¤W¤È 09:25:48²Ä 1779 ½g¦^À³
|
mobile.twitter.com/hoperugo/status/739184104281931776/photo/1 ¹ï¦¸±Ú¸s¨S¦³¤Ó¤j®t§O¡]ªº¦n¡I¡H¡^¡Aglobe-H¥t¤H¦L¶H²`¨è¡]ªº¦³®Ä¡I¡H¡^ ¡]¡^¬O§Ú¦Û¤vªºµù¸Ñ¡I |
|
|
·|û¡G¤ßºC10141111 µoªí®É¶¡:2016/6/5 ¤W¤È 08:20:15²Ä 1778 ½g¦^À³
|
ìPO¦b»ùȵû¦ôª©¡A¦ý¦ü¥G³sµ²³B²z°ÝÃD¾ÉP³Ì·s¦^À³¨Ã¥¼§ó·s¡A¦A¦¸PO¤@¥÷¦b¦¹¡AÁÂÁ¡I BBeth Jo ªº Twtter ¤W¦³ÃöOPT 822§ë¼v¤ù¡A·Ð½Ð¦U¦ì¤j¤j¸Ñ´b¡I twitter.com/BBethJo/status/739174923713683456 OPT-822/821 targets Globo H. 60-80% expressed. twitter.com/BBethJo/status/739175210448871424 Opt821/822. #asco16 #bcsm. twitter.com/BBethJo/status/739175443727712256 Opt821/822 vaccine trial design. twitter.com/BBethJo/status/739176377698549761 Trend toward improved overall survival in OPT 821/822. #ASCO16 #bcsm twitter.com/BBethJo/status/739176777654800384 Patients who responded did better than placebo but exposure to vaccine hurt non responders. #Asco16 #bcsm. twitter.com/BBethJo/status/739177390509678592 Summary: vaccine trial didn¡¦t meet primary end point of Progression free survival. #ASCO16 #bcsm |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/5 ¤W¤È 08:18:50²Ä 1777 ½g¦^À³
|
Cliff¤j¡A ¤U¤È³õ¤p§Ì·|°Ñ¥[¡C |
|
|
·|û¡GPT10139061 µoªí®É¶¡:2016/6/5 ¤W¤È 08:10:41²Ä 1776 ½g¦^À³
|
¥Ø«e³Qpo¥X¨Óªº§ë¼v¤ù¤å¦r¬Ý¨Ó½T¹ê¬O¦p¦¹,Cliff¤jÁÙ¬O¤@ª½³£«Ü¯«^^ ¤§«e»¡¯Î°|ªø·|¥D«ù³õ¥~ªº¥þ²y±M®a¿Ô¸ß·|ij,À³¸Ó¬O³o³õ¤~·|¦³¯S©w²Ó¸`¼Æ¾Úªº´¦ÅS,¥ý«e¬Ý¹LºKn¸£³U¤¤ªºQ¦b³o³õ¤~·|¦³A ¤£ª¾µ²§ô¤F¨S? §Æ±æ¤@ÓÄÁÀY«á¦bOTCªº°OªÌ·|¦h»¡¨ÇºKn¥~ªº¸ê°T. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/5 ¤W¤È 12:53:32²Ä 1775 ½g¦^À³
|
¥x¥_®É¶¡¤W¤È10:27«á¦³¾÷·|¦bASCO½u¤W¬Ý¨ì822ªºSlide show¡A«e´£¬O¶·¦³¨Æ¥ý¥I¶Oªº±b±K¤è¥i¶i¤J¡F©Ò¥HºN¶Â¦b¥x¥_®É¶¡¤W¤È04:15°_§É¡AÀ³¸Ó¬Ý¤£¨ì822ªº¤º®e¡C±À´ú©Ò§e²{ªº¸òºKn¬Û¥h¤£»·¡Aµuµu12¤ÀÄÁ¯à»¡´X±iSlide¡H ¤]¤£®t´XÓ¤p®É¡A´Nµ¥¬Ý¤½¥q´£¨Ñªº§a¡I ¤p§Ìn¨ì¤U¤È³õ¤~¯à¨ì¡A¤p©_¤j¡A±z·|°Ñ¥[¶Ü¡H |
|
|
·|û¡GSeanYang10141436 µoªí®É¶¡:2016/6/4 ¤U¤È 11:03:18²Ä 1774 ½g¦^À³
|
Ävª§¹ï¤â¤§¤@: Abemaciclib (CDK4/6 inhibitor)Phase II³æ¿W¥ÎÃĪº¼Æ¾Ú Objective response rate (ORR) was the primary outcome measure. Secondary endpoints included duration of response, PFS, OS, clinical benefit rate, and safety. The investigator-assessed, confirmed ORR was 19.7% (n = 26; 95% CI, 13.3-27.5), which included all partial responses (PR). The rate of patients with stable disease (SD) ≥6 months was 22.7%, leading to a clinical benefit rate (complete response + PR + SD ≥6 months) of 42.4%. The median time to response was 3.7 months and the median duration of response was 8.6 months. Median progression-free survival (PFS) was 6 months (95% CI 4.2-7.5) Median overall survival (OS) was 17.7 months (95% CI, 16 to not reached) Adverse events...... ©ú¦¥i¥H¨Ó¶W¯Å¤ñ¤@¤ñ ¥þ¤å¡G global.onclive.com/conference-coverage/asco-2016/abemaciclib-active-against-hrher2-breast-cancer |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/4 ¤U¤È 04:51:32²Ä 1773 ½g¦^À³
|
À³¥Ñ¬F©²¥D¾É¦X¨Ö¡A¦X¨Ö¤~¦³¤O¶q¡A¯E¹©¥HÀù¯g¬ãµo¬°¥D¡AÁÞ°ò¥H¬ãµo·s¤@¥N§ÜÅéÃĬ°¥D¡A¬Û»²¬Û¦¨¡A¦@³ÐÂùĹ ³o³¡¤À§Ú¤]¬O³o¼Ë·Qªº ¤£µM¨ì®ÉԨⶡ¤½¥q¦³«Ü¦h¹³ªºªF¦è Åܦ¨Ävª§¤Ï¦Ó¤£¦n |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/4 ¤U¤È 04:20:07²Ä 1772 ½g¦^À³
|
©Ó¤Ñ¤j 1ÁÞ°ò¥ÍÂåP¤O©ó§ÜÅéÃĪ«§¡¬Û¤Æ¡AÅý§ÜÅéÃÄÃĮĴ£°ª¡A°Æ§@¥Î°§C¡A¬ãµo½d³ò¦bÀù¯g§ÜÅéÃĪ«¡A¦ÛÅé§K¬Ì§ÜÅéÃÄ¡A§Ü·R´þ¯f§ÜÅéÃĪ«»P§Ü·P¬V§ÜÅéÃĪ«¡C 2ÁÞ°ò¥ÍÂå¬O¤@®a¦³¼ç¤O¤½¥q¡A¥u¬O¬ãµo²£«~»P¶i«×¤´µM¦bÁ{§É«e¡A³o®a¤½¥q«Ü¾A¦X30-40·³ ¦~»´§ë¸ê¤H¨Óªø´Á§ë¸êºCºC¶R¤Q¤¦~«á¦A¨Ó¦¬¾ÔªG 3¦pªG¥xÆW·Qµo®i¥@¬É¯Å¥Í§Þ¤½¥q¡A¯E¹©»PÁÞ°ò À³¥Ñ¬F©²¥D¾É¦X¨Ö¡A¦X¨Ö¤~¦³¤O¶q¡A¯E¹©¥HÀù¯g¬ãµo¬°¥D¡AÁÞ°ò¥H¬ãµo·s¤@¥N§ÜÅéÃĬ°¥D¡A¬Û»²¬Û¦¨¡A¦@³ÐÂùĹ¡C |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/4 ¤U¤È 01:16:50²Ä 1771 ½g¦^À³
|
½Ð°Ý¥xÁÞ¤j«ç»ò¬ÝÁÞ°ò(CHO)©O? |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/6/4 ¤U¤È 12:41:26²Ä 1770 ½g¦^À³
|
§Ú¤]«Ü´Á«ÝÁÞ´¹¤ù(OBI-868)ªº¶}µo¡A¦]¬°³o²£«~°·±dªº¤H¥Îªº¨ì¡A ¥B¤£»Ýn°µ¡u¤¾ªøªº¡vÁ{§É¸ÕÅç¡A¶}µo®É¶¡·|«Ü§Ö¡I¡H 3¨ì5¦~¶}µo¦¨¥\¡A¦³¥i¯à¶Ü¡H ¦pªG¤@¦¸¯àÀËÅç10ºØÀù¯g¥ª¥k¡A¦¬¶O100¬ü¤¸¡A ¨º¬ü¡B¤é¡B¼Úªº¤H¡AÀ³¸Ó¯à±µ¨ü³oºØÀËÅç»ù®æ¡A¦ý¥xÆW¤H¤£ª¾¹D¯à¤£¯à±µ¨ü¡H ¦pªG¬ü°ê1¦~¦³5000¸U¤HÀËÅç¡A¨º¥þ¥@¬É1¦~¦³1»õ¦¸ÀËÅç¡AÀ³¸Ó¤£Ãø¡C 100¬ü¤¸*1»õ¦¸¡×100»õ¬ü¤¸ ³o¥«³õ¤]«Ü¤j¡I¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/4 ¤W¤È 10:30:31²Ä 1769 ½g¦^À³
|
6 OBI833¬ãµo¨ÅÀù ªÍÀù ¤j¸zÀù GÀù¡A³o¥|ºØÀù¯g³£¬O¤jÃÄ¡A¥HGÀù¨Ó»¡2012¦~µo¥Í¼Æ950000¤H¡A¦º¤`¼Æ723000¤H¡A¥xÆW¯E¹©¬ãµoªºÃij£¬O¥Hµo¥Í¤H¤f¼Æ¦hªºÀu¥ý¬ãµo¡C¥t¥~822¥H«e¤j®a¾á¤ßIgG§ÜÅé¶q¤£¨¬¡A³o¦¸Á{§É¸ÕÅçÃÒ©ú¤£¬O³o»ò¤@¦^¨Æ¡A¹êÅç²Õ¦³50%ªº¨ü¸Õ²£¥Í¥|¿>=160§ÜÅé¶q¡A¯E¹©ÁÙ®³OBI822¨Ó¬ãµo¥û®«ªº§Z±_Àù¡AOBI833°t¤è¤¤QS21¤]¨S®³±¼¡A¨¬¨£OBI822²£¥Íªº§ÜÅé¶q¬Û·í±j¡A¯S§O¬OIgG§ÜÅé |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/4 ¤W¤È 10:01:26²Ä 1768 ½g¦^À³
|
5°O±o¥H«e¤½¥q¦³´£¨ì¤£n¤@¦¸§â¸üÅé³J¥Õ»P¦õ¾¯§ó´«¡A¤@¦¸´«¤@Ó¡AòÏÃ¥´¡A833/834¡A ¤]¦³¥i¯à¬OCRM197/C34,¤»¤ë¤¤é¦A°Ý²M·¡ ¦pªG¬O³oºØ²Õ¦X¡A¤U¤@Ó¥X²{ªº´N¬ODT/C34 |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/4 ¤W¤È 09:47:54²Ä 1767 ½g¦^À³
|
C34 ¦nª« ¤ñ¸û²³æªº¤@Ó¤À¤l |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/4 ¤W¤È 09:42:16²Ä 1766 ½g¦^À³
|
4¥Ø«e¤w¶i¤J¤@´ÁÁ{§ÉªºOBI833»POBI833/834®t²§¦b©ó¸üÅé³J¥Õ»P¦õ¾¯ «eªÌ¨Ï¥ÎCRM197 /QS21,«áªÌ¨Ï¥ÎDT/C34 ¯E¹©´x´¤833³o¨âÓ¨t¦C¡A¦p¦P´x´¤Àù¯g§K¬ÌÀøªkªº±OÀs¤M¡A¯E¹©822¬ãµo¨ÅÀù´x´¤¬Û·í¦hÁ{§É¼Æ¾Ú¡A¬°¤F©µÄò¥þ²y¨ÅÀù¥«³õªº´x±±Àu¶Õ¡A¯E¹©§Ô¤£µÛ¤@©wn´ú¸Õ´X¦ì¨ÅÀù¯f±w¬Ý¬Ý§ÜÅé²£¥Í±¡ªp¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/4 ¤W¤È 09:16:47²Ä 1765 ½g¦^À³
|
²³¤j¤j 1¥xÆW¯E¹©105¦~«×¦~³ø19-37¶¤º®e§ó·s¡A²£«~½u¬ãµo²{ªp¡AÀç¹Bª¬ªp¡An¦h¬Ý´X¹M¡AÓ¤H»{¬°¥»¦¸Á{§É¸ÕÅçµo²{·|²£¥Í¨¬°÷§ÜÅ骺¨ü¸Õ´N·|¦³Á{§ÉªºÀø®Ä¡A¤j®a·Q¤@·Q¡AOBI888 ÁöµM¬O³Q°Ê§K¬ÌÀøªk¡AÀuÂI¬O888¤@©w·|²£¥Í¨¬°÷§ÜÅé¡A¥[¤W888¬O¯E¹©¿W¦Û¬ãµo¥iÅý°Æ§@¥Î°§C¡AÃĮĴ£°ª¡A¥Ø«e¥þ²yÀù¯gÃĪ«ÁÙ¬O¥H³æ§ÜÃĦû³Ì¤j©v¡A¯E¹©¬ãµoªºOBI888¼ç¤OµL½a¡A¦b°t¦X¬Û¦P§ÜÀù¾÷¨î¡A¤j®aÀ³µ¹¤©°ª«×Ãöª`¡C 2 833¤w¦b¥h¦~12¤ë¦¬²Ä¤@¦ìªÍÀù¨ü¸Õ¡AªÍÀù¬O¤jÃÄ¡A¯E¹©¤w¬ãµo¨âÁû¤jÃÄ¡C 3833/834 ¤]¥[³t¬ãµo·Ç³Æ¶i¤JIND |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/6/3 ¤U¤È 11:24:29²Ä 1764 ½g¦^À³
|
¦³¤H³Q¨ú®ø¤F, ªÑ»ù¶^§Ö 20% Immunomedics (IMMU) Says ASCO Presentation Cancelled Because of Complaint It Violated Embargo www.streetinsider.com/Corporate+News/Immunomedics+(IMMU)+Says+ASCO+Presentation+Cancelled+Because+of+Complaint+It+Violated+Embargo/11705958.html |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/3 ¤U¤È 09:58:31²Ä 1763 ½g¦^À³
|
¬O³o½g¶Ü¡H http://cancerres.aacrjournals.org/content/75/17/3568.full ¤p§Ì¬Ý¤£À´ ¦³«Ý¹F¤H¸ÑŪ¡AÁÂÁ¡I ¤µ±ß¤£¬OÁÞ¤À¤lªº¥þ²y±M®aµø°T·|¶Ü¡H¡I Y¤j®a¦³°T®§ ½Ð¤Î®É¤À¨É ÁÂÁ¤j®a¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/3 ¤U¤È 05:42:56²Ä 1762 ½g¦^À³
|
²³¤j¤j ¹ï©ó¯E¹©ªºÄvª§¹ï¤ân¯d·N¤G´ÁÁ{§É¼Æ¾Ú«GÄRªºÃĪ«¡A¤@¯ë¨Ó»¡¡A¤G´Á¹LÃö¡A¤T´Á¦¨¥\¾÷·|´N¤ñ¸û¤j¡A¯E¹©¤µ¤Ñ¯à¨«¨ì¤T´ÁÁ{§É¨Ãµo²{¦¸²Õ¸s¦³ÅãµÛÀø®Ä¡A¤wÄÝÃø¯à¥i¶Q¡A¦óªp¨ÅÀùOBI822¨«¦bÀù¯g§K¬ÌÀøªkªº¥ýµo¡A¶]²Ä¤@´Î¡A ¤j®a¥iÀH®Éª`·N°l§L¡A¤£¥i»´¼Ä¡AÓ¤H»{¬°¯E¹©³oÁû¨ÅÀùÃÄ¥unòÏÃ¥´¡A¿z¿ï¯à²£¥Í¨¬°÷§ÜÅ骺¯f±w¡A´Nºân°µ¤T´Á¡A¦¨¥\¾÷·|¤w¸g¬O·¥¤j¤Æ¤F¡A¨C¦~¯à®³¨ì¬ü°êFDAÃÄÃÒ¥§¡¸¨¤J35Áû¦Ü45ÁûÃĤ§¶¡¡A¯u¬O¦Ê¤¤¨ú¤@¡A¥»¦¸»¡©ú·|©Îªk»¡·|§Ú³Ì·QÅ¥¨ìªº¦^µª¬OMOS¼Æ¾ÚÁÙ¨S¦¨¼ôÁÙ¦bÆ[¹î¤¤»P¬ü°êFDA¹ï¨ÅÀùÃĪº½T©w¤è¦V¬O........ |
|
|
·|û¡GJj10142460 µoªí®É¶¡:2016/6/3 ¤U¤È 05:01:57²Ä 1761 ½g¦^À³
|
°ª¤âÂæb¥Á¶¡¸Ì¡A¤]³\µL¤ß´¡¬h¬h¦¨½®¡I¶^¯}©Ò¦³¤Hªº²´Ãè¡I |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/6/3 ¤U¤È 04:22:50²Ä 1760 ½g¦^À³
|
³o¦¸·sµo²{ªºÃĪ«²Õ¦X¡A«h¬O§ïÅܳJ¥Õµ²ºc¡AªA¥Î«á¥i¯}ÃaÀù²ÓM²É½uÅé ¨º·|¤£·|¯}Ãa¥¿±`²ÓMªº²É½uÅé¡H¡H¡H ¥u¬O¦³Ó¼v¤l¦Ó¤w¡In§ë¸ê¡AÁÙ¦ªº«Ü¡I¡I |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/3 ¤U¤È 04:16:49²Ä 1759 ½g¦^À³
|
³o¦¸·sµo²{ªºÃĪ«²Õ¦X¡A«h¬O§ïÅܳJ¥Õµ²ºc¡AªA¥Î«á¥i¯}ÃaÀù²ÓM²É½uÅé¡A§Ï©»¡u§âÀù²ÓMµo¹q¾÷Ãö±¼¡A¦A¥ÎÅF¬µ¾÷ÅF¬µ¡v¡Aª½±µ®ø·ÀÀù²ÓM¡A§JªA§ÜÃÄ©ÊÃøÃD¡C----¡Ö³oÁÙ¬O¨«Âªº¤è¦V °Æ§@¥Î¤@©w«Ü¤j ¸ò¯E¹©¤£¯à¤ñ ½Ð°O¦í¥xÁÞ¤j»¡ªº ¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀøªk ¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀøªk ¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀøªk ¥B°Æ§@¥Î»´ ¦w¥þ©Ê°ª ³o¤~¬O»ùÈ©Ò¦b¡ã ¤£n¥Î¦ÑÃÄ¥h¸ò822¤ñ... |
|
|
·|û¡GJj10142460 µoªí®É¶¡:2016/6/3 ¤U¤È 04:00:48²Ä 1758 ½g¦^À³
|
¤£ª¾þ®aÃļt±µ¤â¬ãµoªº¡Aªø´Á§ë¸ê¡I |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/6/3 ¤U¤È 03:59:11²Ä 1757 ½g¦^À³
|
Á¢²ï¥Ë½¤¦ç¿õªº¤¶²Ð http://www.kfsyscc.org/cancer/cancer-treatment/med/info/Sorafenib http://www.cancer.gov/about-cancer/treatment/drugs/fda-sorafenib-tosylate GW5074ªº¤¶²Ð http://www.medchemexpress.cn/GW-5074.html?gclid=CL2uyMSwi80CFYaXvAodgI8N1Q YÁp¦X¥ÎÃĦ³¦nªº®ÄªG¤£¿ù§r¡A¥»¨ÓÃÄ«~´N¬OÄvª§¥«³õ¡A¥u¬O"¯u¹ê"Àø®Ä¦p¦óÁÙ¨¥¤§¹L¦ ³oºØ·s»D¤@¦~¦Ü¤ÖNÓ¡A¹³X·¥¬P¤§«e¤]¬O¤Þ°_ÅF°Ê §Æ±æ¥xÆWÀùÃĥͧ޲£·~¯àºÙÅQ¥þ²y¡A¥i¥H¦³«Ü¦h®a·sÃĤ½¥q¦¨¥\ ©ÎY¦³¦nªº¼Ðªºª«¡A©¡®É¯E¹©¤â¤W¦³º¡º¡²{ª÷¤]¥i¨ÖÁʩΦX§@³£¦³¥i¯à |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/3 ¤U¤È 03:55:49²Ä 1756 ½g¦^À³
|
ÁÙ¦bÁ{§É«e°Êª«¹êÅ綥¬q¡A°Êª«¦³®Ä¤HÅ饼¥²¦³®Ä¡AÃĪ«¬ãµo¬OnªvÀø¤HÃþ¯e¯f¡An¥H¤HÅ鬰¥D¡A¬Ý¬Ý¯E¹©±q°Êª«¹êÅç¨ì²{¦b°µ´X¦~Á{§É¸ÕÅç¤F¡A¨ì²{¦b³£ÁÙ¨S¤W¥«¡A³oÁûÃĤQ¦~¤º·|¤W¥«ªº¥i¯à©Ê«Ü§C¡C¥un¦³Àù¯g¬ã¨sªkªíªº¬O°Êª«¹êÅç¡An¦ô10¦~¤~¦³¤W¥«¾÷·|¡A¦Ó¥Bn¬ã¨s¶¶§Q¡A¤£¤ÖÃĪ«°µ¨ì¤G´Á´NGame Over |
|
|
·|û¡GJj10142460 µoªí®É¶¡:2016/6/3 ¤U¤È 03:39:40²Ä 1755 ½g¦^À³
|
Ävª§¹ï¤â¨Ó¤F¡A¥t¤@¯«ÃÄ¡I ¤TÁ`§ä¥X§ÜÀùÃÄ·s²Õ¦X ¥i±æªv8¦¨Àù¯g ¤¤¥¡ªÀ°OªÌ±i¯ú³Ù¥x¥_2¤é¹q¡^Àù¯g¥ÎÃÄ·s¬ð¯}¡A¤TÁ`¹Î¶¤¬ã¨s5¦~µo²{¡A§â¨âºØ¯S©w§ÜÀùÃĪ«¨Ã¥Î³º¯à®ø·ÀÀù²ÓM¡A¤£¶È¯à¸Ñ¨M§ÜÃÄ©Ê°ÝÃD¡A¾¯¶q¥un쥻ªº1/10¡A§ó«nªº¬O¡A¹ï8¦¨Àù¯g³£¦³®Ä¡C ¤TxÁ`Âå°|¥~¬ì³¡¥D¥ô¬d©§Às¦Û2007¦~±a»â¬ã¨s¹Î¶¤¡A¯Ó®É5¦~§ä¥X³Ð·sÃĪ«²Õ¦X¡A¥]§t2ºØ¤p¤À¤lÃĪ«Á{§É§ÜÀùÃĪ«¡uSorafenib¡v¤Î¯Â¤Æ¦Xª«¡uGW5074¡v¡A¥unìÃĪ«1/10¾¯¶q¡A´N¯àµo´§¤ñì¥ý§ó¦nªº§ÜÀù®ÄªG¡A¬ã¨s¦¨ªG¤wµoªí©óª¾¦WÀù¯g¬ã¨sÂø»x¡uCancerResearch¡v¡C ¬d©§Às»¡¡A¥Ø«eªvÀøÀù¯gªº¼Ð¹vÃĪ«¦h¥b³z¹L§í¨î³J¥Õ¬¡©Ê¡A¹F¨ì´î»´Àù¯g¯gª¬®ÄªG¡A±wªÌªAÃĪì´Á¥i¯à¦³®Ä¡A¦ý¹L¤F¥b¦~¨ì1¦~¡AÀù²ÓM´N·|¬ðÅܲ£¥Í§ÜÃÄ©Ê¡A¤£¶ÈìÃĪ«¥¢®Ä¡BÀù¯gÁÙ¥i¯à´_µo±o§óÄY«¡C ³o¦¸·sµo²{ªºÃĪ«²Õ¦X¡A«h¬O§ïÅܳJ¥Õµ²ºc¡AªA¥Î«á¥i¯}ÃaÀù²ÓM²É½uÅé¡A§Ï©»¡u§âÀù²ÓMµo¹q¾÷Ãö±¼¡A¦A¥ÎÅF¬µ¾÷ÅF¬µ¡v¡Aª½±µ®ø·ÀÀù²ÓM¡A§JªA§ÜÃÄ©ÊÃøÃD¡C ¬ã¨s¹Î¶¤¦b¤p¹«¹êÅ礤¡A±NµÇŦÀù²ÓM´Ó¤J¤p¹«µÇŦ¡A¨Ãµ¥¨ìÀù²ÓMÂಾ¨ì¥þ¨¤~¶}©lµ¹ÃĪvÀø¡A¨Ï¥Î¶Ç²ÎÃĪ«ªº¤p¹«4¦Ü6¶g´N¥þ¼Æ¦º¤`¡A¦Ó¨Ï¥Î²Õ¦XÃĪ«ªº¤p¹«¦³7¡B8¦¨¦s¬¡¡A¥B´X¥G±d´_¡C ¬d©§Às«ü¥X¡A·sÃIJզX¤£¦ý°Æ§@¥Î¤Ö¡A¤£©ö²£¥Í§ÜÃÄ©Ê¡A¹ï¤w¦³§ÜÃĩʪº±wªÌ¤]¦³®Ä¡A¦Ó¥B¥u»ÝìÃĪ«1/10¾¯¶q¡A¬OÀù¯gºë·ÇÂå¾Çªº¤@¤j¬ð¯}¡C §ó«nªº¬O¡A¦h¹F8¦¨Àù¯g³£¾A¥Î³o¶µÃĪ«²Õ¦X¡A°w¹ïªÍÀù¡B¤j¸zÀù¡B¨ÅÀù¡B¶Â¦â¯À²ÓMÀù®ÄªG¯S§O¦n¡A¤TÁ`¹Î¶¤¥¿µÛ¤â¬ã¨sÀË´ú¤èªk¡A¥¼¨Ó±wªÌ¥un©â¦å´N¯àª¾¹D¬O§_¾A¥Î³o¶µÀøªk¡C ¬d©§Àsªí¥Ü¡A³o¶µ²Õ¦XªvÀø®×¤w¦¨¥\¦b¥xÆW¤Î¬ü°ê±M§Q¥Ó½Ð¡A¨Ã³v¨B¦b¨ä¥L°ê®a±M§Q¥Ó½Ð¤¤¡A¥Ø«e¤]¤w§ÞÂà¥Í§Þ¤½¥q¶i¦æ°Êª«¬r©Ê¤ÎÁ{§É¤@´Á¤HÅé¸ÕÅç¡C1050602 |
|
|
·|û¡GPT10139061 µoªí®É¶¡:2016/6/3 ¤U¤È 03:28:43²Ä 1754 ½g¦^À³
|
³o°OªÌ³£¤£Ä±±o¦Û¤v¤å³¹®¼¥Ù¬Þªº¶Ü? ¦Ó¥B¦~©³¤~¤@´ÁÁ{§É,«á¦~´N¥i¥H¤W¥«?¥i¥H³o¼Ë¼ÖÆ[¼Ú?? --------------- ¡u¬d©§Àsªí¥Ü¡A¸ÓÃĦ~©³±N¶i¦æ¤@´Á¤HÅéÁ{§É¹êÅç¡A³Ì§Ö«á¦~¡i¤WÉ]¡j¹B¥Î¡v ¡u®Éµ{¡G³Ì§Ö«á¦~¡iÁ{§É¡j¹B¥Î¡v |
|
|
·|û¡G¸ô¤H¥Ò10135334 µoªí®É¶¡:2016/6/3 ¤U¤È 03:12:20²Ä 1753 ½g¦^À³
|
¤TÁ`¬ãµo·sÃÄ ¥i±þ¦ºÀù²ÓM 8¦¨Àù¯g¦³®Ä ³Ì§Ö«á¦~¨Ï¥Î ¹ï¶H¡G¾A¥Î8¦¨ªºÀù¯g¡A¹ï¤j¸zÀù¡B¨ÅÀù¡BªÍ¸¢Àù¡B¶Â¦â¯ÀÀù¯S§O¦³®Ä www.appledaily.com.tw/appledaily/article/headline/20160603/37249600/ ½Ð°Ý¦U¦ì¤j¤j¦³¦ó¬Ýªk |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/3 ¤U¤È 02:20:07²Ä 1752 ½g¦^À³
|
¹x¥Û¤j ÁÂÁ¤À¨É ©Î³\160¨S¦³¤°»ò²z½×®Ú¾Ú ¦ý¬O§_¦³¨ä¥L¬ã¨sµ²ªGªº¨Ì¾Ú¡H |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/3 ¤W¤È 11:08:11²Ä 1751 ½g¦^À³
|
¯E§J¤j¡A µe¦b160³o±ø½u¬O¤£¥i¯à¦³¤°»ò²z½×®Ú¾Úªº¡C³o´N¹³·íªìnq822ªº¾¯¶q®É¡A¤]¬O±q¦hÓ¾¯¶q¬I¥´¤§«áªº¯f¤H¤ÏÀ³±o¥Xªº³Ì¨Î¾¯¶q¡C¤Á¦b160ªº²z¥Ñ¡A¥²µM¬O°l¨D²Îp¤WªºÅãµÛ©Ê»P¾A¥Î¯f¤H±Ú¸sªº³Ì¤j¤Æ³o¨âÓ«ü¼Ð¤§¶¡°µ©Þªe¡C°ª©ó160¡A¥i¯à²Îp®ÄªG§óÅãµÛ¡A¦ý¬O¯f¤H¾A¥Î¤ñ²v°§C¡C§C©ó160¡A¯f¤H¾A¥Î¸s¼W¥[¡A¦ý¬O²ÎpªºÅãµÛ©Ê«o°§C¡C ¥Íª«Å骺¤ÏÀ³¤Ó½ÆÂø¡AMOA¥u¯à°µ¨ì©w©Ê¡CYn½Í©w¶q¡A¥u¯à±q¸ÕÅçµ²ªG¨Ó±À¦ô§ä³Ì¨Î¸Ñ¡C¨ä¹ê¡A160³o±ø½u¤]¥u¯à»¡¬O±q³o¦¸ªº¹êÅç²Õ¼Æ¾Ú·í¤¤±o¥Xªº³Ì¨Î¹º¤ÀÂI¡Cµ¥¤T´Á°µ§¹¡A©Î³\160³oӼƦr¤S¥i¯àn©Ô°ª¨Ç©Î¬OÀ£§C¨Ç·|Åýµ²ªG§óº}«G¡A¦ý¬O¦]¬°Á{§É³]p¬O160¡A¥H«á´N°Ê¤£¤F¤F¡C¤½¥q¤]¤£¤j¥i¯à¬°¤FÅçÃÒ120©Î200¬O§_§ó¨Î¦A°µÓÁ{§É¤T´Á¡Aµe³D²K¨¬¡C¦ý¬OÀù¯gÂå®v¬O¥i¥H«Øij¯f¤H¥´¥|°w¥u¦³120§K¬Ì¤ÏÀ³ªºÄ~Äò¬I¥´¡A¦]¬°µL®`¡C¤]³\þ¤Ñ²Ö¿n¨¬°÷¯f¾úÃÒ©ú¥|°w¨ì¹F120´NÀ³¸ÓÄ~Äò¥´¡A¨º®É¦A¬Ý¤½¥q«ç»ò¥Ó½ÐÂX¥R¾AÀ³¯g¡C²{¦b¥²µM¬O¶V³æ¯Â¶V¦n¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/3 ¤W¤È 09:52:36²Ä 1750 ½g¦^À³
|
²³¤j¤j «e±¤»ÃD¦Û°Ý¦Ûµª¬O²³¤j¥i¯àªººÃ°Ý,Ó¤H¤À¨É¬Ýªk,¦]¨CÓ¤H¤Á¤J¨¤«×»P¬Ýªk¤£¦P ¶È¨Ñ°Ñ¦Ò,¤]½ÐºÞ±±§ë¸ê·ÀI,°ö¾i¿W¥ß«ä¦Ò»P¬ã§P,ª`·N¤½¥q°ò¥»±µo®i»P¸Û«H §ó¥¿¿ù»~ ¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀø >>¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀøªk Q3 2010¦~¦Ü¤µ¬ü°êFDA®Öã¨ÅÀù §Z±_ÀùÃÄÃÒ±¡ªp? >> 2011¦~¦Ü¤µ¬ü°êFDA®Öã¨ÅÀù §Z±_ÀùÃÄÃÒ±¡ªp? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/2 ¤U¤È 11:59:32²Ä 1749 ½g¦^À³
|
Q6 Michael½×z822¥¼¨Ó¤TºØ¥i¯à»PYK4¥i¯à ¦³¦ó®t²§? A YK3´N¬OMichael 1, YK2 ±µªñMichael 2 YK1 ª½¨úÃÄÃÒ P Valuen¤p©ó0.001, ¤£ª¾¹D¥»¦¸½×¤åºKn¯à²£¥Í¨¬°÷§ÜÅé»P¥¼¯à ²£¥Í¨¬°÷§ÜÅé²Õ¤º¤ñ¸û¨äMPFS PȤp©ó 0.0001 ¬O§_²Å¦XYK1? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/2 ¤U¤È 11:40:23²Ä 1748 ½g¦^À³
|
Q4¥»¦¸½×¤åºKn¨S¦³¤½§GHer2¶§©Ê¨ü¸Õ¤ñ²v¡A ³oÓ¤ñ²v·|¬O¦h¤Ö? A 100%-70%(¶Pº¸»X¶§©Ê)-13%(¤T³±©Ê) §Ú²q¬ù17%¨ü¸Õ¬OHer2¶§©Ê Q5¥¼¨Ó¨ÅÀùOBI822®Öã¤W¥«¬O§_·|¨î¨Ï¥Î ½d³ò? A ¥unÁ{§É¼Æ¾ÚÃÒ©ú¦UºØ¨ÅÀù¨È«¬³£¦³Àø®Ä¬ü°êFDA¨S¦³²z¥Ñ¨î¨Ï¥Î½d³ò |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/2 ¤U¤È 10:04:04²Ä 1747 ½g¦^À³
|
¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀø ¹w´Á±N¿W»â·Ä̤G¤Q¦~ ²³¤j¤j±ß¦w ¤À¨É¤@¨Ç°ò¥»Æ[©À (¦Û°Ý¦Ûµª) Q1 ¨ÅÀùOBI822¸ó°êÁ{§É¥xÆW¦¬®×¼Æ¤ñ¬ü°ê¦h ¬ü°ê·|¤£·|¤£©Ó»{Á{§Éµ²ªG ? A ¨ÅÀùOBI822 2014¦~8¤ë¤w§¹¦¨349¦W¸ó°ê¯f±w¦¬®×¥Ø¼Ð¡A¨ä¤¤¥xÆW185¤H¡B¬ü°ê71¤H¡B«nÁú66¤H¡B »´ä20¤H¡B¦L«×7¤H¡C¤@´ÁÁ{§É¦¬27¦ì¬ü°ê¤H¦Xp¦³98¦ì¬ü°ê¤H°Ñ»P¨ÅÀùOBI822 1 2 3 ´ÁÁ{§É¸ÕÅç (ÃÄÃÒ¼f¬d®É¤@´ÁÁ{§É¸ê®Æ¤]n¤@¨Ö°e¼f) ¥xÆWÂåÀø¤ô·Ç«Ü°ª,°ê»Ú¤jÃļt¨C¦~°Ñ»P¬°¼Æ²³¦hªº¤£¦P´Á§OÁ{§É¸ÕÅç,¦Ó¥B³£n¦V¬ü°êFDA´£¥X´ÁÁ{§É¸ÕÅç¥Ó½Ð,³Q®Öã«á¤~¯à¶}©l¶i¦æÁ{§É,¦pªG¬ü°ê¤£©Ó»{Á{§Éµ²ªG,°ê»Ú¤jÃļt«ç´±¨Ó¥x°Ñ»P¬°¼Æ²³¦hªº¤£¦P´Á§OÁ{§É¸ÕÅç¦X§@, ¬Q¤Ñ¥xÆW¦w¶i¦¨¥ß ±À°ÊÁ{§É·sÃĬãµo³o¬O³Ì¦nªº»¡©ú:¥xÆWÂåÀø¤ô·Ç«Ü°ª,°ê»Ú¤jÃļt¨C¦~°Ñ»P¬°¼Æ²³¦hªº¤£¦P´Á§OÁ{§É¸ÕÅç Q2¥xÆW¤T´Á¤G¤ë¤½§iªì¨B¤ÀªRTop-line ¥DnÀø®Ä«ü¼Ð¥¼¹F¼Ð ¬O§_¯àÀò±o¥xÆWÃÄÃÒ? A ½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p¼fÃĪk³W¤w¤ñ·Ó°ê»Ú, ¯E¹©¦b¤G¤ëªk»¡·|¤wªí©ú¤£·|n¨D¹Ãĸpקïªk³W. ¥H¤U¬O´CÅé³ø¾É¹Ãĸp¹ï¯E¹©¸Ñª¼«áªº¬Ýªk: ½ÃºÖ³¡¹Ãĸp²¥ô§Þ¥¿½²¤h´¼«hªí¥Ü¡A¥Ø«e©|¥¼¦¬¨ì¯E¹©¬ÛÃö¸ê®Æ¡AÁÙµLªkÂç²M¸ÕÅ籡ªp¡A¦ý§Ú°ê¹ïÀù¯gÃÄ«~ªºªk³W§¡¤ñ·Ó°ê»Ú¡AµL¸¨«á°ÝÃD¡A¤£·|¦]®×קï¡A¦ý±À´ú·~ªÌ©Ò«ü¨Ã«D¬Oקïªk³W¡AÀ³¬O¬ã¨sµ²ªGÁö¥¼¹F¹w´Á¥Øªº¡A¦ý¥i¯à¹ï©ó¯S©w±Ú¸s¦³ÅãµÛªº²Îp·N¸q¡A¤£±Æ°£·Q¶i¤@¨B×¥¿ì¥ýªº¬ã¨s³]p¡AÂÇ¥H¹F¼Ð¡A©Z¨¥³o½T¹ê¬O¦³¥i°Q½×ªºªÅ¶¡¡A¦ý¤´nµ¥Âù¤è·¾³q«á¦A»¡¡C news.ltn.com.tw/news/focus/paper/960468 ¥xÆW¯E¹©¤wªí©ú·|§â³Ì¦nªº¼Æ¾Ú©Ó§e²{µ¹¹Ãĸp,¦]¬°822¦w¥þ¤S¦³Àø®Ä,ÃĶV¦w¥þ®Ö㪺¼u©Ê»P¾÷·|´N¶V¤j(¥x¬ü³£¤@¼Ë) Á{§É¼Æ¾Ú¤½¥¬ ¤£¬O¤@½¨âÀü²´ www.chinatimes.com/newspapers/20160201000199-260206 Q3 2010¦~¦Ü¤µ¬ü°êFDA®Öã¨ÅÀù §Z±_ÀùÃÄÃÒ±¡ªp? A: 2011 ¨ÅÀù 0 2012 ¨ÅÀù 2 Afinitor (everolimus); Novartis; For the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012 Perjeta (pertuzumab); Genentech; For the first-line treatment of HER2+ metastatic breast cancer, Approved June 2012 2013 ¨ÅÀù 1 Kadcyla (ado-trastuzumab emtansine); Genentech; For the treatment of HER2-positive metastatic breast cancer, Approved February 2013 2014 ¨ÅÀù 0 §Z±_Àù 1 Lynparza (olaparib); AstraZeneca; For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014 2015 ¨ÅÀù 1 Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015 2016 06 ¨ÅÀù 0 2011¦~¦Ü2013¦~¦³3Áû¨ÅÀùÃijQ®Öã 2014¦~¦Ü2016¦~6¤ë¥u¦³1Áû¨ÅÀùÃijQ¬ü°êFDA®ÖãÃÄÃÒ (3:1) 2011¦~¦Ü2016¦~6¤ë2¤é¥u¦³1Áû§Z±_ÀùÃijQ¬ü°êFDA®ÖãÃÄÃÒ, ¦pªG§Ú¨S¦³¬Ý¿ùªº¸Ü2000¦~¦Ü2016¦~6¤ë2¤é16¦~¥b ¤]¬O¥u¦³1Áû§Z±_ÀùÃijQ¬ü°êFDA®ÖãÃÄÃÒ ¥i¨£§Z±_Àù ¨ÅÀù·¥»Ý¦nÃĨӺ¡¨¬¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D, °¨°ºÂå°|¥D¾É§Z±_Àù¤G´ÁÁ{§É¡A¥h¦~2014¦~11¤ë©Òµoªíªº¼Æ¾Ú¡A¦b°lÂܪº33¦ì¯f¤H¤¤¡A°lÂܤ¤¦ì¼Æ4Ó¤ë¡A¦b±µ¨ü¦Ü¤Ö¥|¾¯ªº±wªÌ¤¤¡A¦³88%(29¦ì)ªºÅ餺IgM¿@«×¤W¤É¡A43%(14¦ì)ªºÅ餺IgG¿@«×¤W¤É¡A°£¤F¦³¤@¨Ç§C·Åªºµo¿N»P§½³¡ªº¥Ö½§¬õ¸~¤§¥~¡A¨S¦³«¤jªº°Æ§@¥Î¡C§Z±_Àù¤ñ¸û aggressive ,¥un¯à¤ñ²{¦³ªºÃĦn¦³¸û°ªªº¦w¥þ©Ê»P¥Í¬¡«~½è¤ÎÀù¯g§K¬ÌÀøªk¯S¦³ªºªø´Á¦s¬¡Àu¶Õ,Ó¤H»{¬°³oÁûÃĬO¦³¼ç¤OªºÃÄ,¥t¥~2014¦~¦Ü2016¦~6¤ë¥u¦³1Áû¨ÅÀùÃijQ¬ü°êFDA®ÖãÃÄÃÒ,Ó¤H»{¬°¨ÅÀùOBI822¤w²Å¦XÀò±o¬ü°êFDA®ÖãÃÄÃÒªº±ø¥ó(¦w¥þ,¦³Àø®Ä,MOA,QOL,¥i¤j¶q»s³y«~½è¤@PéwªºÃĪ«) 2017¦~¬O¥Rº¡¾÷·|ªº¤@¦~ (¥i¯à¹J¨ì®ÖÃÒ°ª®p´Á) ³æÃĶPÀù¥M PFS 6-7Ó¤ë¤W¥«¥H¨Ó½æ¤Fªñ600»õ¬ü¤¸ ¶W¹L2¥ü¥x¹ô,¨ÅÀùOBI822¬O·s¤@¥N¥HÁÞ¤À¤l¬°¼Ð¹vªºÀù¯g¥D°Ê§K¬ÌÀøªk,¤£¶Ë¥¿±`²ÓM, ¹w´Á±N¿W»â·Ä̤G¤Q¦~ www.centerwatch.com/drug-information/fda-approved-drugs/ ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ½Ð¿W¥ß«ä¦Ò¬ã§P |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/6/2 ¤U¤È 09:35:14²Ä 1746 ½g¦^À³
|
¥¬¤j ^°ê¿W¥ß³ø¦³¬ÛÃö³ø¾É, ¦ý¥i¥H¬Ý¬Ý¤U±¯d¨¥... www.independent.co.uk/news/science/cancer-vaccine-immunotherapy-universal-immune-system-rna-nature-journal-a7060181.html ·Q¹³¤@¤U³oºØ universal cancer vaccine, ¤H̶}©lÊ¿à vaccine, ¤£«µø°·±d¦a°µ³\¦h¶Ë®`¨Å骺¨Æ, e.g. ©âµÒ³Ü°s... ¤HÅ餺³¡ÁÙ¯à°÷ºû«ù¥¿Å¦Ó¤£Ãz¥X¬Æ»ò°ÝÃD¶Ü? §ÚÆZÃhºÃ |
|
|
·|û¡G¥¬µÜ®¦10140670 µoªí®É¶¡:2016/6/2 ¤U¤È 05:40:41²Ä 1745 ½g¦^À³
|
·sªº§K¬ÌÀøªk·s»D §ÜÀù§Þ³N¬ð¯}¡I ¬ì¾Ç®a¡G¬Ì]¿Eµo¤HÅé§ðÀ»¸~½F -------------------------------------- §ÜÀù§Þ³N¥X²{¤j¬ð¯}¡A¬ì¾Ç®a¨ú±oªø¨¬¶i®i¡A§Y±N¬ãµo¥X¹ï§ÜÀù¯gªº¼s®Ä«¬¬Ì]¡C¦pªG¬ãµo¦¨¥\¡A±N¯à³z¹L¬Ì]¥þ±±Ò°Ê¤HÅé§K¬Ì¨t²Î¡A¤õ¤O¥þ¶}§ðÀ»¸~½F¡C °ê»Ú¬ã¨s¹Î¶¤¦b¬ì¾Ç´Á¥Z¡m¦ÛµM¡n¡]Nature¡^³ø§i»¡©ú¡A¦p¦ó¸ÑŪÀù²ÓMªº®Ö¿}®Ö»Ä¡]RNA¡^°ò¦]±K½X¡A¨Ã±N¥¦Ì©ñ¤J¯×ªÕªº©`¦Ì²É¤l¤¤¡AµM«áª`®g¦X¾¯¨ì3¦WÀù¯g¥½´Á¯f±wªº¦å²G¤¤¡C µ²ªGÅã¥Ü¡Aª`®g«á¡A³o¨Ç¯f±wªº§K¬Ì¨t²Î¶}©l²£¥Í¡u¬r±þ«¬¡vT²ÓM¡A§ðÀ»Àù¯g¡C ¥Ñ¼w°ê¬ü¯ô¯÷¤j¾Ç±Ð±Â¨FªY ¡]Ugur Sahin¡^»â¾Éªº¬ã¨s¤Hû»¡¡A³o¨Ç¬Ì]¤]¥i¥H¦³®Ä§ðÀ»¦Ñ¹«Å餺¡u¨³³t½¯©µ¡vªº¸~½F¡C ³ø§i«ü¥X¡A³oÃþ¬Ì]¦¨¥»§C¡A»sµ{§Ö¡A¦Ó¥B´X¥G¥ô¦ó¸~½F§Üì³£¥i³QRNA½sµ{¡A·N¬°³o´Ú¬Ì]¤]³\¥i¥H¹ï§Ü¦UºØÀù¯g¡C ¡u¦]¦¹¡A³ø§i´£¤Îªº©`¦Ì²É¤lRNA§K¬ÌÀøªk¥i³Qµø¬°¤@ºØ¼s®Äªº·s«¬¬Ì]¯ÅÀù¯g§K¬ÌÀøªk¡C¡v ³ø§i»¡¡A3¦W¯f±w¬I¥´ªº¾¯¶q³£«Ü§C¡A¸ÕÅç쥻ªº¥Ø¼Ð¨Ã¤£¬O¬Ý¬Ì]ªº¥\®Ä¡C¦ý¯f±wªº§K¬Ì¨t²Î¦ü¥G¤w¦³¤ÏÀ³¡A¦ý·íµM¥Ø«eÁÙ¨S¦³ÃÒ¾ÚÅã¥Ü¡A¥L̤w§¹¥þ²¬Â¡¡C ±µ¨ü¸ÕÅ窺¨ä¤¤¤@¦W¯f±w¬O¿©±w²O¤ÚÀù¡A±µ¨ü¬Ì]«á¡A¥Lªº¸~½FºÃ¦üÅܤp¤F¡C¥t¤@¦W¯f±w¥ý«e´¿±µ¨ü¸~½F¤Á°£¤â³N¡A¬I¥´¬Ì]7Ó¤ë«á¡AÅ餺¨S¦³Àù²ÓMÂಾ¸ñ¶H¡C ²Ä3¦W¯f±wÅ餺¦³8Áû¸~½F¡A¥B¥ý«eÀù²ÓM¥Ñ¥Ö½§Âಾ¨ìªÍ³¡¡C³ø§i»¡¡A³o¦W¯f±w¨¤Wªº¸~½F¨ÌµM³B©ó¡uÁ{§Ééw¡vª¬ºA¡C ¬ã¨s¹Î¶¤´Á±æ¬Ì]5¦~Àòã¤W¥« ³o´Ú¬Ì]¥i¥H±Ò°Ê÷¨Å°Êª«ªº¤@ºØ¥Õ¦å²y¡u¾ð¬ðª¬²ÓM¡v¡A·í¡u¬r±þ«¬¡vT²ÓM¥X°Ê³B²z·P¬Vµ¥ª¬ªp«á¡A¾ð¬ðª¬²ÓM´N·|¬°¤HÅé§K¬Ì¨t²Î¿ï¾Ü§ðÀ»¥Ø¼Ð¡C ¦Ó¥B¬Û¸ûÀù¯g¤ÆÀøªº¹Ã¦R¡B¨r¾v¡BºAµ¥·¥ºÝ°Æ§@¥Î¡A³o´Ú¸ÕÅ礤ªº¬Ì]¶È·|±a¨Ó¤@¨ÇÃþ¦ü·P«_¯gª¬ªº¤£¾A¡C Àù¯g§K¬ÌÀøªkÅýÂå¾Ç¬É«D±`®¶¾Ä¡I³\¦h¯f±w¦b±µ¨üªvÀø«áªº10¦~´Á¶¡¡A¨ÌµM±µ¨ü²{¦sªºÀù¯g§K¬ÌÀøªk±±¨î¯f±¡¡C ¨FªY»¡¡A¬ã¨s¹Î¶¤¥¼¨ÓÁÙ·|®i¶}§ó¤j³W¼Òªº¤HÅé¸ÕÅç¡A§Æ±æÅý³o´Ú¬Ì]¦b5¦~¤ºÀòã¤W¥«¡C¥þ²y¥Ø«e¶È®Öã¨â´ÚÀù¯gªvÀø©Êªº¬Ì]¡A²Ä¤@ºØ¬O¨ü«Xù´µ®Ö㪺Àù¯g¬Ì]¡A±Mªù¥Î©óªvÀø¦´ÁµÇŦÀù¡A¥t¤@ºØ¬O¨ü¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½®Ö㪺«e¦C¸¢Àù¯g¬Ì]¡C ¾¨ºÞ²{¦æªºÀù¯gªvÀø¥i¥HÅý¬Y¨ÇÀù¯g²¬Â¡¡A¦ýªÍÀù¡B¶Â¦â¯À½F©M¤@¨Ç¸£³¡©MÀV³¡Àù¯g«hÃø¥HªvÀø©M²¬Â¡¡C ¦pªG½T¹ê¬ãµo¥X¯àÅýªvÀøª«¶i¤J¯f±w¦å²Gªº¬Ì]¡A±N¬OÀù¯gªvÀøªº¤@¤j¶i®i¡C ^°êÛ´°Àù¯g¬ã¨s°|±ö«´º¸¡]Alan Melcher¡^±Ð±Â»¡¡A¡uÀù¯g§K¬ÌªvÀø§Ö³tµo®i¡A¥B¬OÓ¥O¤H®¶¾Äªº¬ã¨s»â°ì¡C³oÓ°w¹ï¦Ñ¹«©M´X¦W¯f±wªº·s³ø§i¡A®i²{¤F§K¬Ì¨t²Î¥i¥H¦p¦ó¹ï§Ü¸~½F§Üì¡A³Ì²×¦³±æÅý¥þ·s«¬ºAªºÀù¯g¬Ì]°Ý¥@¡C¡v ·íµM¡A±ö«´º¸¤]»¡¡A³oÓ¸ÕÅçÁÙ»Ýn¶i¤@¨BÃÒ¹ê¬Ì]¹ï¯f±w¦³¯q¡C ¡u¯S§O¬O¡A¬ã¨s¥²¶·Âç²M¦b¦Ñ¹«¨¤W¥X²{ªºªvÀø®ÄªG¡A¬O§_¤]¥i¥H½Æ»s¨ì¤HÃþ¨¤W¡A¥H¤Î¾Þ§@©`¦Ì²É¤lÀøµ{¦b¹ê»ÚÁ{§É¤Wªº¬D¾Ô¡C¡v - See more at: www.cw.com.tw/article/article.action?id=5076642&utm_source=Facebook&utm_medium=Social&utm_campaign=Daily#sthash.Npvt7Yrd.dpuf |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/2 ¤W¤È 12:43:30²Ä 1744 ½g¦^À³
|
²³¤j¤j ¬Ý¬Ý¨ÅÀùªvÀø»Pµo®i²{ªp»P¥½´Áº[Âಾ©Ê¨ÅÀùªvÀø²{ªp ¤~ª¾¹D¨ÅÀùOBI822ªº¬Ã¶Q ¦w¥þ ¦³Àø®Ä ¦nªº¥Í¬¡«~½è §K¬ÌÀøªk¯S¦³ªºªø´Á¦s¬¡Àu¶Õ °ª¶Q¤£¶QªºÃÄ»ù...... ¥H¤U¸ê°T: ¥xÆW¯E¹© 103¦~«×¦~³ø 104¦~4¤ë30¤é¥Z¦L A.¨ÅÀùªvÀø»Pµo®i²{ªp¡G ¨ÅÀùªvÀø»P¦s¬¡ªºÅܼƫܤj¡A³q±`¦]¸~½F¥Íª«ªí²{¤Î¯f±¡´c¤Æª¬ªp¦Ó²§¡A¤Q¦~µL¯f¦s¬¡²v¥i¯à¬° 10%¡ã98%¤£µ¥¡A¨ä¤¤¤S¥HÂಾ©Ê¨ÅÀùªvÀøµ²ªG³Ì®t¡C°ò¥»¤W¡A¨ÅÀùªvÀø¥i¤À¬°¤»¤jÃþ: ¤â³N (surgery)¡B©ñ®g½uªvÀø(radiation therapy)¡B²üº¸»XÀøªk (hormone therapy)¡B¤ÆÀø(chemotherapy) ¡B¼Ð¹vªvÀø (target therapy) ¤Î§K¬ÌÀøªk(immunotherapy)¡C ¨ÅÀùªvÀø¶Ç²ÎÃĪ«¥]¬A¤ÆÀø¤Î²üº¸»XÃĪ«¡A¨ä¥L¼Ð¹vªvÀø©Î§K¬ÌÃĪ«¤£¦h¡A¦UÃþÃĪ«¤¤¥H¤ÆÀø¤Þ°_ªº°Æ§@¥Î³Ì¤j¡A§K¬ÌÀøªkÃĪ««h°Æ§@¥Î¬Û¹ï¸û¤p¡C²{¦æ¨ÅÀùÃĪ«ªvÀø¬O¨Ì¾Ú¨ÅÀù²ÓM¯S¼x¨Ó¿ï¾Ü¾A¦XªºÃĪ«¡A°w¹ï¤£¦P¨ÅÀùÃþ«¬¡Aµ¹¤©¤£¦PÃĪ«ªvÀø¡C ¨ÅÀù¯f¤H¤ÀÃþ²Ä¤@Ãþ¬O²üº¸»X±µ¨üÅ鶧©Ê¡A¨ÅÀù±wªÌ¤j¦h¼Æ¾A¥Î²üº¸»XÀøªk¡A°w¹ï²üº¸»X¨üÅéªvÀøÃĪ«¦³ Tamoxifen (®õ²ö¦èªâ)¤Î¨ä¥L§í¨î¾¯¡A¥]¬A anastrozole¡Bexemestane¡Bfulvestran µ¥¡C®õ²ö¦èªâµ¥²ü º¸»X§í¨î¾¯·|±a¨Ó¼ö¼é¬õ¡Bäú¤ß¡B¹Ã¦R¡B¸g´Á§ïÅÜ¡B¼W¥[¤l®c¤º½¤Àù¤Î¤l®c´c©Ê¦×½F¦MÀI¡A¤]¥i¯à¤Þµo¦å®ê¡B¤¤·µ¥±`¨£°Æ§@¥Î¡C¥t¥~¡AmTOR §í¨î¾¯ everolimus ·|§í¨î²ÓM¤º°T®§¶Ç¾É¸ô®|¡A°§CÀù²ÓM¥Íªø¤Î¦X¦¨¡A«P¨ÏÀù²ÓMä¤`¡CEverolimus ¦X¨Ö exemestane¡A¾A¥Î©óªvÀø²üº¸»X±µ¨üÅ鶧©Ê¡BHER2 ¨üÅé³±©Ê¥B¤§«e¨Ï¥Î letrozole ©Î anastrozole ´_µo©Î´c¤Æ¤§°±¸g«á±ß´Á¨ÅÀù±wªÌ¡C¸û±`¨£ªº°Æ§@¥Î¥]¬A¤fµÄ¼ìºÅ¡B¥Ö¯l¡B¸¡Âm¡B¹¼¤°§Cµ¥¡AÄY«°Æ§@¥Î¦³ªÍŦ©Î©I§l²§±`¡C¦AªÌ¡A¤À¤Æ酶 cyclin D kinase 4 »P cyclin D kinase 6 §í¨î¾¯ palbociclib ·|ªýÂ_Àù²ÓM¤Àµõ¹Lµ{¡A¸~½F¦]¦Ó°±¤î¥Íªø¡A¦X¨Ö letrozole ¾A¥Î©ó°±¸g«á»Û¿E¯À¨üÅ鶧©Ê¡BHER2 ¨üÅé³±©Ê¤§±ß´ÁÂಾ©Ê¨ÅÀù¯f±w¡Cȱoª`·Nªº¬O¡A¨ä°Æ§@¥Î·|¾ÉP¥Õ¦å²y¼Æ¶q´î¤Ö¡C ²Ä¤GÃþ¨ÅÀù¯f¤H¬° HER-2 ³J¥Õ½èªí²{¶§©Ê¡A³oÃþ¯f±w¬ù¦û 25¢M¡F¦oÌ¥i±Ä¥Î¶PÀù¥¡]Herceptin®¡AGenentech/Roche¡^§K¬Ì§ÜÅé¼Ð¹vªvÀø¡C¶PÀù¥¦X¨Ö¤Æ¾ÇªvÀø¤ñ°_³æ¯Â¥u°µ¤ÆÀø¡A¥i©úÅ㩵½w¨ÅÀù¶i¤@¨B´c ¤Æ¡A¨Ã´£°ª¦s¬¡²v¡F¤£¹L¡A°Æ§@¥Îµo¥Í²v¤]¸û³æ°µ¤ÆÀø°ª¡A¥]¬Aµo¿N¡B¹Ã¤ß¡B¹Ã¦R¡B¸¡Âm¡B·P¬V¡B«y¹Â¡B¥Õ¦å²y´î¤Ö¡B³h¦å¡B¦Ù¦×µmµhµ¥¡C¹ï©ó¦³¤ßŦ¯f¥vªº±wªÌ¡A¤Ö³¡¤À·|³y¦¨¤ßŦ¥\¯à¨ü·l¡C¶PÀù ¥»ù®æ©ù¶Q¡A¤@¦~ªvÀø¶O¥Î¶W¹L·s¥x¹ô 80 ¸U¤¸¡A¦Ü©ó·s¤@¥NHER-2/neu ¨üÅé§í¨î¾¯¡A¦³ GlaxoSmithKline (¸¯蘭¯À¥v§JÃļt)ªºTykerb® (lapatinib)¡A¤@¦~ªvÀø¶O¥Î¬ù¥x¹ô 110 ¸U¤¸¡A¸û Herceptin ©ù ¶Q¡C¥t¦³ pertuzumab ¥i»P Herceptin ¤Î docetaxel ¨Ö¥Î¡AªvÀøÂಾ«á¥¼´¿¥H§Ü HER2 ©Î¤Æ¾ÇÀøªkªvÀøªº HER2 ¶§©ÊÂಾ©Ê¨ÅÀù¯f±w¡C¥i¯à°Æ§@¥Î¬°»P¿éª`¬ÛÃöªº¤ÏÀ³¡B¹L±Ó¤ÏÀ³¡B¥ª¤ß«Ç¥\¯à¤£¥þµ¥¡C Trastuzumab emtansine (T-DM1) «h¥i¨Ï¥Î©óªvÀø HER2 ¶§©Ê¡B¤§«e¤À§O±µ¨ü¹L trastuzumab »P¤@ºØ taxane ÃĪ«ªvÀø©Î¨ä¦X¨ÖÀøªkªºÂಾ©Ê¨ÅÀù¯f±w¡A«n°Æ§@¥Î¥]¬A¨xŦ¬r©Ê¡B¤ßŦ¬r©Ê¡BFL-L¨à¬r©Êµ¥¡C Trastuzumab emtansine ¬O¤p¤À¤l²ÓM¬r¯À DM1(·LºÞ§í¨î¾¯)µ²¦XHER2 §ÜÅ骺½Æ¦XÃĪ«¡FDM1 µ²¦X·LºÞ³J¥Õ(tubulin)ªº¹Lµ{¡A·|¯}Ãa²ÓM¤º·LºÞºôµ¸¡A¾ÉP²ÓM©P´Áªýº¢»P²ÓMä¤`¡CÅé¥~¸ÕÅç¥çÅã¥Ü¡A trastuzumab emtansine »P trastuzumab Ãþ¦ü¡A¤]·|§í¨î HER2 ¨üÅé°T®§¶Ç»¼ªº¥\¯à¡C ²Ä¤TÃþ«h¬°¡u¤T³±©Ê«¬¡v¨ÅÀù¡A§Y²üº¸»X±µ¨üÅé ER¡]°Ê±¡¯À±µ¨üÅé¡^¡BPR¡]¶ÀÅé¯À±µ¨üÅé¡^»P HER-2 §¡§e³±©Ê¡A¦û¥þÅé¨ÅÀù±Ú¸s 15¡ã20%¡F¦¹Ãþ±wªÌ¹w«á¤£¨Î¡A¥Ø«e¥u¯à¨Ï¥Î¤Æ¾ÇªvÀø¡C¥»¤½¥q©Ò¶}µoªº OBI-822 ¨ÅÀùªvÀø©Ê¬Ì]¡AÄÝ¥D°Ê§K¬ÌÀøªk (ActiveImmunotherapy)¡A¥H¦b¨ÅÀù²ÓM¤W°ª«×ªí²{ªº Globo ¨t¦CÁÞ¬°¼Ðªº¡A¥i¾A¥Î©ó²üº¸»X±µ¨üÅ鶧©Ê¡BHER-2 ¨üÅ鶧©Ê»P¤T³±©Ê¯f¤H¡A¹w¦ô¥«³õ²[¬A©Ò¦³¨ÅÀù±Ú¸s¡C Evaluate Pharma ³ø§i¹w¦ô¥þ²y 2013 ¨ÅÀù¥«³õ¬ù 110 »õ¬ü¤¸¡A¦b 14% ½Æ¦X¦~¦¨ªø²v(CAGR) ¤U¡A¦Ü 2020 ¦~¦¨ªø±N¦¨ªø¦Ü 290 »õ¬ü¤¸¡]¹Ï¤E¡^¡AOBI-822 ±N¬°²Ä¤@Ó°w¹ï Globo ¨t¦CÁÞ§Ü쪺¨ÅÀù¼Ð¹v·sÃÄ (First-in-class)¡A¨ä¥«³õ¼ç¤O¤£¨¥¥i³ë¡C ¨ÅÀùªºªvÀøÃĪ«¥Dn¥]¬A¤T¤jÃþ¡G¼Ð¹vÃĪ«ªvÀø¡B²üº¸»XªvÀø»P¤Æ¾ÇÃĪ«ªvÀø¡CEvaluate Pharma ³ø§i¦¹¤TÃþÃĪ«ªvÀø¦b 2013 ¦~¥«³õ¦û¦³²v¨Ì§Ç¬° 64%¡B20% »P 16%¡C¥«³õ¹w¦ô¨ì 2020 ¦~¡A¼Ð¹vÃĪ«¥«¦û²v±N¦¨ªø¦Ü 89%¡C B. ¥½´Áº[Âಾ©Ê¨ÅÀù¡G Âಾ©Ê©Î²Ä¥|´Á¨ÅÀù©w¸q¬°Àù²ÓM¤w¸gÂX´²©M½¯©µ¡A¨Ã²£¥Í»·³BÂಾ¡C¾¨ºÞ¨ÅÀù¤w¦³·sªºÃĪ«¤ÎÀøµ{¡A¦ýÂಾ©Ê¨ÅÀù¯f±w¦s¬¡²vÁÙ¬O«Ü§C¡A¸~½F´c¤Æ¤§¤¤¦ì®É¶¡(median time to progression)¬°¤»¨ì¤EÓ¤ë¡A¤¤¦ì¦s¬¡¬ù 18~24 Ó¤ë¡A5 ¦~¦s¬¡²v¬° 15~18%¡CÂಾ©Ê¨ÅÀù³Ì±`¥Îªº²Ä¤@½u²Õ¦X¦¡¤ÆÀø¬°蒽ÀôÃþÃĪ«(anthracycline)¤ÎÀôÁCñQÓi (cyclophosphamide)©Î¤Ó¥¬vµµ§ü¾J(paclitaxel)¤Î/©Î 5-¬t§¿áGÔr(5-fluo |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/1 ¤U¤È 12:29:07²Ä 1743 ½g¦^À³
|
½Ð±ÐCliff¤j ¦Ñ´¤j¤Î¨ä¥L¯«¤H ¤G´Á¹êÅçºKn¤wª¾IgG¨ú160¬°°Ï¤À¦³®Ä»PµL®Ä²Õ¤§¼Ð·Ç±q¦ó¦Ó¨Ó? ¦³¨ä¥L¬ã¨s¤åÄm¤ä«ù¶Ü?¥i§_¤À¨É¸ê®Æ¨Ó·½? ·P®¦°Õ |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/5/31 ¤U¤È 01:39:22²Ä 1742 ½g¦^À³
|
µL¦W¤j¤j§A¦n, ÁÂÁÂ |
|
|
·|û¡GµL¦W10141903 µoªí®É¶¡:2016/5/31 ¤U¤È 01:32:31²Ä 1741 ½g¦^À³
|
Chen6053¤j ¥»¦¸Á{§ÉÁö¥¼¹Fªk³WÀø®Ä ¦ýHope Rugo«Øij¯E¹©¤ñ¸û¦³²£¥Í§ÜÅé(À³¬O1:40)»P¥¼²£¥Í§ÜÅé¨â±Ú¸sªºÃö«Y µo²{PÈ<0.05 ¯Î°|ªøºÙ¹êÅç²Õ80%²£¥Í§ÜÅé¡A¦³²£¥Í§ÜÅé´N¨ã¦³Àø®Ä¡A¬O«ü¤Wzªº²Õ¤º¤ñ¸û ¦ýYn»P¹ï·Ó²Õ¥þÅé¯f±w¤ñ¸û ¦]¹êÅç²Õ¤¤¥¼²£¥Í§ÜÅé¡B¶q¤£¨¬¡B©µ¿ð¡B®û¼í»P¯f±w¤Ö¼Æ¥¼±aGH series§Üìµ¥¦]¯À¼vÅT »Ý¨ú¥H¤U±ø¥ó¿z¿ï¡A¤~¯à¹F¨ìP<0.05¡A¥H²Å¦Xªk³Wn¨D 50%ªº¹êÅç²Õ±wªÌ¡A¹ï OPT-822/OPT-821 ²£¥Í Globo H ¯S²§IgG §ÜÅé (³o¬O«ü§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160) |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/5/31 ¤U¤È 12:36:19²Ä 1740 ½g¦^À³
|
80% 85%®t²§ ¸t¦®¨º¦³»¡©ú ¯E¹©2/22ªk»¡ ¤å¦rÀÉ ³o¸ÌÁÙn±j½Õ¤@ÂI¡A¯Î°|ªø¬O§Ú̪º±M®a·|ij¦¨û¡A¥L¤]¬Ý¨ì§Ú̪º¼Æ¾Ú¡A¥L¤]§â³oӼƾڤ½¥¬¡A©Ò¥H§Ú¤]¦b³oÃä§â¥¦«·s»¡©ú¤@¤U¡A¤j¦h¼Æªº¯f¤H¥´§Ú̪º822(¶À:¶W¹L¯Î°|ªøªº¼Æ¦r¡A±i:¬°¤°»ò¬O¶W¹L¯Îªº¼Æ¦r¡A¦]¬°¥L¥Îªº¬O¥§¡È)¡A¦bÁ{§É¤Wµo²{¥un³æ¤@§ÜÅé¼W¥[¡A(IGM¼W¥[¡A¦³Á{§ÉÀø®Ä¡A³æ¤@IGG¼W¥[¡A¤]¦³Á{§ÉÀø®Ä¡A¨âÓ¥[¦b¤@°_¶W¹L¯Î°|ªøÁ¿ªº¼Æ¦r)´N¬Oµ´¤j¦h¼Æªº¤H³£·|²£¥Í§ÜÅé¡A¦³¤F§ÜÅé¡A´N¦³Á{§ÉÀø®Ä¡C µJÂIªÑ¡G¯Î±Ò´f½T©w¥D«ùASCO±M®a·|ij¡A¯E¹©½L¤¤ªÑ»ù¤jº¦¡A¤@«×¹Gªñ600¤¸¤jÃö °]°T·s»D 2016/05/31 11:13 ¦rÅé©ñ¤j ¤À¨É¦ÜFB ¤À¨É¦ÜTwitter ...... ¯E¹©¤é«e¤½¥¬±N©óASCO¦~·|µoªí¤§¨ÅÀù·sÃÄOBI-822ªº¤G/¤T´ÁÁ{§É¸ÕÅç½×¤åºKn¡A¹êÅç²Õ¤¤¡AY¥H¤@¯ë³Ì°ò¥»²£¥ÍGlobo H¯S²§IgG§ÜÅé¿@«×40¨Ó¬Ý¡A¦³85%¡AY¥H³ÌÄY®æ§ÜÅé¿@«×160¡A§Y40ªº4¿¡Aµ²ªG¦³50%ªº¹êÅç²Õ±wªÌ¹F¨ì¡A¦¹»P¨S¦³§ÜÅé¤ÏÀ³ªÌ¡B±±¨î²Õ¬Û¸û¡A§¡¹F²ÎpÅãµÛ®t²§¡Cªk¤H»{¬°¡A¦¹½×¤åºKnÃÒ©ú¡A¬I¥´OPT-822/OPT-821«á²£¥Í¨¬¶q§ÜÅ骺¯f¤H«D±`¦³®Ä¡A¤]¬Ý¦n¯E¹©±N¦bASCO¤j©ñ²§±m¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/5/31 ¤U¤È 12:03:58²Ä 1739 ½g¦^À³
|
chen¤j, ¨ä¹ê§Ú¤]¬O¤µ¤Ñ¤~¬Ý¨ìªº µJÂIªÑ¡G¯Î±Ò´f½T©w¥D«ùASCO±M®a·|ij¡A¯E¹©½L¤¤ªÑ»ù¤jº¦¡A¤@«×¹Gªñ600¤¸¤jÃö °]°T·s»D 2016/05/31 11:13 ¦rÅé©ñ¤j ¤À¨É¦ÜFB ¤À¨É¦ÜTwitter ¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡j¥xÆW¯E¹©(4174)±N¦b¥xÆW®É¶¡6¤ë5¤éâ±áu¬ü°êÁ{§É¸~½FÂå¾Ç·|(ASCO)µoªíÁ{§É¼Æ¾Ú¡A¥Ñ©ó¥ý«e¤½¥¬ªº½×¤åºKn¤º®e³zÅS¡A¹êÅç²Õ¦³50%²£¥Í°ª§K¬Ì¤ÏÀ³ªÌ¹FÅãµÛÀø®Ä¡A¥[¤W¤¤¬ã°|«e°|ªø¯Î±Ò´fÀò¦P·N¸Ñ°£¹ÒºÞ¨î¡A¥i¦p´Á¥H±M®a¾ÇªÌ¨¤À¦b³õ¥~¥D«ù¥þ²y±M®a¿Ô¸ß·|ijªº½Ã¬P·|ij¡A¥«³õ°¾¦h¹w´Á¯E¹©¦bASCO©ñ¥ú¨~¡A¿EÀy½L¤¤ªÑ»ù¤@«×¤jº¦6.4%¡A®t2¤¸´NIJ¤Î600¤¸¤jÃö¡C ASCO±N¦b¬ü°ê®É¶¡6¤ë3¤é¦Ü7¤é©óªÛ¥[ôÁ|¦æ¡A¯E¹©±N©ó¬ü°ê®É¶¡6¤ë4¤é¤U¤È(¥xÆW®É¶¡¬°6¤ë5¤éâ±á)¦bASCO¶i¦æ¤fÀY½×¤å³ø§i¡A¸Ó½×¤å²Ä¤@§@ªÌ¬O¥x¤jÂå¾Ç°|¥~¬ì±Ð±Â¶À«T¤É¡A¤fÀY³ø§i¤H¬O¬ü°ê¥[¦{¤j¾Çª÷¤s¤À®Õ®üÛ¡Ð}°Ç®a®xºî¦XÀù¯g¤¤¤ß¨ÅÀùÁ{§É¸ÕÅç±Ð¨|¥D¥ô±Ð±ÂH.Rugo¡C ¯Î±Ò´f¥ý«e¾D¤hªL¦aÀ˸p¨î¥X¹Ò¡A¤@«×¼vÅT¹w©w6¤ëu¬üpµe¡A¤£¹L¡A30¤é¤hÀ˦P·N¥[«O200¸U¤¸¸Ñ°£¯Îªº¹ÒºÞ¨î¡A¥i¦b6¤ë1¤é¦Ü7¤é¥X°ê¡A¯Î±Ò´f±N¥H±M®a¾ÇªÌ¨¤À°Ñ¥[¯E¹©ASCO³õ¥~¥D«ù¤§¥þ²y±M®a¿Ô¸ß·|ijªº½Ã¬P·|ij¡C ¯E¹©¤w¤½§i¡A±N¦b¥xÆW®É¶¡6¤ë5¤é¤W¤È10ÂI30¤À©óÂdÂi¶R½æ¤¤¤ß¥l¶}§ë¸ê¤H»¡©ú·|º[«¤j°T®§°OªÌ·|¡A¤U¤È2ÂI©ó¥x¥_É]´°¤Æ«n¸ô¤G¬q97¸¹11¼Ó(¤¸´IÃÒ¨é±Ð¨|°V½m¤¤¤ß)¥l¶}ªk»¡·|¡C ¯E¹©¤é«e¤½¥¬±N©óASCO¦~·|µoªí¤§¨ÅÀù·sÃÄOBI-822ªº¤G/¤T´ÁÁ{§É¸ÕÅç½×¤åºKn¡A¹êÅç²Õ¤¤¡AY¥H¤@¯ë³Ì°ò¥»²£¥ÍGlobo H¯S²§IgG§ÜÅé¿@«×40¨Ó¬Ý¡A¦³85%¡AY¥H³ÌÄY®æ§ÜÅé¿@«×160¡A§Y40ªº4¿¡Aµ²ªG¦³50%ªº¹êÅç²Õ±wªÌ¹F¨ì¡A¦¹»P¨S¦³§ÜÅé¤ÏÀ³ªÌ¡B±±¨î²Õ¬Û¸û¡A§¡¹F²ÎpÅãµÛ®t²§¡Cªk¤H»{¬°¡A¦¹½×¤åºKnÃÒ©ú¡A¬I¥´OPT-822/OPT-821«á²£¥Í¨¬¶q§ÜÅ骺¯f¤H«D±`¦³®Ä¡A¤]¬Ý¦n¯E¹©±N¦bASCO¤j©ñ²§±m¡C |
|
|
·|û¡GµL¦W10141903 µoªí®É¶¡:2016/5/31 ¤U¤È 12:02:27²Ä 1738 ½g¦^À³
|
¶Â½ü§B¤j §Aªº²Ä2ÂI¡A¦P·N ¦³Ãö²Ä1ÂI¡A»¡©ú¦p¤U ¼Ë¥»¥Î¨Ó±À½×¥ÀÅé ¥»¦¸¹êÅç¼Ë¥»¥¼¿z¿ï¡Aµ¥¦P±À½×©Ò¦³²¾Âà©Ê¨ÅÀù¯f±w Y¦³¶W¹L50%¥H¤W¥»¦¸¹êÅç²Õ¯f±w¡A¸g¨}¦n³]p«á±À½×¹F²ÎpÅãµÛÀø®Ä ´Nªí¥Ü¦³¶W¹L50%¥ÀÅ馳®Ä |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/5/31 ¤W¤È 11:58:12²Ä 1737 ½g¦^À³
|
walker¤j¤j§A¦n, ÁÂÁ ¨º§Ú¯uº|¤F ÁÙ¥H¬°¨S»¡ ÁÂÁ |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/5/31 ¤W¤È 11:50:14²Ä 1736 ½g¦^À³
|
Chen ¤j IgG ¿@«× 40, ¦³85% ¥H¸ûÄY®æªº¼Ð·Ç¨Ó¬Ý¡A¿@«×160®É¬O 50% ªº±wªÌ¹F¨ì Thanks |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/5/31 ¤W¤È 10:18:29²Ä 1735 ½g¦^À³
|
50%ªº¹êÅç²Õ±wªÌ(§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160) ¤§«e©ÒÁ¿80% ¨º§ÜÅé¬O¹F??¥H¤W ¯u¬O¦n©_ ¦]¬°»¡80%¤]¦³Àø®Ä ¯u¬O´Á«Ý ¦A¸Ñª¼ |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/5/31 ¤W¤È 10:09:19²Ä 1734 ½g¦^À³
|
µL¦W¤j ±z¦n 1.±z©Ò»¡ªº ¥un¹êÅç³]pªº¦n¶W¹L50¢Hªº¯f±w¦³®Ä ³o¤@½×ÂI ¤p§Ì¦³¤£¦P¬Ýªk À³¸Ó¬O»¡ ³]pªº¦n ¿z¥X¾A¦Xªº¯f±w ´N·|¦³Àø®Ä ³o´N¬O«Ü¦h¤H·Q§ðÀ»ªºÂI ... 2.¦ý ¤p§Ì¬Ýªk¬O 4174¤½¥qªº¼ç¤O¤£¤î¦b©ó822©Î GLOBE H«Y¦C ¦ý¥un822¦³¦n¦¨ÁZ ©¹«á¬ì¾Ç¬É¦bÀù²ÓMªí±¤S§ä¨ì¤£¦P¥B¯S²§©ÊªºÁÞ³J¥Õ ¥H4174ªº§Þ³N¤Î¯à¤O ·|ÂǥѦb822ªº¦¨¥\¸gÅç¤Î¬Ì]¶q²£¯à¤O ·|Åý·s«¬ªº¬Ì]¶}µo¨ì¤W¥«®Éµ{ÁYµuªº ©Ò¥H ¯E¹© ¯uªº¬O ¼ç¤OµL½a... ¤p§Ì ²L¨£¨Ñ°Ñ |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/5/30 ¤W¤È 11:24:11²Ä 1733 ½g¦^À³
|
ÁÂÁ¦³«í¤j©M¦³Fu¤jªº¸Ñ»¡ |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/5/30 ¤W¤È 09:53:44²Ä 1732 ½g¦^À³
|
¤µ¤Ñ¤Ñ®ð¯u¥¿¦n¡A¯E¹©¦bª¦¼Ó±è¡A·|¤£·|¨ì³»¤~¥ð®§¡H¬Ý¬Ý¡C ¸Ñª¼°OªÌ·|ªº±¡´º¡A¤j®aÀ³¸Ó¦L¶H²`¨è¡C¨º®É¤p§Ì©M²³¤H¤@¼Ë¡A·¥«×¾_Åå©ó¡§«ü¼Ð¬Ò¥¼¹F¨ì²ÎpÅãµÛ®t²§¡§¡A¥i¬O¿Ã¹õ¸Ìªº±i³\¶À¡A¨äªí±¡©M»y¨¥¡A«o¬OªY³ß³Ó©óªq³à¡C¹ï¬ì¾Ç¦¨¥\ªº³ß®®¡A¤Q¿©ó¹ï¹êÅçªk³W¥¢±Ñªº±{±¤¡C¤p§Ì·í®Éı±o©Ç©Çªº¡A¾ãÓ°OªÌ·|¥H¤Î¹j¤éªºªk»¡·|¡A³ø³ßªº¦¨¤À©~¦h¡C³o©MªÑªF´²¤á´CÅé³ø¾Éªº¥¢±Ñ¥¢¸¨®ðª^¡AÅã±o®æ®æ¤£¤J¡C ¤TӤ몺··«B«B¹L«á¡A²{¦b¥i¥H»{¦P±i³\¶À·í®Éªºªí±¡©M»y¨¥¡A¨º³£¬O¸Û«Hªº¬yÅS¡A¤£¬OºtÀ¸¡C |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/5/30 ¤W¤È 09:03:02²Ä 1731 ½g¦^À³
|
©Ó¤Ñ¤j ¨Ì·Ó¤p§Ìªº¸gÅç,°£«D¬O°OªÌ©Û«Ý·|n¥X¥ÜÃÒ¥ó,§_«h¹³¬O§ë¸ê¤H»¡©ú·|©Îªk¤H»¡©ú·|,§ÚÌ´²¤á§ë¸ê¤H¬Ò¥i°Ñ¥[ ,¥t°OªÌ©Û«Ý·|,Y·Q¦bªù¤f®ÇÅ¥¤]¬O¥i¥Hªº,¨âÓ³õ¦a§Ú³£¥h¹L,¤£¹LÂd¶R¤¤¤ß³õ¦a¸û¤p,¤¸´I³õ¦a¸û¤j,Yn°Ñ¥[¦¤W³õ, ¥i¯àn¦ÂI¨ì,§K±oÀ½¤£¶i¥h,¥H¤W¤p§Ì¦Û¤v¸gÅç,¨Ñ±z°Ñ¦Ò |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/5/30 ¤W¤È 08:53:00²Ä 1730 ½g¦^À³
|
©Ó¤Ñ¤j~~~°Ý°Ý§A¨Ã䦳µL¤¸´IªºªB¤Í,½Ð¥L°Ý°Ý¯à¤£¯à¨ì¤ÀÂI¥h¬Ý§ë¼vªk»¡·| |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/5/30 ¤W¤È 12:10:36²Ä 1729 ½g¦^À³
|
²³¤j¤j, ¥xÆW¯E¹©¨ÅÀùOBI822±N¦b6¤ë5¤é¤W¤È¸Ñª¼ 1¦p¦P§Ú¥ý«eªº¹w´ú¤½¥qÅé½ÌªÑªF¤£·|ÅýªÑªF¦°_¬Ý´Î²yÁÉ,¥xÆW¯E¹©OBI822±N¦A6¤ë5¤é¤W¤È10ÂI30¤À¦bÂd¶R¤¤¤ß¥l¶}§ë¸ê¤H»¡©ú·| ¤U¤È¨âÂI¤¸´IÃÒ¨éÁÙ¦³ªk¤H»¡©ú·|,¤@Ó¸Ô²ÓªºÁ{§É¼Æ¾Ú¤ÀªR±N§e²{¦b¥þ°ê§ë¸ê¤H»Pªk¤H±«e 2¬ü°êÁ{§É¸~½FÂå¾Ç·|ASCO¬O¥þ²y³Ì¤j³Ì¨ã«ü¼Ð©ÊªºÀù¯g¡B¸~½F·sÃĵoªíÂå¾Ç¦~·|¡A¨C¦~§l¤Þ¼Æ¸U¦W ¾ÇªÌ¡BÂå®v¡B¬ì¾Ç®a¡B¥Í§Þ¤ÀªR®v ,§ë¸ê¾÷ºc¥Nªí, ¥Í§Þ¤½¥q¬ãµo¤Hû, FDA±M®a, ¥Í§Þ¤½¥qÃı´ , °ê®a¯ÅÀù¯g¬ã¨s¤¤¤ß¬ã´N¤Hû°Ñ¥[ 3¤j·|¬ã¨sºKn¤§µoªíp¦³¥|ºØ§Î¦¡¡A¨ä«n©Ê¨Ì§Ç¬°¤fÀY³ø§i(Oral Abstract Sessions)¡BÁ{§É¬ì¾Ç½×¾Â (Clinical Science Symposia)¡B®ü³ø°Q½×(Poster Discussion Sessions)¤Î®ü³ø®i¥Ü (Poster Sessions)¯E¹©«h±N¦bASCOªº¤fÀY½×¤å³ø§iÄÝ©ó«n©Ê³Ì°ªªºµ¥¯Å (¤µ¤Ñ¯E¹©¤½§i¸ê°T) 4¥xÆW¯E¹©¨ÅÀùOBI822±N¦b6¤ë5¤é²M±á½×¤å¼Æ¾Ú¦V¥þ²y¤½§iªº¦P®É¦pÀò±o¥þ²yªÖ©w»PÆgÅA,§Æ±æ¥ý«e»~»{¯E¹©¸Ñª¼¥¢±Ñªº´CÅé¦W¼L ¥ß©e °]¸gÂø»xt³d¤H¯à¹ï¦Û¤vªºµLª¾·P¨ì²Û·\,¨Ã¦V¥xÆW¥Í§Þ²£·~¹Dºp,¦V¥xÆW¯E¹©¤½¥q¹Dºp,¦V¯Î°|ªø¹Dºp,¨Ã¥B¤£Â_¥R¹ê¥Í§ÞÂåÃĪº±M·~¯à¤O,ÁA¸Ñ¥Í§Þ²£·~±o¯S©Ê»Pµû»ù,ÁקK¦A¥Ç¬Û¦P¿ù»~ 5¨ÅÀùOBI822¬OÄÝ©óÀù¯g¥D°Ê§K¬ÌÀøªk ¦b5¦~ªººN¯Á¤¤¤w§ä¨ì¤@±ø±d²ø¤j¹D,5¦~ªººN¯Á¨ä¹ê¬O¦¬Àòº¡º¡ ¤j®a¤£¥²¬°¬Q¤Ñªº¨Æ¯Õ¯Õ©óÃh,¤Ï¦ÓÀ³§âµJÂI©ñ¦b¥Rº¡§Æ±æªº©ú¤Ñ ,¦]¬°·|Åý¤j®a¯Õ¯Õ©óÃhªº¨Æ±¡¥¼¨Ó¤£·|¦Aµo¥Í, §K¬ÌÀøªk¥¼¨Ó¦b¤ñ¦³²£¥Í¨¬°÷§ÜÅé»P¥¼¯à²£¥Í¨¬°÷§ÜÅ鶡ªº¤ñ¸û,¯E¹©¤w¸g·Ç³Æ¦n¿z¿ï¯f±wÅý¥þ²y¤T´ÁÁ{§É¸ÕÅ禨¥\ ·¥¤j¤Æ ¦U¦ì¤j¤j·Ç³Æ¦n¤F¶Ü? ( °²¦pn°µ¥þ²y¤T´ÁÁ{§É¸ÕÅ窺¸Ü) 6¥þ²y¤T´ÁÁ{§É¸ÕÅç¤H¼Æ¹w´Á·|¤ñ¥xÆW¤T´Á¤H¼Æ¤Ö«Ü¦h (°²³]¥þ²y¦³25Ó¦¬®×Âå¾Ç¤¤¤ß ¦¬150¤H ¨CÓ¤¤¤ß¥§¡¥u¦³6Ó¾÷·|,¯E¹©¤w¨Æ¥ý°µ¦n¥þ²y¤T´ÁÁ{§É¸ÕÅ窺·Ç³Æ,¦¬®×³t«×·|¤ñ¥xÆW¤T´Á§Ö«Ü¦h,Ó¤H¬ã§P¤£±Æ°£¥þ²y¤T´ÁÁ{§É¸ÕÅç¥u´ú§ÜÅé¶q,¯à²£¥Í¨¬°÷§ÜÅ骺¯f±w¥´§¹9°w¬Ý¬Ý¬O§_¯à²£¥Í¬Û¦P¤ñ²vªºIgG ¥xÆW¤T´Á¤w¦³§ÜÅé¶q»PÀø®Ä¹ïÀ³¬ÛÃö½×¤åºKn ¨Ò¦p ¦³50%ªº¹êÅç²Õ±wªÌ¡A¹ï OPT-822/OPT-821 ²£¥Í Globo H ¯S²§IgG §ÜÅé (³o¬O«ü§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160)¡C a ³o¨Ç²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A·í»P¹ï·Ó²Õ¤ñ¸û¡A¦³¥H¤Uµ²ªG:(HR PFS OS ³£¦³ÅãµÛ®t²§) PFS¡AHR = 0.71 [95%CI 0.52-0.97]¡Ap= 0.029¡F OS¡AHR=0.57 [95%CI 0.33-0.97]¡Ap = 0.04¡F b ²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û¡A¦³¥H¤Uµ²ªG:(³oÓ²Õ¤º¤ñ¸ûªºµ²ªGÀ³¬O¯E¹©¬ãµo¤Hû³Ì³¶ÅDªº) PFS¡AHR = 0.52 [95%CI 0.37-0.71]¡Ap< 0.0001¡F OS¡AHR = 0.52 [95%CI 0.29-0.92]¡Ap= 0.025 ¡]µ²ªG¸g°ò¦¯e¯fª¬ºA/²üº¸»XÀøªk¨Ï¥Î±¡ªp®Õ¥¿)¡C ³o¨âÓµ²ªGÅã¥Ü¡A²£¥Í§K¬Ì¤ÏÀ³±wªÌªºPFS ©MOS³£¦³ÅãµÛ§ïµ½¡C ¤G¤ëªk»¡·|«á´£°Ý°Ýµª: Michael 2 ¬O§_´N¬O´ú§ÜÅé¶q ? 7¤£¥i§â¤w¤½§iªº½×¤åºKn¤¤ªºPÈ¥þ³¡·í¬°¦¨¼ô¼Æ¾Ú,¦³¨Ç¼Æ¾ÚÁÙ¦bÆ[¹î©|¥¼¦¨¼ô,ÀHµÛ®É¶¡±À¶i,¨Æ¥ó¼Æ¼W¥[PÈ ÁÙ·|¦A©¹¤U° |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/5/30 ¤W¤È 12:08:17²Ä 1728 ½g¦^À³
|
©Ò¥H¦¤Wªº³¡¤À¬O¤½¶}ªºÁÙ¬O¥u¯à¬Ý²{³õª½¼½? ¤U¤Èªº¬Oªk¤H¬°¹ï¶H¡A©Ò¥H§Ṳ́p´²¤á¤£¯à°Ñ¥[¹ï¶Ü? ÁÂÁ :) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/5/29 ¤U¤È 10:46:03²Ä 1727 ½g¦^À³
|
¨Ì¤µ±ßªº«¤j°T®§¤½¥¬¡G ¡u¥»¤½¥q±N©ó105/06/05¤W¤È10¡G30©óÂd¶R¤¤¤ßÁ|¦æ§ë¸ê¤H»¡©ú·|¡A¨Ã©ó·í¤é¤U¤È 14¡G00©ó¤¸´IÃÒ¨é(¥x¥_É]´°¤Æ«n¸ô¤G¬q97¸¹11¼Ó)Á|¦æªk¤H»¡©ú·|¡C¡v ¦³§O©ó¤µ±á5/29»P5/19ªº´CÅé³ø¾É¡A§O¶]¿ù¤F®É¬q¡C¡]www.chinatimes.com/newspapers/20160519000036-260202 ¡^ |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/5/29 ¤U¤È 10:34:04²Ä 1726 ½g¦^À³
|
¦U¦ì¤j¤j ¤£n¨º»ò¤ß«æ°Õ¡ã¯E¹©´±§â³õ¤l·d¨º»ò¤j¡A·Q¥²¬O¤Q¨¬§â´¤¡A§¤¦bÃâ¤l¤W¡A¦n¦n¬Ý·´º... |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/29 ¤U¤È 10:13:16²Ä 1725 ½g¦^À³
|
999¤j GLOBO Hªí²{²v60%*¤ÏÀ³²v80%(¯Î°|ªø»¡ªº ¦³§ÜÅé ´N¦³§K¬Ì¤ÏÀ³ ¬ù¤K¦¨)µ¥©ó48%¦³®Ä²v(¹êÅç²ÕªvÀø¦³®Ä¤ñ²v) ¨Ñ°Ñ |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/5/29 ¤U¤È 07:48:13²Ä 1724 ½g¦^À³
|
ÁÂÁ¦U¦ì¤j¤j¡I«¢«¢¡A§Úº|¬Ý¤F¨âÓ¦r¡I ¥HOBI-822ªº§@¥Î¾÷Âà(MOA)¡A¡u¤@©w¡v¥i¥H®³¨ì¬ð¯}©ÊÀøªk(BTD)¡A ®Ú¾Ú²Î¤@§ëÅUªºµû¦ô³ø§i(20151019)¡AP.20¡A©Ò¦C¥Xªº18ºØ·sÃĦӨ¥¡G ¬ð¯}©ÊÀøªk³Q®Öã«á¡A³Ì§Ö3Ӥ뮳¨ìÃÄÃÒ¡A³ÌºC19Ӥ뮳¨ìÃÄÃÒ¡A¥§¡¬O10.2Ӥ뮳¨ìÃÄÃÒ¡C (¦³³o»ò§Ö¶Ü¡H¤£ª¾¹D¦³¨S¦³¦Aº|¬Ý¨âÓ¦r¡I«¢¡I) ²Î¤@§ëÅUªºµû¦ô³ø§i(20151019) pcmc.uni-psg.com/VIP/20151019-4174.pdf ¦ý¤¤¸Î¬O2015¦~2¤ë®³¨ì¬ð¯}©ÊÀøªk³Q»{©w¡A¦pªG¦b2017¦~2¤ë®³¨ìÃÄÃÒ¡A «e«áÁ`¦@24Ó¤ë¡Aºâ«ÜºC¡AÀ³¸Ón¦A¥[ªo¡I |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/5/29 ¤U¤È 06:23:37²Ä 1723 ½g¦^À³
|
ÁÙ¯u¤j ·PÁ¡A·PÁÂ... ©Ò¦³¯E¤Í¤j¤j̯uªº¬OÓÓ¬O...´Î·¥¤F¡I |
|
|
·|û¡Gmetrostar10141472 µoªí®É¶¡:2016/5/29 ¤U¤È 06:21:27²Ä 1722 ½g¦^À³
|
¦Ñ¥v¤j ÁÂÁ§Aªº¸Ñ»¡^^ Ó¤H«ü¤@¦~¬O±q¶}©l¦¬®×¨ì§¹¦¨¦¬®×¥Ø¼Ð,µM«áÁ{§É¹êÅçµ²§ô ¨Ã¤£¥]§t«e¸m§@·~®É¶¡,¦p°µ§¹¤G´ÁÁ{§Én¥ý©MFDA¶}ÓEOP2·|ij, ¦A¨M©w¦ó®É¶}©l¤T´Á¹êÅç, ¦b¥xÆWªº¤T´ÁÁ{§É¸ÕÅç¬O±q2012¦~8¤ë¶}©l¦¬®×¡A2014¦~7¤ë21¤é§¹¦¨340¾l¨Òªº¦¬®×¥Ø¼Ð Á`¦@ªá¤F¤G¦~¤~§¹¦¨¦¬®×,¨ì2016¦~2¤ë¸Ñª¼,¤T´Á±q¦¬®×¨ìµ²§ôÁ`¦@¬ù¤T¦~¤»Ó¤ë. Ó¤Hı±o,¦p¶À¸g²z©Ò»¡,¼Ú¬ü¤T´Á¤H¼Æ·|¤j´î,¥[¤W©ú½TªºÀø®Ä,¦p¦¹¹F¨ì¦¬®×¤H¼Æ, ¤£P¹³¥xÆW¤T´Á¤@¼Ë,nªá¤G¦~¤~¯à逹¨ì¦¬®×¤H¼Æ, ¥t¥~¼Ú¬ü¤T´Á¨Ã«DÂùª¼³]p,¤]µL¸Ñª¼ªº°ÝÃD, ¾ãÓ¤T´Á®É¶¡À³·|¤j´TÁY´î! ©Ò¥HÓ¤H¤~»¡¦³¥i¯à¦b¤@¦~¤º§¹¦¨! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/5/29 ¤U¤È 05:41:13²Ä 1721 ½g¦^À³
|
metrostar¤j ¨Æ±¡¤£¬O³o¼Ëªº °µ§¹¤G´ÁÁ{§Én¥ý©MFDA¶}ÓEOP2·|ij¡A¥Øªº¤§¤@´N¬O To obtain agreement on pivotal study designs,and safety and efficacy endpoints for Phase 3 studies ¤½¥qn·Ç³Æ¦n¤T´ÁÁ{§Épµe¸òFDA²á...... ¥HKeytruda¬°¨Ò 2012.8.21¶}EOP1(Keytruda¬OÁ{§É1b¦ý³Qµø¬°¤G´ÁÁ{§É) 2013.1.11¶}Pre-Phase3 meeting ¯E¹©³sEOP2³£ÁÙ¨S¶}...... |
|
|
|